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SUMMARY
Eight types of X-linked immunodeficiency diseases 
have been described. In this thesis, I will focus on 
four, viz X-linked agammaglobulinaemia (XLA), X-linked 
severe combined immunodeficiency (X-linked SCID), Wiskott- 
Aldrich syndrome (WAS) and X-linked hyperimmuno­
globulinaemia M (X-linked hyperlgM). Their clinical 
features, treatment and prognosis as well as cellular and 
genetic aspects are reviewed in Chapter 1; followed by 
objectives of the studies presented in this thesis, viz 
localization of the gene loci of XLA and X-linked SCID, 
clinical application of the linked DNA probes in families 
with XLA and identification of the B cell defects in 
patients with XLA and WAS. The practical issues of 
collecting patients and families for linkage analysis, as 
well as their immunological profiles and pedigrees are 
given in Chapter 2. Various laboratory techniques 
employed in these studies are detailed in Chapter 3. 
There are five sections in Chapter 4, which is on the 
genetic studies of XLA. Section one reviews the principle 
of linkage analysis, genetic heterogeneity and restriction 
fragment length polymorphism (RFLP). Results of the 
genetic localization of XLA to Xq21.3-q22 are presented in 
section two. Evidence of non-allelic genetic hetero­
geneity in XLA is presented in section three, followed by 
the analysis of all the family data of XLA in the 
literature in order to estimate the proportion of families 
unlinked to Xq21.3-q22, which is probably 10-20%. The
Page 13
posterior probability of each family being linked to 
Xq21.3-q22 is also estimated. Section four describes the 
clinical application of the two linked probes, S21 and 
pXG12, in the genetic counselling of thirteen families 
with XLA; as well as developing a method of risk 
calculation allowing for non-allelic genetic hetero­
geneity. Seven obligate carriers under the age of 45 can 
all be offered prenatal diagnosis. Of the thirty-four 
females at risk of being carriers, seventeen have their 
risks increased, fifteen decreased and two unchanged by 
the RFLP results. Eleven of the seventeen women whose 
risks were increased are under 45 years of age and seven 
of them can be offered prenatal diagnosis. Successful 
predictions have been made in a newborn male infant and a 
male fetus at risk of being affected with XLA. Section 
five presents the evidence that X-linked hyperlgM is not 
an allelic genetic disease with XLA. Chapter 5 presents 
the results of the genetic localization of X-linked SCID 
to Xqll-ql3 and the clinical application of the linked 
probe, cpX73, in carrier detection. The results of the 
functional studies of Epstein-Barr virus (EBV) tranformed 
B cell lines from patients with XLA and WAS are presented 
in Chapter 6. B cell lines from patients with WAS did not 
differ from normal B cell lines in any of the functional 
assays I have used. However, differences were found in B 
cells from patients with XLA. EBV-transformed B cell 
lines from patients with XLA did not proliferate in 
response to KGl-a supernatant and they did not produce IgG 
in the presence or absence of various B cell growth and
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differentiation factors. Finally, Chapter 7 summarises the 
two approaches of investigations adopted in this thesis, 
which are applicable in investigating any diseases of 
single gene defect; future directions are also speculated.
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Chapter 1 INTRODUCTION
1.1 PRIMARY IMMUNODEFICIENCY DISEASES
Since the first recorded case of primary 
agammaglobulinaemia in a boy over 35 years ago by Bruton 
(1952), an ever increasing number of primary immuno­
deficiency diseases have been described, affecting nearly 
all aspects of immunity (Rosen et al 1983, 1984a, 1984b). 
Specific deficiencies in the B-cell (antibody) system, T- 
cell (cellular immune) system, phagocytic system or 
complement system have all been described (Rosen et al
1983) and the primary immunodeficiencies can be classified 
into these four types depending upon which arm of 
immunity is predominantly affected (Stiehm and Fulginiti 
1980).
Antibody immunodeficiencies are the most common and 
comprise about 50 percent of the primary immuno­
deficiencies; cellular immunodeficiencies comprise about 
40 percent and most of these patients also have associated 
antibody deficiencies. Phagocytic immunodeficiencies 
account for 6 percent and complement deficiencies 4 
percent of the total primary immunodeficiencies (Stiehm 
and Fulginiti 1980).
1.1.1 INCIDENCE
The most prevalent immunodeficiency is selective IgA 
deficiency, with an average frequency of 1 in 568 among 
blood donors (Hanson et al 1983). It can occur in healthy 
individuals but may also be associated with recurrent
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infections, atopy and autoimmunity. There is otherwise 
very little data on the incidence of primary immuno­
deficiencies. In countries where immunodeficiency 
registers were established (Sweden, Australia and Japan), 
the incidences of various primary immunodeficiencies have 
been estimated (Fasth 1982, Hayakawa et al 1981, Hosking 
and Roberton 1983). The overall incidence of significant 
symptomatic antibody deficiency was between 1 in 8,000 to 
1 in 11,000 live births and that of severe combined 
immunodeficiency to be 1 in 70,000 live births (Hosking 
and Roberton 1983, Fasth 1982). In Sweden, the incidence 
of granulocyte deficiencies was estimated to be 1 in 
15,000 live births (Fasth 1982). Apart from C9 
deficiency, which is relatively common (0.1%) in Japanese 
people, other complement deficiencies are extremely rare 
(Rother 1986). C9 deficiency is not associated with 
clinical disease.
1.1.2 AGE AND SEX
The age and sex profile of the primary 
immunodeficiencies can be estimated from a survey of 
hypogammaglobulinaemia in 176 patients (MRC working party 
1969). Although it is a study on hypogammaglobulinaemia 
only and may include some acquired immunodeficiency cases, 
it still reflects the overall impression of the age and 
sex pattern of primary immunodeficiencies; 17 percent of 
the diagnosed cases were in infants less than 1 year old 
and 41 percent were in children age 1 to 15 years old. 
Therefore, children accounted for 58 percent of the cases
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and three-quarters of these were under age 5 years (MRC 
working party 1969). There was a predominance of males 
(83 percent) in these children under age 15 years while in 
adults over age 15, only 41 percent were male (MRC working 
party 1969). This probably reflects that late-onset 
common variable immunodeficiency is more prevalent in 
females (Stiehm and Fulginiti 1980).
1.1.3 BASIC DEFECTS
The basic defects in most of the primary immuno­
deficiencies are not known. The few diseases whose 
biochemical defects are well understood include adenosine 
deaminase deficiency (Cohen et al 1978a), purine 
nucleoside phosphorylase deficiency (Cohen et al 1978b), 
X-linked chronic granulomatous disease (Teahan et al 
1987), bare lymphocyte syndrome (de Preval et al 1985, 
Lisowska-Grospierre et al 1985) and leucocyte adherance 
defect (Lisowska-Grospierre et al 1986). For the majority 
of the immunodeficiencies, identification of the defect is 
still limited to the cell types and function involved.
■1.1.4 GENETIC INHERITANCE
Genetic factors are pre-eminent in many of the 
immunodeficiencies and genetic predictions are possible in 
some of the well-defined diseases (Lau and Levinsky 
1988a). Several immunodeficiency diseases are inherited as 
single-gene defects, either in X-linked or autosomal 
inheritance (Table 1). There are others in which 
inheritance pattern is not clear but familial occurence is
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Table 1
PRIMARY IMMUNODEFICIENCY DISEASES OF MENDELIAN INHERITANCE
AUTOSOMAL RECESSIVE INHERITANCE
Severe combined immunodeficiency due to:
1. Adenosine deaminase deficiency
2. Purine nucleoside phosphorylase deficiency
3. Absence of HLA class I and/or II (Bare lymphocyte syndrome)
4. Reticular dysgenesis
Leucocyte adhesion deficiency 
Ataxia telangiectasia 
Chronic granulomatous disease 
Chediak-Higashi syndrome
Short-limbed dwarfism with severe combined immunodeficiency
X-LINKED INHERITANCE
X-linked agammaglobulinaemia
X-linked severe combined immunodeficiency
Wiskott-Aldrich syndrome
X-linked hyperimmunoglobulinaemia M
X-linked chronic granulomatous disease
X-linked lymphoproliterative disease
X-linked properdin deficiency
X-linked agammaglobulinaemia with growth hormone deficiency
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evident, e.g. selective IgA deficiency (Nell et al 1972).
There are at least eight X-linked immunodeficiency 
diseases described (Table 1). Six of these result from 
some defects within the lymphoid system, viz X-linked 
agammaglobulinaemia, X-linked severe combined immuno­
deficiency, Wiskott-Aldrich syndrome, X-linked hyper­
immunoglobulinaemia M, X-linked lymphoproliferative 
disease (Purtilo et al 1977,Hamilton et al 1980) and X- 
linked agammaglobulinaemia with growth hormone deficiency 
(Fleischer et al 1980). The remaining two, viz chronic 
granulomatous disease and properdin deficiency, involve 
the phagocytic and the complement systems respectively, 
and their basic biochemical defects have been elucidated 
recently (Teahan et al 1987, Dinauer et al 1987, Densen et 
al 1987).
1.1.5 X CHROMOSOME AND THE LYMPHOID SYSTEM
Since at least six immunodeficiency diseases 
involving the lymphoid system are X-linked and neither the 
immunoglobulin genes nor the T-cell receptor genes are 
themselves X-linked, it has been suggested the X-linked 
disease loci might include regulatory genes responsible 
for lymphocyte development. This hypothesis is supported 
by some work on a mouse model (CBA/N mice) for X-linked 
immunodeficiency (Cohen et al 1985a, 1985b). CBA/N mice 
have an X-linked mutation, xid, which renders them 
incapable of producing antibodies to soluble poly­
saccharide (Scher 1982). Cohen et al (1985a, 1985b) 
isolated a murine X-linked cDNA clone, termed XLR (X-
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linked, lymphocyte-regulated) which is closely linked to 
the xid locus and is developmentally expressed in 
lymphocytes from normal mice but not from those carrying 
the xid mutation; XLR represents a family of about ten 
genes. Therefore, with a developmentally-regulated 
expression which is restricted to lymphocytes, the XLR 
genes may well be responsible for regulating lymphocyte 
development in the mouse. Recently, Siegel et al (1987) 
found a single major XLR transcript, termed pMl, expressed 
by both B and T lymphocytes by analysing XLR cDNA clones 
generated from B-lineage tumours and from thymic tissue. 
This XLR transcript codes for a protein of 24 kilodaltons 
and its predicted amino acid sequence displays homology to 
the nuclear envelope constituents lamins A and C. 
However, the gene as defined by pMl is not closely linked 
to xid, in contrast to other members of the XLR gene 
family (Siegel et al 1987, Cohen et al 1985a). Moreover, 
a cDNA clone identical to pMl was isolated from a cDNA 
library from splenic RNA from a mouse strain BXSB.xid with 
the disease xid, thereby ruling out the possibility that 
the xid mutation is associated with any direct change in 
the sequence of this major XLR transcript, pMl (Siegel et 
al 1987). In humans with Wiskott-Aldrich syndrome, there 
is also a defect in producing antibodies to polysaccharide 
antigens (Blaese et al 1968) as with the CBA/N mice, but 
unlike the mouse disease, Wiskott-Aldrich syndrome affects 
T-cell and platelet function as well (Blaese et al 1968). 
Therefore, it is probable that there is also a series of
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X-linked genes in the human responsible for regulating 
lymphocyte development, the abberations of which will lead 
to the various X-linked immunodeficiency diseases. In 
this thesis, I will focus on X-linked agammaglobulinaemia, 
X-linked severe combined immunodeficiency, Wiskott-Aldrich 
syndrome and X-linked hyperimmunoglobulinaemia M only.
1.2 X-LINKED AGAMMAGLOBULINAEMIA
1.2.1 DEFINITION
X-linked agammaglobulinaemia (XLA) is a syndrome in 
boys with serious and recurrent bacterial infections 
starting usually in the second half of first year of life, 
characterised by a markedly diminished level of all serum 
immunoglobulin isotypes, a lack of circulating B cells, 
inability to make antibodies even after stimulation with a 
potent antigen and absence of plasma cells in lymphoid 
tissue (Rosen et al 1984a, 1984b). Cellular immunity is 
intact and X-linked inheritance ascertained from pedigree 
analysis.
1.2.2 CLINICAL FEATURES
In 1952, Bruton described the first boy with 
agammaglobulinaemia. Lederman and Winkelstein (1985) then 
reviewed 96 patients with XLA. The patients usually 
present with recurrent bacterial infections between three 
and nine months of age as earlier onset is prevented by 
maternal antibodies which only decline to insignificant 
levels after first few months of life. The pyogenic 
infections include mainly recurrent sinopulmonary
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infections, osteomyelitis, meningitis and sepsis; the 
organisms are usually encapsulated such as haemophilus 
influenzae, pneumococci and streptococci. Immunity to 
viruses is in general intact with the exception of 
persistent and usually fatal echovirus infection, 
especially of the central nervous system (Wilfert et al 
1977, Bardelas et al 1977) and possibly to hepatitis B as 
well (Good and Page 1960, Thomas et al 1974). Resistance 
to fungal infection and to tuberculosis, which depends on 
cellular immunity, remains intact. Other infectious 
complications include diarrhoea and malabsorption 
secondary to giardiasis (Ochs et al 1972) and chronic 
arthritis secondary to ureaplasma urealyticum (Stuckey et 
al 1978). Inadvertent administration of live oral 
poliovirus vaccine has also led to paralytic poliomyelitis 
(Wright et al 1977) and therefore no live vaccine should 
be given to patients with XLA.
1.2.3 TREATMENT AND PROGNOSIS
The main stay of treatment is adequate immunoglobulin 
replacement therapy and aggressive treatment of any 
infection. This is in order to minimise end-organ damage 
such as bronchiectasis and cor pulmonale, which now 
accounts for the majority of morbidity and mortality 
(Lederman and Winkelstein 1985). Unlike certain other 
immunodeficiencies, such as Wiskott-Aldrich syndrome and 
ataxia-telangiectasia, there is only a minor association 
with malignancy. Only 2 cases of cancer were observed 
amongst 274 patients with XLA in the immunodeficiency-
Introduction Page 23
cancer registry survey between 1975 and 1977 (Spector et 
al 1978).
1.2.4 CELLULAR DEFECTS
The primary defect in XLA is a lack of B lymphocytes 
in the circulation and lymphoid tissue (Siegal et al 1971) 
although pre-B cells are usually present in the bone 
marrow (Pearl et al 1978). It has been postulated that 
the underlying defect involves differentiation of B 
lymphocytes. However this defect is not complete as these 
patients do have small amount of serum immunoglobulins and 
very low number of circulating B cells (Conley 1985). 
Epstein-Barr virus transformed lymphoblastoid cell lines 
have been derived from the peripheral blood (Levitt et al
1984) and bone marrow (Fu et al 1980) of these patients 
and were shown to secrete IgM (Levitt et al 1984). 
Therefore, these patients do have small number of B 
lymphocytes which are capable of differentiating into 
antibody forming plasma cells.
The defect in B cell differentiation could be 
intrinsic or extrinsic to the B cells. In vitro study of 
peripheral blood mononuclear cells from patients has 
demonstrated a suppressor effect upon differentiation of 
normal lymphocytes to plasma cells (Siegal et al 1976, 
Herrod and Buckley 1979). However, this in-vitro 
suppression was not observed in all the patients studied 
and could be a secondary phenomenon. No in-vitro 
immunoglobulin synthesis or secretion was demonstrated 
from the patients' peripheral blood mononuclear cells,
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whether unstimulated or stimulated with pokeweed mitogen 
(Choi et al 1972, Herrod and Buckley 1979). The 
functional in-vitro study has not been able to resolve the 
issue whether the primary defect involves the B cells 
intrinsically or whether the failure of B cell development 
is secondary to some non-B cell defect. However, it is 
now clear from X chromosome inactivation analysis of the 
carriers (see following section) that the primary defect 
of XLA does involve the B cells intrinsically.
Edwards et al (1978) reported deficiency of ecto-5'- 
nucleotidase in patients with congenital agamma­
globulinaemia but it has been subsequently shown to be a 
secondary effect due to absence of B cells (Thompson et al 
1979). B cells have at least three times the activity of 
ecto-51-nucleotidase of T cells and hence the simplest 
explanation for reduced activity of ecto-51-nucleotidase 
in peripheral blood mononuclear cells from patients with 
XLA is the absence in these patients of B cells (Thompson 
et al 1979, 1980). Ecto-51-nucleotidase seems to be a
marker of B cell maturation and its role in normal B cell 
function is unknown. Banks et al (1976) has reported 
absence of B lymphocytes in a horse with primary 
agammaglobulinaemia, which may be comparable to XLA in 
man.
1.2.5 PHENOTYPIC HETEROGENEITY WITHIN AND BETWEEN FAMILIES 
In an extended pedigree of XLA with seven affected 
males, Leickley and Buckley (1986) demonstrated 
heterogeneity in terms of clinical presentation, serum
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immunoglobulin concentrations (one had a normal IgA and 
tetanus antibodies) and B cell phenotypes (the two 
youngest patients had normal percentage of surface 
immunoglobulin positive cells). This suggests the primary 
defect in XLA may affect B cells at more than one stage
of development rather than just at the level of pre-B
cell.
There are reports of phenotypic heterogeneity between 
patients from different families as well (Landreth et al 
1985a, Dobozy et al 1986, Golay and Webster 1986). 
Landreth et al (1985a) divided six boys with agamma- 
globulinaemia and lack of circulating B cells into two 
groups based on absence and presence of pre-B cells in the 
bone marrow. The group with normal percentage of pre-B
cells in bone marrow is that of classical XLA and that
without is a variant. Dobozy et al (1986) reported 4 boys 
with XLA in one family had high percentages of mouse 
erythrocytes rosette forming (MERF) cells in their 
peripheral blood while 2 other boys with XLA in another 
family had few MERF cells; hence suggesting B cell defects 
in XLA occur at different stages of differentiation in 
these two families. MERF cells represent a subpopulation 
of human B cells positive for both slgM, slgD and C3 
receptors but largely negative for IgG Fc receptors 
(Lucivero et al 1981). Therefore, there may be genetic 
heterogeneity in XLA giving rise to differences in the 
phenotypes observed between families.
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1.2.6 GENETIC ASPECTS
Early studies to demonstrate linkage between XLA and 
other X-linked phenotypic and protein polymorphisms, viz 
colour blindness and Xg blood group, have been 
unsuccessful (Sanger and Race 1963, Goldblum et al 1973, 
Mensink et al 1984). With the availability of X- 
chromosome specific DNA probes which detect restriction 
fragment length polymorphism (RFLP), linkage study of X- 
linked diseases have become more feasible (Drayna and 
White 1985). During the tenure of my research fellowship 
several studies have been reported concerning genetic 
linkage in XLA. Kwan et al (1986) demonstrated close 
linkage between XLA and 2 random DNA probes, 19.2 (DXS3) 
and S21 (DXS17), mapping the XLA locus to Xq21.3-q22. 
This finding was confirmed by Mensink et al (1986a) but 
the question of non-allelic genetic heterogeneity was 
raised. Our group (Chapter 4, this thesis) again 
confirmed the mapping of the XLA locus to Xq21.3-q22 and 
extended the linkage with another probe, pXG12 (DXS94) 
(Malcolm et al 1987).
The question of non-allelic genetic heterogeneity has 
complicated the clinical application of such linked DNA 
probes (Mensink et al 1987a) but a novel method of genetic 
risk calculation has been described to take into account 
the uncertainty due to non-allelic genetic heterogeneity 
(Chapter 4, this thesis, Lau et al 1988b). It will be 
essential to investigate the few XLA families which do 
show non-allelic genetic heterogeneity whether the
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patients have other less apparent difference in their 
immunological defects from those with XLA which map to 
Xq21.3-q22.
The Lyon hypothesis states that permanent inactivation 
of one of the two X chromosomes occurs at random in every 
somatic cell in the female early in embryogenesis (Lyon 
1961). The pattern of X chromosome inactivation is then 
transmitted in a stable fashion to all progeny cells. It 
seems the gene, the abberation of which leads to XLA, is 
essential for the development of B cells. Therefore there 
is only one population of mature B cells with the normal X 
chromosome active in female carrier of XLA who is 
immunologically indistinguishable from normal (Conley et 
at 1986, Fearon et al 1987). Conley et al (1986) 
established this by demonstrating XLA female carriers who 
were heterozygous for glucose-6-phosphate dehydrogenase 
(G6PD) and who only expressed one of the G6PD isoenzymes 
in their mature B cells while T cells and granulocytes 
expressed both isoenzymes. Using recombinant DNA probes 
which simultaneously detect RFLP and patterns of 
methylation of X chromosome genes, Fearon et al (1987) 
demonstrated the pattern of random X chromosome 
inactivation in T cells and granulocytes in female 
carriers of XLA, but not in B cells where only one of the 
two X chromosomes was preferentially active.
Furthermore, Schwaber et al (1983) reported Epstein- 
Barr virus (EBV) transformed pre-B cells from patients 
with XLA produced exclusively immunoglobulin u-heavy chain
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constant (Cu ) region without the normally associated 
heavy chain variable (VH ) region while only 5 percent of 
normal pre-B cells produced these incomplete u-heavy 
chains. It was postulated that the enzymes specific for 
translocation of variable genes or regulatory genes 
necessary for pre-B cells to differentiate to a stage 
utilizing these enzymes may be encoded on the XLA locus. 
However, EBV-transformed B cell lines from XLA patients 
were shown to be able to form complete v h djH 
rearrangements (Mensink et al 1986b). It was suggested 
that if the XLA gene is involved in IgH and/or IgL chain 
rearrangement, such rearrangements can still occur but at 
a reduced frequency (Mensink et al 1986b). It has been 
further postulated that the XLA gene may control the 
relative accessibility of the VH locus to the common 
recombinase system which assemble the V-region genes of 
both the immunoglobulin and T-cell receptor of B and T 
cells respectively (Yancopoulos et at 1986, Mensink et al 
1986b). Therefore, it seems the XLA defect is a relative 
but not an absolute block in B cell differentiation at the 
pre-B cell stage.
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1.3 X-LINKED SEVERE COMBINED IMMUNODEFICIENCY
1.3.1 DEFINITION
X-linked severe combined immunodeficiency is 
diagnosed on the basis of a complete absence of mature T 
cells, lack of T cell proliferation whereas B cells are 
detected in normal or increased numbers, suggesting this 
disease results from a block in T cell differentiation 
(Griscelli et al 1978, Gelfand and Dosch 1982,1983). 
Patients have significant functional deficiency of both T 
and B cell systems, despite presence of B cells. 
Unequivocal X-linked inheritance can only be ascertained 
from pedigree analysis of disease segregation.
1.3.2 CLINICAL FEATURES
Patients most commonly present with a triad of 
failure to thrive, persistent oral candidiasis which is 
refractory to treatment, and recurrent diarrhoea, commonly 
secondary to enteric viruses (Gelfand and Dosch 1983). 
The age of presentation is usually within the first six 
months of age. Pulmonary infections with pneumocystis 
carinii, cytomegalovirus, measles virus or parainfluenza 
virus are usually fatal. Chronic hepatitis secondary to 
cytomegalovirus or other unknown agents is common and a 
variant of sclerosing cholangitis with focal disappearance 
of bile ducts is also recognised. Progressive multifocal 
leukoencephalopathy due to a papova-virus, JC, has also 
been described in a four year old with severe combined 
immunodeficiency (ZuRhein et al 1978).
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1.3.3 TREATMENT AND PROGNOSIS
Patients usually die before the age of two unless 
bone marrow transplantation (BMT) is attempted. With human 
leucocyte antigen (HLA) matched BMT, the success rate is 
over 90 percent and with HLA mismatched BMT, only 50 
percent (Fischer et al 1987). Various means of depleting 
T cells in the donor marrow in order to prevent graft- 
versus-host disease in HLA-mismatched BMT have been 
attempted (Reinherz et al 1982, Morgan et al 1986, Buckley 
et al 1986).
In the past when no HLA-matched donor has been 
available, several approaches have been followed. These 
include fetal liver transplantation (Buckley et al 1976), 
fetal thymus transplantation (Hitzig et al 1965) and 
cultured thymic epithelium transplantation (Hong et al 
1976). These are now considered not to be an option since 
HLA-mismatched BMT for severe combined immunodeficiency 
has become a relatively successful treatment (Fischer et 
al 1987).
1.3.4 CELLULAR DEFECTS
Severe combined immunodeficiency (SCID) is a 
heterogenous group of diseases (Gelfand and Dosch 1983), 
of which the X-linked form is only one variety. The B 
lymphocytes from these patients have been shown to undergo 
terminal differentiation in vitro in the presence of 
normal T cells and pokeweed mitogen (Pahwa et al 1980), 
however it is not clear which type of SCID is actually 
involved. Another piece of evidence for the functional
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integrity of SCID B cells is that following donor T-cell 
engraftment in bone marrow transplantation in two 
patients, one of which has the X-linked variety, host B 
cells have become functional (Griscelli et al 1978). The 
origin of the B cells was determined by sex chromosome 
analysis as the donor and the host were of opposite sexes.
The primary defect seems to be a block in the T-cell 
differentiation (Gelfand and Dosch 1982) and the thymus is 
also uniformly dysplastic with marked lymphocyte 
depletion, absence of corticomedullary demarcation and 
absence of Hassall corpuscles.
1.3.5 GENETIC ASPECTS
Female carriers of X-linked severe combined 
immunodeficiency are immunologically normal and there is 
no immunological means of detecting carrier status. 
However, there are now two approaches to resolve this.
Our group has mapped the gene of X-linked SCID to 
Xqll-ql3 in a study of 9 families (Chapter 5 this thesis, 
de Saint Basile et al 1987). There is no evidence of non­
allelic genetic heterogeneity so far and a lod score of 
5.27 at 9=0.00 was obtained with the marker cpX73 (DXS 
159), which can be used carefully for carrier detection 
and prenatal diagonsis.
Another approach is based on the effect of 
Lyonisation. Puck et al (1987) first demonstrated non- 
random X-chromosome inactivation pattern in the T cells of
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three obligate female carriers of X-linked SCID by a 
combination of two techniques: first, human/rodent hybrids 
to separate and identify the active and inactive human X 
chromosomes, and second, Southern blot hybridization with 
X-linked restriction fragment length polymorphisms to 
distinguish the two X chromosomes. They then identified 
an at-risk female as a carrier and excluded two using this 
approach. Recently, our group has used gene probes from 
the 5' end of the hypoxanthine phosphoribosyltransferase 
(HPRT) and phosphoglycerate kinase (PGK) genes, which will 
detect both a restriction fragment length polymorphism and 
also a difference in methylation between the active and 
inactive X chromosome, to demonstrate non-random X- 
chromosome inactivation pattern in the T cells of obligate 
female carriers of X-SCID (Goodship et al 1988) and used 
this approach to ascertain carrier status.
1.4 WISKOTT-ALDRICH SYNDROME
1.4.1 DEFINITION
Wiskott-Aldrich Syndrome (WAS) is an X-linked 
recessive immunodeficiency characterised by the triad of 
thrombocytopaenia, eczema and recurrent infections 
involving all classes of microorganisms. Immunologically 
there is defective antibody response to a variety of 
bacterial, viral and protein antigens, especially to 
polysaccharide antigens. Blood group antibodies (IgM 
isohaemagglutinins) are usually absent. Delayed skin 
hypersensitivity responses are also impaired (Blaese et al 
1968).
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1.4.2 CLINICAL FEATURES
Wiskott first described the syndrome in 1937 (Stiehm 
and Fulginiti 1980) and Aldrich et al (1954) described 
another child in which the pedigree analysis suggested an 
X-linked inheritance, and it was confirmed rapidly by 
other workers (Wolff and Bertucio 1957, Krivit and Good 
1959). Patients usually present with petechiae or a 
bleeding episode in the first six months of life. They 
soon develop eczema and recurrent infections with various 
bacterial, viral (herpes simplex and cytomegalovirus) and 
fungal (Candida) agents (Cooper et al 1968). Severe 
reactions to immunization, particularly polysaccharide 
vaccines, may ensue with exacerbations of bleeding and 
eczema.
Variants of WAS have been described. Canales and 
Mauer (1967) described 7 male members of a 4-generation 
family with thrombocytopaenia and some with low 
isohaemagglutinins and isolated increases in IgA levels, 
but without recurrent infection or eczema. Evans and 
Holzel (1970) described a girl with features of WAS but no 
thrombocytopenia.
1.4.3 TREATMENT AND PROGNOSIS
Acute bleeding episodes usually respond to 
transfusion of fresh platelets which should be irradiated 
to prevent graft-versus-host reactions. Bleeding in WAS 
tends to decrease with advancing age and splenectomy 
should not be undertaken lightly as it results in
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increased risk of fulminating septicaemia. Infections 
should be treated early and aggressively. However, 
patients still die of the consequences of bleeding, as 
intracranial haemorrhage, or infection, as disseminated 
herpes simplex virus infection in the first ten years of 
life (Cooper et al 1968). Later, there is a high risk of 
developing malignancies, particularly lymphomas and 
systemic reticuloendotheliosis (Spector et al 1978).
Bach et al (1968) achieved reconstitution in a 2 year 
old boy with WAS by histocompatible bone marrow 
transplantation following high-dose cyclophosphamide. A 
15-year follow-up report of the same patient showed he has 
had full T cell, partial B cell and no haematopoietic 
engraftment (Meuwissen et al 1984). He has had no serious 
infections or bleeding episodes. With better results of 
bone marrow transplantation (Fischer et al 1987), it is a 
definite option to be considered seriously as most 
patients eventually develop malignancies (Spector et al 
1978).
1.4.4 CELLULAR DEFECTS
Both T and B cell defects occur in the WAS, but the 
most consistent and characteristic defect is the inability 
to form antibody to polysaccharide antigens (Krivit and 
Good 1959, Cooper et al 1968, Blaese et al 1968). 
Patients do not form isohaemagglutinins or antibodies to 
such antigens as pneumococcal polysaccharide and 
lipopolysaccharide Vi from E. Coli. Although IgG
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antibodies to polysaccharides are predominantly restricted 
to IgG2 in man, patients with WAS have been shown to have 
normal levels of the different IgG subclasses, including 
IgG2 (Nahm et al 1986). Blaese et al (1968) also 
demonstrated poor antibody responses to various bacterial 
and viral antigens.
T cell abnormality was demonstrated by decreased 
responsiveness to dinitrochlorobenzene sensitisation and 
skin-test antigens (Blaese et al 1968) and it has been 
shown there is a gradual loss of cellular elements in the 
thymus-dependent areas of the lymphoid organs (Cooper et 
al 1968).
Haematological abnormalities include thrombo- 
cytopaenia, lymphopaenia, eosinophilia and haemolytic 
anaemia. The platelets in the WAS are small when compared 
to normals or other acquired destructive thrombocytopaenia 
(Murphy et al 1972).
It is difficult to explain the above cellular defects 
with a unifying mechanism but Parkman et al have (1981) 
suggested an absence of a surface glycoprotein of 
molecular weight 115 kDa could be the primary defect in 
the WAS (Remold-0’Donnell et al 1984).
1.4.5 GENETIC ASPECTS
Female carriers of WAS are clinically normal and 
cannot be detected by immunological means. Shapiro et al 
(1978) has reported a method of carrier detection based on 
a stress test to demonstrate abnormal platelet
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aggregation, but it has not been substantiated elsewhere. 
Later, Gealy et al (1980) described a WAS carrier who was 
also heterozygous for glucose-6-phosphate dehydrogenase 
(G6PD), and who only expressed one of the isoenzymes in 
platelets and T cells, but both isoenzymes in erythrocytes 
and neutrophils. It was soon substantiated by Prchal et 
al (1980) in another female who was doubly heterozygous 
for both WAS and G6PD. This WAS carrier only expressed 
one of the G6PD isoenzymes in her platelets, T cells, B 
cells, monocytes and granulocytes, while her fibroblasts 
expressed both isoenzymes. This method of carrier 
detection can only be applied to a minority who are 
heterozygous for G6PD.
Recently, the WAS gene locus has been mapped to the 
pericentric region using restriction fragment length 
polymorphism (Peacocke and Siminovitch 1987) and genetic 
prediction becomes possible by gene tracking . Kohn et al 
(1987) also demonstrated non-random X chromosome 
inactivation pattern in the T cells of obligate WAS 
carriers by using the same technique as Fearon et al 
(1987) for XLA and Goodship et al (1988) for X-linked 
SCID. This can be used to detect carriers who are 
heterozygous for the DNA probes from the 51 end of the 
genes of PGK and HPRT.
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1.5 X-LINKED HYPERIMMUNOGLOBULINAEMIA M
1.5.1 DEFINITION
X-linked hyperimmunoglobulinaemia M (X-linked 
hyperIgM) is a syndrome in boys with recurrent bacterial 
infections, characterised by absent or decreased serum 
levels of IgG, IgA and IgE, but elevated or normal IgM. 
X-linked inheritance can only be ascertained from pedigree 
analysis of disease segregation. (Stiehm and Fulginiti 
1980).
1.5.2 CLINICAL FEATURES
Rosen et al (1961) reported the first two cases in 
two separate families and the X-linked inheritance has 
since been established in several families. The patients 
usually present with recurrent bacterial sinopulmonary 
infections during the first or second year of life. 
Neutropaenia is a frequent concomitant feature and is 
associated with stomatitis and mouth ulcers. Pneumocystis 
carinii pneumonia in early infancy can be the presenting 
feature, suggesting abnormal T cell function (Marshall et 
al 1964). In addition to susceptibility to infections, 
some patients are prone to various manifestations of 
autoimmune process, such as thrombocytopaenia, haemolytic 
anaemia, nephritis and arthritis (Goldman et al 1967). 
This syndrome has been reported in a few females (Rosen 
and Bougas 1963), indicating clinical and genetic 
heterogeneity (Kyong et al 1978). Furthermore the 
syndrome can be secondary to infection as it may be seen
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in children with congenital rubella (Schimke et al 1969, 
Geha et al 1979).
1.5.3 TREATMENT AND PROGNOSIS
Treatment is the same as for X-linked agamma- 
globulinaemia, viz adequate immunoglobulin replacement and 
aggressive treatment of any infection to minimise end- 
organ damage. A return of the IgM to normal levels 
usually indicates an adequate immunoglobulin replacement. 
Prognosis is generally better than in X-linked 
agammaglobulinaemia (Stiehm and Fulginiti 1980).
1.5.4 CELLULAR DEFECTS
The central defect of this syndrome is a failure of 
switch from IgM to IgG secretion, but whether it is due to 
an intrinsic B cell defect or lack of help from another 
cell type is not clear. Geha et al (1979) in a study of 9 
such patients, reported normal T cell function and 
identified a unique subpopulation of large B cells which 
secrete IgM spontaneously in large amounts; they concluded 
that the defect is intrinsic to B cells, which fail to 
switch from IgM to IgG synthesis. However, Mayer et al 
(1986) demonstrated IgM to IgG switch in B cells of 8 out 
of 9 such patients by using T cells derived from a patient 
with a Sezary-like syndrome. They concluded a defect in 
"switch T cells" may be pathogenic in this syndrome.
1.5.5 GENETIC ASPECTS
This syndrome of immunodeficiency with hyperIgM can 
result from either genetic or environmental causes, such
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as congenital rubella (Schimke et al 1969). The 
inheritance pattern is initially described of X-linkage 
but families with autosomal recessive inheritance have 
also been reported (Mayer et al 1986). Recently, the gene 
locus for X-linked hyperlgM has been mapped to Xq24-q27 by 
linkage with restriction fragment length polymorphism in 
one family (Mensink et al 1987b). We also analysed 
another family with X-linked hyperlgM in which at least 
two recombinations were observed with the DNA probes 
linked with XLA, viz 19-2 (DXS3), S21 (DXS17) and pXG12
(DXS94), thereby indicating a distinct localisation for 
the genetic defect in X-linked hyperlgM from that for XLA 
(Chapter 4, this thesis). Carrier detection and prenatal 
diagnosis should not be attempted by gene tracking in this 
disease until more such families are studied to see 
whether there is non-allelic genetic heterogeneity.
1.6 DECLARATION AND OBJECTIVES OF STUDIES PRESENTED
1.6.1 DECLARATION
When I started my research fellowship in the 
Institute of Child Health in January 1986, there was 
already an active research programme into X-linked 
immunodeficiencies as well as basic B cell physiology. My 
responsibility within this extensive research programme 
has been defined as mainly in the family linkage study of 
X-linked agammaglobulinaemia and X-linked severe combined 
immunodeficiency, subsequently the genetic counselling 
using the linked probes, as well as investigation into the 
in-vitro B cell function of patients with X-linked
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agammaglobulinaemia and Wiskott-Aldrich syndrome. I was 
personally involved in recruiting all the families, except 
families 15 and 17, and collecting blood samples for DNA 
extraction and establishing B cell lines. I did all the 
Southern blotting in the linkage study of XLA using pXG12 
(DXS94) and in that of X-linked SCID using cpX73 (DXS159) 
and pXG12 (DXS94). After establishing the linkage of XLA 
with probes from Xq21.3-q22, I was responsible in 
contacting potential female carriers in these families and 
providing genetic counselling with the use of probes S21 
(DXS17) and pXG12 (DXS94), including doing the Southern 
blotting. I carried out the mathematical analysis of the 
RFLP data and was personally involved in developing the 
risk calculation which takes into account non-allelic 
genetic heterogeneity presented in this thesis. I also 
designed and performed all the B cell functional studies 
described in chapter 6.
1.6.2 LOCALIZATION OF THE GENE LOCI OF X-LINKED 
AGAMMAGLOBULINAEMIA AND X-LINKED SEVERE COMBINED 
IMMUNODEFICIENCY
Human X chromosome accounts for about 6 percent of 
the total genomic DNA and its total genetic length was 
estimated to be about 200 centimorgans (Davies 1985). 
With the application of restriction fragment length 
polymorphisms (RFLP) as genetic markers (Botstein et al 
1980), a map spanning the entire X chromosome is almost 
complete (Drayna and White 1985) and any X-linked disease 
locus could now be mapped within ten centimorgans of at 
least two markers.
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Since the basic genetic defects of neither X-linked 
agammaglobulinaemia nor X-linked severe combined 
immunodeficiency is known, it would be desirable to map 
these disease loci using RFLPs which then open up the 
possibility of carrier detection and first trimester 
prenatal diagnosis. It may also lead to the accurate 
delineation of the underlying genetic defect, as has been 
achieved with X-linked chronic granulomatous disease 
(Royer-Pokora et al 1986, Dinauer et al 1987). We 
therefore carried out linkage analysis of families with 
these two X-linked immunodeficiency diseases (Chapter 4 
and 5, this thesis).
1.6.3 CLINICAL APPLICATION OF THE LINKED DNA MARKERS IN 
FAMILIES WITH X-LINKED AGAMMAGLOBULINAEMIA
Using the strategy of gene tracking (Pembrey 1986), 
there is enormous potential for carrier detection and 
first trimester prenatal diagnosis in monogenic diseases. 
However, non-allelic genetic heterogeneity has complicated 
this approach in X-linked agammaglobulinaemia (Mensink et 
al 1987a). We have nevertheless evaluated the feasibility 
of this approach in genetic prediction in thirteen 
families and developed a novel method of genetic risk 
calculation which takes into account the uncertainty due 
to non-allelic genetic heterogeneity (Chapter 4, this 
thesis).
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1.6.4 IN VITRO STUDY OF B CELL FUNCTIONS OF PATIENTS WITH 
X-LINKED AGAMMAGLOBULINAEMIA AND WISKOTT-ALDRICH 
SYNDROME
There is both immunological and genetic evidence to 
implicate that the B cells are primarily affected in both 
X-linked agammaglobulinaemia and Wiskott-Aldrich syndrome 
as reviewed above. Therefore, it will be essential to 
investigate these patients' B cell functions in detail and 
we have chosen the Epstein-Barr virus transformed B cell 
lines as an experimental model for evaluation of their 
responses to various B cell growth and differentiation 
factors in order to detect any possible defect (Chapter 6, 
this thesis).
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Chapter 2 PATIENTS AND FAMILIES
2.1 INTRODUCTION
Several practical issues of linkage analysis arose 
from this study which are by no means unique. Since X- 
linked agammaglobulinaemia (XLA) and X-linked severe 
combined immunodeficiency (X-linked SCID) are relatively 
rare diseases, any one paediatric centre is not likely to 
have enough affected families for linkage study. 
Therefore over one hundred letters were initially sent to 
paediatricians, geneticists and immunologists in the 
United Kingdom just to ascertain such families suitable 
for linkage analysis. Obviously, families with sporadic 
cases or with only one surviving son, whether affected or 
unaffected will not be informative. The next step was to 
ensure the diagnosis was correct in the index patient. 
The clinical history should be compatible. Immunological 
investigations should also be characteristic of the 
disease concerned. No family refused to co-operate in the 
study after the nature and possible benefits of the 
project were explained to them. A detailed and extended 
family history was then taken. A decision was made which 
members would contribute to the lod score in the linkage 
analysis, and they were then approached for their blood to 
be taken.
Since there was no test available for female carriers 
of XLA or X-linked SCID, a woman was only considered to be 
a carrier if she has had two or more affected sons or she 
has had at least an affected brother and an affected son.
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Such defined female carriers were then generally typed 
first for the DNA probes. Only if they were heterozygous 
would their offsprings be informative for linkage analysis
multigenerational family, due to missing or partial 
information, the situation is not always that cut and 
dried. There is as yet no best schedule such that the 
number of individuals to be typed is minimized (Ott 1985).
Another assumption made for the linkage analysis was 
that XLA and X-linked SCID in a male should usually 
manifest some symptoms before one year of age. Therefore, 
any absolutely healthy male over one year of age could be 
classified as unaffected, without their immunological
criterion was applied to the healthy brothers of both 
affected boys and female carriers, as well as the men who 
married into the pedigree from the population.
In one family (family 7), a case of monozygotic male 
twins was encountered. Genetically, they have to be taken 
as a single individual whose genotype has been 
independently expressed twice. For linkage analysis, they 
have to be coded as one and the same individual. If they 
were dizygotic twins, they should obviously be coded as 
two separate individuals.
and hence they were typed in turn. However in a
investigated. This classification
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2.2 X-LINKED AGAMMAGLOBULINAEMIA
Index patients of families 1-14 (Figure 2-1) have all 
been investigated either in the Hospital for Sick Children 
and Northwick Park Hospital, London, Newcastle General 
Hospital or East Birmingham Hospital. They all fulfilled 
the clinical features and immunological profiles (Table 2) 
of X-linked agammaglobulinaemia (XLA). Parents of all 
index patients were contacted directly. Explanations 
regarding the study were given and consent to participate 
obtained before a detailed family history was taken. 
Blood samples from patients and other relevant family 
members were then collected in ethylenediamine 
tetraacetate (EDTA) directly or via their own family 
doctors in order to extract DNA. Attempts were also made 
to establish Epstein-Barr virus transformed B cell lines 
from separated mononuclear cells from the patients.
Family 15 (Figure 2-1) reported initially by Jamieson 
and Kerr (1962) was obtained through Dr. Donnai, 
Manchester. The only affected surviving male was 
reinvestigated by Dr. Roifman in Toronto, Canada and 
confirmed to have panhypogammaglobulinaemia and lack of 
peripheral B cells, the characteristic immunological 
profile of XLA.
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Table 2
IMMUNOLOGICAL PROFILES OF INDEX PATIENTS WITH XLA
(G/L) %
Family Patient IgG IgA IgM
T
cells
B
cells
1 II-3 *3.1 <0.1 <0.1 85 <1
11-15 *1.9 <0.1 <0.1 nd nd
2 II-2 *2.3 <0.1 <0.1 75 <1
II-4 *1.9 <0.1 <0.1 60 nd
3 II-3 <0.6 <0.1 <0.1 normal <1
4 III-l 0.45 0.05 0.45 normal <1
III-2 *1.9 0.02 0.07 normal <1
5 III-l <0.6 <0.1 <0.1 nd nd
III-3 0.55 <0.1 <0.1 nd nd
6 III-l <0.6 <0.1 <0.1 normal <1
III-2 <0.6 <0.1 <0.1 normal <1
7 III-l *1.85 0.05 0. 02 nd nd
III-3 trace not
detected
trace nd nd
III-4 *1.26 0.1 0.05 nd nd
8 III-l 0.15 0.05 0.2 nd nd
III-2 0.01 0.05 0.05 75 <1
9 III—2 <0.6 <0.1 <0.1 normal <1
10 III-l <0.6 <0.1 <0.1 normal <1
III-2 <0.6 <0.1 <0.1 normal <1
III-3 <0.6 <0.1 <0.1 normal <1
(continued next page)
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Table 2 (continued)
(G/L) %
Family Patient igG IgA IgM
T
cells
B
cells
11 II-l <1.0 <0.1 <0.1 nd <1
III-2 1.2 <0.1 <0.2 75 <1
12 III-2 0.95 <0.1 <0.1 nd nd
III-3 0.1 <0.1 <0.1 nd nd
III-4 0.8 <0.2 0.09 nd nd
13 II-l *2.0 <0.1 <0.1 normal <1
14 II-l <0.1 <0.1 <0.1 normal <1
nd = not done
* = on immunoglobulin replacement
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2.3 X-LINKED SEVERE COMBINED IMMUNODEFICIENCY
Three families were collected (Figure 2-2) and the 
index patients all fulfilled the diagnostic criteria of 
the World Health Organization Committee on Immuno­
deficiency (Rosen et al 1983), viz absence of T 
lymphocytes and lack of T-lymphocyte proliferation with 
normal or increased numbers of B lymphocytes. One family 
was obtained through Dr. S. Strobel from Germany, one 
through Dr. T. Espanol from Spain and the last family has 
been under our care for years and is of Turkish-Cypriot 
origin from London. Similarly, blood samples were 
collected from family members for DNA analysis.
2.4 X-LINKED HYPERIMMUNOGLOBULINAEMIA M
One family was studied (Figure 2-3) and the index 
patient was diagnosed as having X-linked hyperlgM at the 
Hospital for Sick Children, London. He had abnormally 
high serum IgM levels, no serum IgG or IgA and his B cells 
which were present in normal numbers had only IgM and IgD 
on the cell surface.
2.5 WISKOTT-ALDRICH SYNDROME
Six patients, all from different families, were 
diagnosed as having Wiskott-Aldrich Syndrome (WAS) either 
in the Hospital for Sick Children, London or Booth Hall 
Hospital, Manchester. They again fulfilled the diagnostic 
criteria of WAS, viz thrombocytopaenia, eczema, lack of 
isohaemagglutinins and variable degree of T cell 
deficiency. Preservative-free heparinised blood were 
obtained from these six patients for establishing Epstein-
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Figure 2 -2  Pedigrees of three famil ies with X-l inked  
severe combined immunodeficiency (Families 1 6 -1 8 )
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Figure 2 -3  Pedigree of the family with X-linked  
hyperimmunoglobulinaemia M (Family 19)
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Barr virus transformed B cell lines. Linkage study was 
not possible due to limitation of suitable families for 
linkage analysis.
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Chapter 3 METHODOLOGY
During the tenure of my research fellowship, the 
following laboratory techniques have been used in the 
various projects. Materials used are detailed in appendix 
1. The mathematical aspects of linkage analysis are given 
in Chapter 4.
3.1 PREPARATION OF DNA FROM VENOUS BLOOD
Fresh blood has to be collected in tubes containing 
the anticoagulants ethylenediamine tetraacetate (EDTA) or 
heparin, otherwise the sample will clot and provide 
little DNA. The sample may be kept at +4° C for several 
days without deterioration, or frozen and kept 
indefinitely at -70°C or up to six months at -20°C. 30 ml 
of ice-cold distilled water was added to 10 ml of thawed 
venous blood. It was then spun at 2000 RPM, 4°C for 20 
minutes. Supernatant was poured off and the nuclear 
pellet at the bottom was retained. 25 ml of ice-cold 0.1%
Nonidet P40 solution was added to the pellet. The pellet
was re-suspended and was spun at 2000 RPM, 4°C for 20 
minutes; supernatant was decanted again. 2.5 ml of 75mM 
NaCl/25mM EDTA (pH8) was added to pellet and resuspended 
thoroughly. 125 microlitres of 10% SDS, and 1 mg 
proteinase K (10 mg/ml) were added in turn. It was then 
left at 37°C overnight or 56°C for 3 hours. 2.5 ml of 75mM 
NaCl/25mM EDTA (pH8) and 5 ml of phenol (saturated with 
50mM Tris pH8.0) were added. It was mixed well and spun at 
3000 RPM, 4°C for 20 minutes. The top aqueous layer which
contains DNA was retrieved. 2.5 ml phenol and 2.5 ml
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chloroform were added, mixed well and spun at 3000 RPM, 
4°C for 15 minutes. The top layer was taken again and 5 
ml chloroform was added. It was then spun at 2000 RPM, 4°C 
for 5 minutes. The last step was repeated once. The top 
layer was taken. 0.5 ml 3M sodium acetate (pH 5.2) was 
added and topped up to 15 ml with ice-cold ethanol and 
mixed well. DNA would precipitate out as threads and 
could be fished out on glass rod. DNA was allowed to dry 
and put into 0.5 ml TE solution in eppendorf tube and spun 
at 4°C to dissolve overnight.
3.2 SOUTHERN BLOTTING
5 micrograms of DNA, approximately 15 microlitres of 
DNA as prepared in (3.1) were digested with 10 units of 
enzyme under the manufacturer's conditions. 1 microlitre 
of 1 mg/ml bovine serum albumin (BSA) and 1 microlitre of 
0.1M spermidine were added as well in a final volume of 25 
microlitres. Incubation was carried out for at least 4 
hours. 5 microlitres of bromophenol blue/25% glycerol/EDTA 
was added as a loading dye to each sample of digest. 0.8% 
agarose gel plate was prepared by dissolving 2 grams of 
electrophoresis grade agarose powder in 250 ml Tris E 
buffer, then 12.5 microlitres ethidium bromide (10 mg/ml) 
was added. Each sample was loaded into a well. Hind III 
digested lambda marker was put onto the first left hand 
lane. The gel was run submerged in Tris E buffer for 16 
hours at approximately 1.5V/cm or 50 mA. DNA migrates to 
the positive electrode. The gel was checked and 
photographed under ultra-violet light with a ruler by the
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side. The gel was then soaked in denaturing solution for 1 
hour, followed by one hour in neutralising solution, 
twice. The Southern blot was then set up for an overnight 
transfer of DNA to a nitrocellulose or nylon filter with 
20xSSC (Southern 1975). The filter was rinsed with 2xSSC, 
and then baked at 80°C for 3 hours. After baking, the 
filter was damped in 2xSSC and put into a plastic bag. 5 
ml pre-hybridization solution for 125 ml gel was added 
into the plastic bag. All bubbles were squeezed out and 
the bag was double sealed. It was left at 65°C (water 
bath) for 3 to 12 hours. The filter was retrieved from 
the plastic bag and put into a second bag with the radio­
labelled probe (boiled for 5 minutes just prior to use) 
added into the 5 ml prehybridization solution. It was 
left at 65°C (water bath) overnight. The filter was 
removed and washed three times with 3xSSC/0.1% SDS at room 
temperature for 20 minutes each. It was checked with 
beta-counter for background radioactivity and bands. If 
there was too much background, the filter was washed once 
with 0.5xSSC/0.1% SDS at 65°C for 20 to 30 minutes. The 
lower the concentration of SSC and higher the temperature, 
the more strigent the wash is. The filter was dried and 
wrapped in cling film. The position of wells was marked 
and orientation of filter labelled with radioactive ink. 
The filter was then autoradiographed in cassettes with 
intensifying screens at -80°C using Kodak XAR-5 film. It 
was left for varying periods of time depending on strength 
of signals. Examples of the autoradiographs using the
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probes S21, 19-2, pXG12 and cpX73 are presented in figure 
3-1.
3.3 0LIG0LABELL1NG OF DNA PROBES
DNA probe to be used was diluted into 50 ng/ml of 
distilled water. 1 microlitre of DNA probe was added to 8 
microlitres of water, which was boiled for 2 minutes. The 
DNA probe was then added to 11.4 microlitres of LS and 1
qo
microlitre of BSA solution on ice. 50 microCi of [ P] 
dCTP (5 microlitres) was added, followed by 2.5 units of 
DNA polymerase I Klenow fragment. The solution was mixed 
gently and left at room temperature overnight. Two 
microlitres of loading dye was added to the 25 microlitres 
of radio-labelled DNA probe. It was made up to 100 
microlitres with 3xSSC. The solution was put down a 
column of Sephadex G50 in 3xSSC and eluants at 100 
microlitres aliquots were collected as successive 100 
microlitres of 3xSSC were put down through the column. 
Aliquots of eluants were checked for peak level of 
radioactivity and the 4 maximum aliquots were pooled. The 
cpm of the pooled radiolabelled DNA probe was measured on 
a scintillation counter and it was used at 1x10^ cpm/ml of 
hybridization solution.
3.4 ESTABLISHING EPSTEIN-BARR VIRUS TRANSFORMED B CELL 
LINES FROM PERIPHERAL BLOOD MONONUCLEAR CELLS
10 ml of venous blood was collected into a container 
wetted with preservative-free heparin. An equal volume of 
RPM I 1640 medium supplemented with 25mM Hepes was used to 
dilute the blood. It was then layered onto Ficoll-Hypaque
Figure 3-
< * ! * • *
7.2kb
6.5kb
«T . 2.2kb  
2.0kb
P st1 /pX G 12 T aq 1 /S 2 1
5.1 kb
• •
5 .5kb
2 .95kb
m m
■1.6kb
2.15kb
Taq1/ 1 9 - 2
Pst1 /c p x 7 3
1 Autoradiographs showing the DNA polymorphism
detec ted  with the four X chromosome specif ic  probes:  
S 2 1 ,  19 .2 ,  pXG 1 2 and cpX73.
Methodology Page 54
(1.077 kg/1) (2 volumes of diluted blood to 1 volume of 
Ficoll-Hypaque) and spun at 1000 g for 20 minutes at room 
temperature. The centrifuge brake was off to prevent 
disturbance of the interface. Mononuclear cells were 
collected from the interface and washed twice with at 
least an equal volume of RPM1 1640 with 25mM Hepes; these 
were spun at 200g for 15 minutes. 1 ml of marmoset cell 
line B95-8 supernatant (Miller et al 1972) containing the 
Epstein-Barr virus was added to the cell pellet, which 
was resuspended gently and incubated at 37°G for 1 hour. 
It was then washed and spun again. The mononuclear cells 
were then resuspended in RPM1 1640 with 25mM Hepes and 
10% fetal calf serum (FCS) at a concentration of 0.5-1x10^ 
cells/ml. Cyclosporin A at a final concentration of 1 
ng/ml was added. Aliquots of 2 ml were dispensed into
each well of 24-well Costar plate which was then
incubated at 37°C, in an atmosphere of 5% CO2 in air. 
Lymphoblastoid cell clumps were usually seen by the end of 
2 weeks (Figure 3-2). When cell growth was vigorous, the 
cell line was expanded by transferring to an upright 
culture flask. Cell lines obtained from patients were 
either used for experiments immediately or frozen down in 
large number of aliquots for future experiments, in order 
to ensure the cell lines were still polyclonal.
Figure 3 -2  Micrograph showing E pste in -B arr  virus transform ed  
lymphoblastoid cell  clumps.
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3.5 MEASUREMENT OF IgG/IgM IN CULTURED CELL SUPERNATANT 
BY ENZYME-LINKED IMMUNOSORBENT ASSAY
80 microlitres of affinity purified goat anti-human 
IgG/IgM (Sigma), at a concentration of 0.5 microgram/ml (1 
in 2000) in bicarbonate buffer pH9.6, were dispensed into 
each well of a 96-well Sterilin Cooke round-bottomed 
microtitre plate which was then incubated in a moist box 
at room temperature overnight. The plate was washed 
thrice with bicarbonate buffer. 100 microlitres of 4% 
normal goat serum (NGS) diluted in bicarbone buffer were 
added to each well and left at room temperature for one 
hour. The plate was washed thrice with 0.05% Tween 20 in 
normal saline. 80 microlitres of test supernatant, or 
standards diluted in normal saline with 0.05% Tween 20 and 
4% NGS were added and incubated at room temperature for 
60-90 minutes. An 11-point standard curve using double 
dilutions of either pooled normal human serum or partially 
purified IgG/IgM at 1000 nanogram/ml was set up in 
duplicate on each plate along with buffer only zero 
standard. An example of the standard curve is given in
figure 3-3. The plate was washed five times with 0.05% 
Tween 20 in normal saline. 80 microlitres of horseradish 
peroxidase (HRP)-conjugated affinity purified goat anti­
human IgG/IgM diluted to 1:1000 in normal saline 
containing 0.05% Tween 20 and 4% NGS were added to each 
well. The plate was washed five times with 0.05% Tween 20 
in normal saline. 80 microlitres of o-phenylenediamine 
diluted to 0.5 mg/ml in phosphate/citrate buffer 
containing 0.015% hydrogen peroxide were added to each
) 492nm
1000
IgG ng/ml
Figure 3 -3  Standard curve of IgG measurement by enzyme linked 
immunosorbent assay
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well as substrate. This reagent was made up just prior 
to use. The plate was then incubated in the dark at room 
temperature to allow colour development. For HRP, 15 
minutes was usually sufficient. Further development was 
then stopped by adding 40 microlitres of 2M sulphuric acid 
to each well, and the absorbance read on an automatic 
ELISA plate reader at 492 nm. A standard curve was 
constructed, from which the value of test supernatants 
were read.
3.6 ASSAY FOR RESPONSES OF EPSTEIN-BARR VIRUS 
TRANSFORMED B CELL LINES AND INDICATOR B CELL LINES 
TO VARIOUS FACTORS
Cell lines were sub-cultured 24-48 hours prior to use 
in order to ensure vigorous log-phase growth. Cells were 
cultured in triplicate at concentrations between 1 and
q
20x10 cells/well in 96-well flat-bottomed microtitre 
plates. The culture medium was RPM1 1640 supplemented 
with 2mM L-glutamine, 25mM Hepes and FCS (2% for growth 
and 5% for differentiation assay). Various factors were 
added to give final concentrations as indicated in each 
experiment. When assaying for proliferation, the cultures 
were incubated at 37°C, 5% CC>2, for 3 days and pulsed with 
1 microCi/well (37 kBq) of tritiated thymidine (3HTdR) for 
the last 8 hours. Cells were then harvested onto glass 
fibre filter discs using an automated cell harvester and 
incorporated 3HTdR determined on a liquid scintillation 
counter. When assaying for differentiation, the cultures 
were incubated for 5-6 days and the immunoglobulin levels 
in supernatant measured by enzyme-linked immunosorbent
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assay (ELISA). The preliminary experiments to establish 
the above parameters, such as cell concentrations and 
length of culture, are detailed in Chapter 6.
3.7 INDIRECT IMMUNOFLUORESCENCE ANALYSIS OF EPSTEIN-BARR 
VIRUS TRANSFORMED B CELL LINES
0.5x10 cells from normal and XLA EBV-transformed B 
cell lines were incubated with each of the following 
monoclonal antibodies, 8EB1 (CD19), B1 (CD20), BL13/10B1
(CD21), MHM6 (CD23) and G28-10 (CD39), in 100 microlitres 
of holding medium containing 2% FCS and 0.01% sodium azide 
in LP3 tubes for 30 minutes on ice. Medium alone was used 
as the negative control. The cells were then washed twice 
in cold medium containing 2% FCS and 0.01% sodium azide. 
They were then incubated with 100 microlitres of pre­
titrated fluorescein isothiocyanate (FITC)-conjugated goat 
anti-mouse immunoglobulin for a further 30 minutes on ice. 
they were washed twice and were then analysed on a 
fluorescent activated cell sorter.
3.8 COMPUTER PROGRAMMES USED IN LINKAGE ANALYSIS AND 
GENETIC RISK CALCULATION
LIPED (Ott 1974), a computer programme, has been used 
throughout to analyse the two-point linkage data in the 
family studies and to calculate genetic risk on an IBM-PC. 
HOMOG (Ott 1983), another computer programme, was used to 
assess the problem of non-allelic genetic heterogeneity irt 
X-linked agammaglobulinaemia. The underlying concepts and 
mathematical aspects of linkage analysis and genetic 
heterogeneity are discussed in Chpater 4. The calculation
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of the genetic risk depending on the proportion of 
unlinked families will also be explained fully in Chapter 
4. A small computer programme has been written to help to 
do the calculation of the variation of the genetic risk of 
an individual as the proportion of unlinked families 
varies (appendix 2).
Genetic Studies of XLA Page 59
Chapter 4 GENETIC STUDIES OF X-LINKED AGAMMAGLOBULINAEMIA
4.1 INTRODUCTION
4.1.1 GENETIC LINKAGE
Linkage is the occurence of two loci on one
chromosome sufficiently close together so that something 
less than completely independent assortment takes place 
(McKusick 1969). If two loci are on separate non-
homologous chromosomes, then independent assortment 
occurs. Even if the two loci are on the same chromosome, 
if they are far apart, crossing over can still result in 
independent assortment. The proportion of such crossing- 
overs out of all opportunities for crossing-overs is 
called the recombination fraction, denoted by theta (0). 
For linked gene loci, theta is less than 50% and for 
unlinked gene loci, theta is 50%. Linked loci are on the 
same chromosome and theta is a measure of genetic
distance. For two linked loci, the smaller the theta, the 
smaller is the physical distance between them. However, 
there is no linear relationship between genetic and 
physical distance. A mapping function relating genetic to 
physical distance has been used to translate theta into 
map distance, measured in centimorgan (cM) (Emery 1986). 
For smaller map distance (less than 20 cM), one 
centimorgan means 1% recombination (Emery 1986). One
centimorgan is approximately equivalent to one million 
base pairs in human (Barlow and Lehrach 1987). 
Recombination of X-linked genes can obviously only occur 
in females with two X chromosomes.
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4.1.2 LINKAGE ANALYSIS
The objective of linkage analysis of two loci is to 
determine the value of theta and how significantly smaller 
it is than 0.5. The method most used as developed by 
Morton (1955) is nowadays called the "lod scores" method 
(Ott 1985). The principle of this maximum likelihood 
method of linkage analysis can be described as follows. 
The probability or likelihood, L(0.5), that the observed 
family data conform to the behaviour of two loci under 
full recombination without linkage is calculated. 
Similarly, the likelihood, L(0), that the identical family 
data are the result of two linked loci under a specified 
recombination fraction, 0, is determined. The ratio of 
these two likelihoods, L(0)/L(O.5), is called the odds for 
and against linkage, and expresses the odds for and 
against linkage. This odds ratio has to be determined for 
each family. In order to summate the linkage data for 
different families, it is much more convenient to express 
the odds ratio in decimal logarithm, the so-called lod or 
lod score (logarithm of the odds),
Z(0) = log1O[L(0)/L( O. 5 ) ]   (1)
The lod scores, Z(0), for different families can simply be 
added together to give a combined score for a given 0 
value. To estimate the recombination fraction, one 
calculates Z(0) for the sequence of 0 values from 0 to 
0.5. The value of 0 at which Z(0) is largest is the most 
likely value for the recombination fraction. If Z(0) is
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highest at 0=0.5, negative evidence for linkage is 
obtained. By construction, Z(0)=O in this situation. If 
Z(©) is highest at 0<O.5, evidence for linkage is 
obtained. This maximum value of lod score, Z(0), at the 
most likely recombination fraction ,0, is a statistical 
measure in the test of the null hypothesis of free 
recombination, 0=0.5, against the alternative hypothesis 
of linkage, 0<O.5. Linkage is considered significant when 
Z (0) is equal to or greater than a value of 3, 
corresponding to odds for linkage of at least 1000 to 1. 
Likewise, values of 0 with a lod score of Z(0)<-2 are 
considered very implausible and linkage is excluded at 
these values of 0.
It is important to construct confidence intervals for 
the maximum likelihood estimate of the recombination 
fraction by the lod score method described above. A 
simple method is recommended by the committee on Methods 
of Linkage Analysis and Reporting, Eighth Human Gene 
Mapping Workshop (Conneally et al 1985). A horizontal 
line is drawn at a distance of 1 lod score below the peak 
lod score. The two points of intersection between the 
straight line and the lod score curve mark the two end 
points of the confidence coefficient for 0. The 
associated confidence interval is at least one of 90% and 
better than 95% in large data sets. LIPED, a computer 
programme, has been written (Ott 1974) to compute the lod 
scores at various thetas for each family provided with the 
genotypes of the two loci tested. It takes into
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consideration all the pedigree information and is used in 
most two-point linkage analysis.
4.1.3 HETEROGENEITY
Linkage analysis can reveal disease heterogeneity by 
demonstrating a difference in the recombination fraction 
between disease and marker loci in different families. 
One explanation for this is that the same disease 
phenotype can be casued by mutations at different gene 
loci in different families. Assume there are two types of 
families, those with linkage and those without and the 
disease phenotypes in these two types of families are 
impossible to differentiate between one another at the 
present time. One, therefore, cannot predivide these 
families into linked or unlinked types before performing 
the linkage analysis. Under such circumstances, the 
admixture test (A-test) is used to determine whether the 
data support presence of heterogeneity at a significant 
level, and to jointly estimate the proportion of linked 
families (a) and 9, the recombination fraction in these 
families (Conneally et al 1985, Ott 1983, 1985,1986a). 
The proportion of unlinked families will then be (1-a) 
with 0=0.5. Let Li(0) be the likelihood of the ith family 
and Li(0.5)=l. The corresponding lod score is given by 
Zi(0)=log*LgLi(0). With heterogeneity (Ott 1983), the lod 
score of the ith family becomes
Zi(a,9) = log^Q [aLi(0)+l-a]   (2)
where a denotes a sequence of a-values at which lod scores
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are computed. The pair of values (a,0) at which the total 
lod score
Z(a,0) = 2 l o g 10 [aLi(0)+l-a]   (3)
is highest, determines the maximum likelihood estimates of 
proportion of linked families ,a, and recombination 
fraction of these families, 0. Li(0) is then the
conditional likelihood of the ith family, given that this 
is a linked family, while a is the prior probability that 
any family belongs to the linked group. By Bayes1 formula, 
the posterior probability, wi, that the ith family be 
linked, is given by
wi = aLi(0)/[aLi(9)+l-a]   (4)
When a and 0 in (4) are replaced by their respective 
maximum likelihood estimates (a and 0) one obtains the 
estimated posterior probability, wi, of linkage for the 
ith family. The input data for the A-test are the lod 
scores Zi(0) at a sequence of ©-values for each individual 
family. A computer programme (HOMOG) has been written by 
J. Ott (1983, 1985) to carry out the computations.
Approximate 95% confidence intervals for both a and 0 are 
also given by this programme. The number of families 
required to detect or exclude linkage heterogeneity has 
also been estimated (Ott 1986b).
Subsequently, families can be classified as being of 
the linked group by different rules (Ott 1983). The more 
reliable rule under most circumstances for a family to be
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of the linked group is that wi>a. (Ott 1983, 1985).
4.1.4 RESTRICTION FRAGMENT LENGTH POLYMORPHISM
Bacterial restriction endonucleases recognize 
specific sequences in DNA and catalyze endonucleolytic 
cleavages, yielding fragments of defined lengths. 
Throughout the human genome there are neutral base changes 
that may create or remove restriction endonuclease sites, 
leading to differences in the lengths of restriction 
fragments after digestion of genomic DNA by restriction 
endonucleases (Botstein et al 1980). These restriction 
fragment length polymorphisms (RFLPs) can also result from 
differing copy numbers of a simple tandemly repeating 
sequence within a fragment (Jeffreys et al 1985, Wong et 
al 1986). RFLPs are inherited as simple Mendelian co­
dominant markers and provide a potentially large number of 
linkage markers for following disease genes through 
families (Botstein et al 1980). The technique to analyse 
the pattern of RFLPs is called Southern blotting (Southern 
1975), described in Chapter 3, this thesis. The DNA probe 
used to reveal the RFLPs can either be the gene of 
interest or just recombinant DNA sequence of no function 
from various sources, such as human genomic or cDNA 
libraries (Botstein et al 1980), or X-chromosome library 
(Davies et al 1981). For monogenic diseases with unknown 
underlying defects, it is now possible to map the gene 
loci by linkage analysis as long as there are recombinant 
DNA probes which reveal RFLPs near enough to the gene 
loci. It has been calculated in order to provide an
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adequate genetic map for the entire human genome of 33 
Morgans in length, one would need at least 150 polymorphic 
DNA probes evenly spaced at about 0.2 Morgans (Botstein et 
al 1980). For the human X-chromosome, there are now more 
than 20 well characterised DNA marker loci with RFLPs 
spanning a genetic length of about 200 recombination units 
(Drayna and White 1985, Davies 1985). The distribution of 
these RFLP markers on the X-chromosome is such that any X- 
linked disease locus will map within ten recombination 
units of two markers provided enough informative families 
are available for linkage analysis.
One potential limitation of this approach is the 
degree of polymorphism of the RFLP marker loci, which 
should have at least two alleles with appreciable 
frequency. The maximum rate of heterozygosity of any two 
alleles RFLP marker is only 0.5 when the frequency of each 
allele being 0.5. The more polymorphic a locus is, the 
more useful it is for linkage analysis. One way to 
measure the degree of polymorphism is the polymorphism 
information content (PIC) (Botstein et al 1980). The PIC 
is the probability that an offspring of a random mating 
between a carrier of a rare dominant gene and a non­
carrier is informative for linkage between the locus of 
the dominant gene and the marker locus. As more and more 
RFLP markers are defined, this aspect should not be a 
major limiting step in the linkage analysis. For rare 
genetic diseases, the availability of informative families 
is the major limitation. The number of families required
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to establish linkage depends on the size and structure of 
the pedigrees as well as the degree of linkage between the 
disease locus and RFLP marker used. Multigenerational 
pedigrees are more useful than nuclear families and large 
families give considerably more information than smaller 
families (Botstein et al 1980). Less families are needed 
if the linkage between disease locus and the RFLP marker 
is tight.
4.2 LINKAGE ANALYSIS BETWEEN X-LINKED AGAMMAGLOBULINAEMIA
AND RANDOM DNA FRAGMENTS FROM Xq21.3-q22
The underlying defect of X-linked agammaglobulinaemia 
(XLA) is still unclear and there is no immunological 
method of detecting carriers (Chapter 1, this thesis). 
Carrier detection is however feasible by demonstrating the 
pattern of non-random X-chromosome inactivation which is 
present in the B cells of female carriers (Fearon et al 
1987) but the techniques are difficult. Prenatal 
exclusion based on B-cell enumeration has been performed 
but it is only limited to mid-trimester fetal blood 
samplying (Durandy et al 1986). Furthermore the 
heterogeneity with respect to the presence or absence of B 
cells in some XLA patients (Leickley and Buckley 1986) 
renders this approach unreliable for prenatal diagnosis. 
An alternative strategy of offering carrier detection and 
prenatal diagnosis in monogenic diseases of unknown 
aetiologies is to localise the defective gene by linkage 
analysis with DNA probes. Using the approach of gene 
tracking, such genetic prediction then becomes feasible
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(Pembrey 1986). We therefore started a family linkage 
study of XLA two-and-a-half years ago with this objective 
in mind.
X-chromosomes of all mammals are thought to carry 
homologous genes as a special method of control is 
involved in X-chromosome inactivation which would make it 
difficult for genes to be exchanged between the X- 
chromosome and autosomes during evolution (Lyon 1988). 
Since the X-linked immunodeficiency disease (xid) gene in 
the mouse has been mapped between PGK (phosphoglycerate 
kinase) and Ags (alpha-galactosidase) (Berning et al 
1980), it has been thought that the human X-linked 
immunodeficiency genes might also be mapped to a 
comparable location at the middle of the long arm of the 
human X chromosome. Indeed, two separate and parallel 
family studies of XLA (Kwan et al 1986, Mensink et al 
1986a) were published during the tenure of my research 
fellowship demonstrating linkage of the XLA gene locus to 
DXS17 (S21) and DXS3 (19.2) in the region of Xq21.3-q22. 
By that time, we have collected 12 XLA families suitable 
for linkage analysis and in colloboration with a French 
group headed by Professor C. Griscelli in Paris and Dr. J. 
L. Mandel in Strasbourg who contributed data from 3 XLA 
families, we also mapped the XLA gene locus to Xq21.3-22 
with probes S21 and 19.2? in addition we demonstrated 
close linkage with a further probe pXG12 (DXS94) (Malcolm 
et al 1987). The results of this linkage study and of the 
clinical application in genetic counselling in these
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families are presented in this chapter.
4.2.1 LINKAGE OF 19.2, S21 AND pXG12 IN FAMILIES WITH XLA
DNA from members of the XLA families were analysed 
by Southern blotting for RFLPs using the probes 19.2, S21 
and pXG12. The 15 XLA families which were used for the 
linkage analysis are families 1-8, 10-12 and 14 (Figure 2- 
1) plus the 3 French families. The RFLP data with the 3 
probes, viz 19.2, S21 and pXG12 are shown in table 3 and 
the pedigrees with the RFLP data of S21, pXG12 and/or 19.2 
are shown in figure 4-1. 19.2 detects a Taq 1 polymorphism 
with alleles of 5.0 kb or a doublet of 2.9 and 2.2 kb? S21 
a Taq 1 polymorphism with alleles 2.2 kb and 2.0 kb? pXG12 
a Pst 1 polymorphism with alleles 7.2 kb and 6.5 kb.
9 families were informative for linkage analysis with 
19.2, 10 families with S21 and 11 families with pXG12.
The RFLP data for each probe were analysed by the computer 
programme, LIPED (Ott 1974) to test for linkage with the 
XLA disease locus. For LIPED one has to specify the gene 
frequencies at each gene locus. Since XLA is a rare 
disease of unknown frequency, its gene frequency was 
arbitrarily set at 0.0001, which is the lowest allowed for 
in LIPED (Ott 1985). Hence the gene frequency of the
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Table 3
RFLP DATA OF TNE 15 XLA FAMILIES AND ONE X-LINKED HYPERIgM FAMILY
Family Individual 19.2 pXG12 S21
1 1-1 (O.C.) 1,2 1,2 1,2
1-3 1 2 1
1-6 nd 1,2 1,2
1-9 nd 1 2
1-10 nd 1,2 1,2
1-11 1 1 1
1-12 (O.C.) 1,2 1,2 1,2
1-13 1 1 1
1-14 (O.C.) 1,2 1,2 1,2
II-l 1 2 1
II-2 1 2 1
II-3 (aff) 1 2 1
II-5 nd 1,2 1,2
II-7 nd 1,2 1,2
II-8 nd 1,2 1,2
11-11 1 2 1
11-12 1,2 1 1,2
11-13 1 1,2 1
11-14 1,2 1 1,2
11-15(aff) 1 2 1
III-l 1,2 2 1
(continued next page)
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Table 3 (continued)
Family Individual 19.2 pXG12 S21
1 III-2 1 1,2 1
III-4 nd 2 1
III-5 1/2 1/2 1
III-6 2 1 2
III-8 nd 1 2
2 1-1 (O.C.) 1,2 2 1,2
1-2 (O.C.) 1,2 2 1,2
1-3 2 2 1
1-4 1,2 2 1/2
II-l 2 nd 2
II-2 (aff) 1 nd 1
II-4 (aff) 1 nd 1
II-5 1/2 2 1
iHH 2 nd 2
3 1-1 nd 1 1
1-2 (O.C.) 2 1,2 1/2
II-l 1,2 1 1/2
II-2 2 2 1
II-3 (aff) 2 1 2
r-"iHH nd 2 1
III-2 nd 1 1
(continued next page)
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Table 3 (continued)
Family Individual 19.2 pXG12 S21
4 1-1 nd 2 1
1-2 nd 1,2 2
II-l (O.C.) 2 1,2 1,2
II-2 nd 1 2
II-3 nd 2 2
II-4 nd 2 1,2
III-l(aff) nd 1 2
III-2(aff) nd 1 2
III-3 nd 2 1
III-4 nd 2 2
5 1-1 nd 2 1
1-2 nd 1 nd
II-l (O.C.) 1,2 1,2 1
II-2 nd 1 1
III-l(aff) 2 2 nd
III-2 1 1 nd
III-3(aff) 2 2 nd
6 1-1 nd 1 nd
1-2 nd 1,2 1
11-1(0.C.) 1,2 1,2 1
II-2 nd 1 nd
COIHH nd 1,2 1
II-4 nd 1 nd
III-l(aff) 1 2 nd
III-2(aff) 1 2 1
(continued next page)
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Table3 (continued)
Family Individual 19.2 pXG12 S21
7 1-2 (O.C.) 2 1,2 1,2
II-l (O.C.) 2 2 1
II-2 (O.C.) 2 2 1
II-3 nd 2 1
II-4 nd 2 1
II-6 nd 1 2
lHH nd 1 2
III-l(aff) nd 2 1
III-2 nd 2 1
III-3(aff) 2 2 1
III-4(aff) 2 2 1
8 1-2 nd 1,2 1,2
II-l (O.C.) 2 2 lr2
II-2 nd 1,2 1
III-l(aff) 2 nd 2
III-2(aff) 2 nd 2
9 1-1 nd 2 1
1-2 nd 2 1,2
«H1HH nd nd 2
II-2 (O.C.) nd 2 1,2
II-3 nd 2 1,2
III-2(aff) nd 2 1
III-3 nd 2 1,2
(continued next page)
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Table 3 (continued)
Family Individual 19.2 pXG12 S21
10 1-1 2 1 nd
1-2 1 1,2 nd
II-2 (O.C.) 1,2 1,2 1
II-3 1 2 nd
II-6 1,2 1,2 nd
II-7 1,2 1 nd
III-l(aff) 2 1 nd
III-2(aff) 2 1 nd
III-3(aff) 2 1 nd
11 1-1 nd 1 nd
1-2 (O.C.) 1 1,2 1
II-l (O.C.) 1 1,2 1
III-2(aff) 1 2 1
12 I-2 1,2 1,2 1,2
II-2 (O.C.) 2 2 1,2
II-5 1 1 1
II-6 1 nd 1
III-l nd nd 1
III-2(aff) nd nd 2
III-3(aff) nd nd 2
III-4(aff) nd nd 2
(continued next page)
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Table 3 (continued)
Family Individual 19.2 pXG12 S21
13 1-1 nd nd 1
1-2 nd nd 1/2
II-l (aff) nd nd 1
II-2 nd nd 2
14 1-2 (O.C.) 1/2 1 1
II-l (aff) 1 1 nd
II-2 (aff) 1 1 nd
II-3 (aff) 2 1 nd
15 1-1 (O.C.) 2 1/2 1,2
1-2 1 1 1
II-l (O.C.) 1/2 1/2 1/2
II-5 (O.C.) 1/2 1 1
III-l 2 2 2
III-9 2 nd nd
19 1-1 (O.C.) 1/2 2 1,2
X-linked
hyperlgM II-2 2 2 1
II-5 (O.C.) 1/2 1/2 1
II-6 (O.C.) 1/2 1,2 1
III-l 1 1 1
III-2 2 2 1
III-5(aff) 2 2 1
III-8 1 1 1
O.C. = obligate carrier
aff. = affected
nd = not done
allele 1 = larger fragment
allele 2 = smaller fragment(s)
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normal allele at the XLA gene locus was set at 0.9999. 
The gene frequencies of the two alleles of each probe were 
set at the known values. The input and output files of 
LIPED for each of the three probes are included in 
appendix 3. The summation of lod scores at various theta 
values for the three probes against the XLA locus are 
given in table 4. No recombination was found with using 
S21 or pXG12. One cross-over was observed with 19.2 in a 
family which was non-informative for either S21 or pXG12 
(family 14).
4.2.2 MAPPING OF PXG12
pXG12 was originally mapped to the proximal part of 
the long arm of the X chromosome (Davatelis et al 1985, 
Goodfellow et al 1985). Two lines of evidence now suggest 
it lies between 19.2 and S21. In a man with 
choroideraemia but normal immunity, high resolution 
chromosome studies showed that the band Xq21 was about 
half its normal size, probably due to a deletion of sub­
band Xq21.1 (Hodgson et al 1987). DNA studies from him 
showed both the X loci of DXYS1 (pDP34) and DXS3 (19.2) 
were deleted but not the locus of DXS17 (S21). A clear 
6.5kb allele of pXG12 was however observed (Figure 4-2), 
showing that pXG12 lies outside the DXYS1-DXS3 segment. 
Evidence that it falls below 19.2 rather than above pDP34 
comes from a multipoint linkage analysis of 44 families, 
which suggests the order being centromere-pDP34-19.2- 
pXG12-S21 (Arveiler et al 1987a).
Page 7 6
Table 4
LOD SCORES FOR FAMILIES WITH XLA
LOD SCORES
LOCUS DXS 3 DXS 94 DXS 17
Probe 19.2 pXG12 S21
©=0.00 0.49 6.75 4.90
©=0.01 3.39 6.62 4.79
©=0.05 3.68 6.10 4.35
©=0.10 3.46 5.41 3.78
©=0.15 3.09 4.71 3.21
©=0.20 2 . 66 3.98 2.63
©=0.25 2.20 3.23 2.06
©=0.30 1.71 2.48 1.51
©=0.35 1.23 1.75 1.01
©=0.40 0.78 1.06 0.56
©=0.45 0.36 0.46 0.22
Combined lod scores for various recombination fractions (©) 
between XLA locus and the listed loci in 15 XLA families 
(families 1-8, 10-12, 14 and three French families).
a b
6.5kb
Pst1/pXG12
Figure 4 - 2  Autoradiograph showing the 6 .5kb al lele of pXG 1 2 
in a man with choroideraemia and delet ion of sub­
band Xq21.1  ( iane b), normal female ( lane a).
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4.2.3 DISCUSSION
Although XLA has now been mapped to Xq21.3-q22 (Kwan 
et al 1986, Mensink et al 1986a, Malcolm et al 1987), a 
comparable region of the X chromosome as the xid gene 
locus in the mouse (Berning et al 1980, Lyon 1988), the
two diseases (XLA and xid) are not strictly analogous in
their phenotypes. XLA results in decreased immunoglobulin 
of all isotypes in man while xid results in impairment of 
antibody response to polysaccharide antigens in mouse 
(Scher 1982). Moreover, several human X-linked 
immunodeficiencies such as Wiskott-Aldrich syndrome and X- 
linked severe combined immunodeficiency have been mapped 
to outside this homologous region (Peacocke and
Siminovitch 1986, de Saint Basile et al 1987). Hence, 
there does not seem to be a family of genes in this region 
of the human X chromosome which is analogous to the family 
of XLR genes which are linked to the xid in mouse (Cohen 
et al 1985 a&b).
Kwan et al (1986) was the first to find linkage of 
XLA with 19.2 at 9=0.04 with a lod score of 3.65 and with 
S21 at 9=0 with a lod score of 2.17. Mensink et al
(1986a) soon confirmed the linkage of XLA with 19.2 in a 
large pedigree, 66-8, with a lod score of 3.3 at 9=0.06, 
but presented a family, Z, with indistinguishable 
phenotypes from XLA and which had a lod score of -3.14 at 
9=0.06. Using the same set of nine families, Ott et al 
(1986) demonstrated two families, Z and EsB, have negative 
lod scores at the location of the S21 locus by multi-point
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linkage analysis and hence appear not to be linked to the 
region of the S21 locus. The other seven families show 
linkage of XLA to S21. Hence the hypothesis of 
heterogeneity with one linked and one unlinked type is 
much more favoured than that of homogeneity (Ott et al 
1986). Our data certainly confirmed the linkage of XLA 
with 19.2 at 0=0.04 with a lod score of 3.69 and with S21 
at 0=0 with a lod score of 4.90 (Table 4). We also 
extended the linkage of XLA with another proble pXG12 with 
a lod score of 6.75 at 0=0 (Table 4). In this linkage 
study of 15 families (3 families from the French group), 
we have no evidence for genetic heterogeneity. However, 
it does not prove there is no heterogeneity as the number 
of families required to detect heterogeneity can be quite 
large depending on the proportion of linked families (a), 
the value of theta between the disease and marker as well 
as the structure of the families (Ott 1986b). Generally, 
the lower the proportion of linked families and the higher 
the 0, the more families one would need to detect 
heterogeneity at a significant level. Therefore, we may 
simply not have enough families to detect heterogeneity.
On the other hand, there are alternative explanations 
for the observed heterogeneity in families Z and EsB as 
reported by Mensink et al (1986a) and Ott et al (1986). 
The data from family EsB is not totally reliable as one 
female (II-l) was assigned as being a carrier on the basis 
that one of her sons born before 1950 died between 2 
months and 8 years of age (Mensink et al 1986a). For
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family Z, Ott et al (1986) has suggested a possible 
autosomal dominant and male limited inheritance, but no 
affected male has been reported to produce an affected 
son. This hypothesis can be tested by examining the B 
cells of the female carriers in this family for pattern of 
X-chromosome inactivation (Fearon et al 1987, Conley et al
1986). If the inheritance in family Z is autosomal, the 
pattern of X-chromosome inactivation should be random. 
Another explanation has been proposed by Mensink et al 
(1987a) that grandfather (1-1) in family Z could be a 
mosaic in his germ line, in which case grandmother (1-2) 
is not a carrier and no recombination need to be 
postulated between XLA and S21. This phenomenon of germ 
line mosaicism has been demonstrated in Duchenne's 
muscular dystrophy (Darras and Francke 1987) with the 
partial deletion of the muscular dystrophy gene 
transmitted twice by an unaffected male.
S21 and 19.2 were placed within bands Xq21.3-q22 
(Goodfellow et al 1985). The recombination fraction 
between 19.2 and S21 was estimated to be 0.10, that 
between 19.2 and pXG12 0.04 and that between pXG12 and S21 
0.02 (Arveiler et al 1987a). The same study suggested on 
multipoint linkage that the order is centromere-19.2- 
pXG12-S21. Our maximum likelihood estimates of theta of 
0.04 for 19.2 and of 0 for both pXG12 and S21 in these 
families agree reasonably well with these map distances. 
However due to lack of recombination events in these 
families, we are not able to place XLA exactly within the
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cluster of centromere-19.2-pXG12-S21 (Arveiler et al
1987). The XLA locus should nevertheless be nearer to 
pXG12-S21 than 19.2, based on the fact that recombination 
was found with 19.2 but not with pXG12/S21 as well as that
19.2 was deleted in a man with choroideraemia and normal 
immunity, but not pXG12.
The issue of non-allelic genetic heterogeneity has 
certainly complicated the use of linked RFLPs in carrier 
detection and prenatal diagnosis of XLA. In the following 
section, further evidence of heterogeneity from another 
family (family 15) will be presented and the published 
data reviewed together with our own data to ascertain the 
extent of heterogeneity.
4.3 NON-ALLELIC GENETIC HETEROGENEITY
Similar disease phenotypes which cannot be easily 
distinguished clinically can be the result of mutations at 
different gene loci. This phenomenon is called non­
allelic genetic heterogeneity. Linkage analysis has the 
potential to reveal such genetic heterogeneity, such as 
that in insulin-dependent diabetes mellitus (Harris et al 
1985). Another X-linked immunodeficiency disease, X- 
linked lymphoproliferative disease (XLP), has been mapped 
to Xq24-qter by linkage with the probe p43-15 (DXS42) in 
one large pedigree (Skare et al 1987). However, in a 
study of 3 XLP families, Harris et al (1988) could find no 
evidence for linkage of the XLP locus to probes in the 
region Xq24-qter and their data suggested the XLP locus is
Genetic Studies of XLA Page 81
unlikely to be within Xq21.3-qter region. This may be due 
to the small numbers of individuals analysed in their 
study. Alternatively, the single family reported by Skare 
et al (1987) may represent a different genetic disease but 
with similar phenotype. For X-linked agammaglobulinaemia 
(XLA), there is also evidence of non-allelic genetic 
heterogeneity (Ott et al 1986).
4.3.1 FAMILY 15
Subsequent to our original linkage study of XLA as 
described above, another XLA family (family 15) was made 
available for linkage analysis through Dr. Donnai, 
Manchester. This family was first reported by Jamieson 
and Kerr in 1962. The only affected surviving male is in 
Canada and was reinvestigated recently by Dr Roifman, 
Toronto; he was found to have the characteristic 
immunological profile of XLA. The pedigree of family 15 
is shown in figure 4-1 together with the S21 and 19.2 RFLP 
data; the RFLP data are also shown in table 3. There were 
at least two recombinations between the disease locus and 
that defined by S21 out of the three observed meioses; 
there were no recombinations among the three probes. 
LIPED was used to test for linkage of the XLA gene locus 
in this family with S21 and 19.2. The input and output 
files are included in appendix 4. Negative lod scores 
were obtained at all theta values indicating no evidence 
of linkage was present. Moreover, the lod scores for the 
S21 data at theta=0.03 is more negative than -2.0, hence 
linkage is excluded at theta values under 0.03. Germline
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mosaicism cannot explain the two recombinations observed 
in family 15. Together with family Z from Ott et al 
(1986), there are now at least two XLA families which 
appear not to be linked with S21.
4.3.2 ADMIXTURE TEST
To assess the extent of non-allelic genetic 
heterogeneity in XLA, as much linkage data as possible was 
obtained from the published literature (Kwan et al 1986, 
Mensink et al 1986a, 1987a, Ott et al 1986) which was then 
combined with our own data for the admixture test (Ott 
1983). It was analysed with respect to both S21 and 19.2 
only because no other data with pXG12 have been published 
other than our own (Malcolm et al 1987). For 19.2, the 
lod scores for each individual family at various theta 
values were obtained by analysing the raw RFLP data of 
Mensink et al (1986a) using LIPED (8 families) and by 
assuming the 10 families of Kwan et al (1986) contributed 
evenly to the total lod score published. Together with 
our 10 families which are informative for 19.2, there are 
28 families available for the admixture test. Similarly 
for S21, the lod scores for each individual family at 
various theta values were obtained by analysing the raw 
RFLP data of family Z (Mensink et al 1987a) using LIPED, 
by plotting the lod score versus theta curve for family 
66.8 (Mensink et al 1987a) and by assuming the 4 families 
of Kwan et al (1986) contributed evenly to the total lod 
score. Together with our 11 families which are 
informative for S21, there are 17 families available for
Genetic Studies of XLA Page 83
^  /Q m •« « p 4 *i i ^ a a  4*^  « 4 -  
U A i C  a U l l l J . A  U U J . C  t C O  t  •
For input data to run the HOMOG, a computer programme 
which executes the computation of the admixture test (Ott 
1983), the lod scores of each individual family at the 
desired theta values are required. Several runs of the 
HOMOG were initially executed to determine the range and 
interval of the desired theta values for 19.2 and S21 
separately. It was then run at interval of 0.01 for the 
proportion of linked families (a). The output files for 
both 19.2 and S21 are included in appendix 5.
For 19.2, the estimated proportion of linked familes 
(a) is 0.87 with a 95% confidence intervals of 0.52 to 1. 
The estimated recombination fraction (0) of the linked 
families is 0.06 with a 95% confidence intervals of 0.04 
to 0.16. For S21 with a smaller set of families to 
analyse, the corresponding values of a is 0.83 (95%
confidence interval being 0.46 to 0.98) and 0 is 0.00 (95% 
confidence interval being 0.00 to 0.02). The HOMOG also 
tested the hypothesis of heterogeneity with one linked and 
one unlinked family type (H2) versus the hypothesis of 
homogeneity of linkage (HI) as well as versus the 
hypothesis of no linkage (HO). The components of chi- 
square in approximate chi-square tests (df=degree of 
freedom) are given for both 19.2 and S21 as follows.
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Components df
19.2
Chi-square p-value
S21
Chi-square p-value
H2 VS HI 1 2.7 0.0515 12.7 0.0002
HI VS HO 1 42.2 <0.0001 27.1 <0.0001
H2 VS HO 2 44.8 <0.0001 39.7 <0.0001
Both 19.2 and S21 data support the hypothesis of 
heterogeneity more than that of homogeneity, with S21 at a 
much more significant level than 19.2, because S21 is much 
more closely linked with the disease locus (9=0.00 to 
0.02) than 19.2 (9=0.04 to 0.16).
The posterior probability of the ith family being the 
linked type (wi) is also computed with confidence limits 
corresponding to the calculated 95% confidence intervals 
of both the proportion of the linked families (a) and 
theta. The value of wi takes into account of the linkage 
data of all other families as well as that of the ith 
family. The calculated values of wi and the 95% 
confidence limits for our families and families Z and 66-8 
of Mensink et al (1987a) from the analysis of both S21 and 
19.2 data by the admixture test are shown in table 5.
All our families with S21 linkage data apart from 
family 15, have a probability (wi) of over 80% of
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Table 5
POSTERIOR PROBABILITY OF LINKAGE OF FAMILIES WITH XLA
Family name Family
POSTERIOR PROBABILITY OF 
S21 19-2
LINKAGE (wi)
Pomfrett 1 0.95 (0.77-0.99) 0.96 (0.79-1.00)
Lucken 2 0.96 (0.82-1.00) 0.97 (0.82-1.00)
Rushin 3 0.95 (0.77-0.99) ni
Kirsopp 4 0.91 (0.63-0.99) ni
Barton 5 ni 0.96 (0.79-1.00)
Williams 6 ni 0.92 (0.66-1.00)
Pattersen 7 0.95 (0.77-0.99) ni
Cox 8 0.91 (0.63-0.99) ni
Crabbe 9* 0.83 (0.46-0.98) 0.87 (0.52-1.00)
Parry 10 ni 0.96 (0.79-1.00)
Berryman/Fox 11 ni ni
Gerrard 12 0.98 (0.87-1.00) ni
Lindridge 13* 0.83 (0.46-0.98) 0.87 (0.52-1.00)
Mann 14 ni 0. 60 (0.15-1.00)
15 0.00 (0.00-0.04) , 0.60 (0.15-1.00)
Z 0.00 (0.00-0.07) 0.00 (0.00-1.00)
66-8 1.00 (1.00-1.00) 1.00 (1.00-1.00)
Posterior probability of linkage of each XLA family using 
RFLP data from S21 or 19-2 in the Admixture test; 95% 
confidence limits shown in brackets.
* = families with no linkage data
ni = not informative for RFLP tested
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belonging to the linked group of families. The value of 
wi and its 95% confidence limits for each individual 
family depend on the maximum lod score, Zi(0) of an 
individual family. The higher the value of Zi(9) of an 
individual family, the higher the value of wi is and the 
tighter the 95% confidence limits of wi will be. When 
Zi(0) is greater than 0.3, wi is greater than 0.9. As 
Zi(0) rises above 0.9, wi becomes greater than 0.97. In a 
family with no linkage data of S21, i.e. Zi(9)=0, wi is 
the same as (a), the estimated proportion of linked 
families, which is 0.83. For families Z and 15 which 
appear unlinked to the locus of S21, wi is zero with the 
upper confidence limits less than 8%.
Similar observations are made from the analysis of 
the 19.2 linkage data by the admixture test, although the 
estimated proportion of the linked families (0.87) is 
slightly greater than that from S21 data (0.83). It is 
because there are more families with 19.2 data available.
4.3.3 DISCUSSION
With the knowledge of the likely proportion of linked 
families (a) and the posterior probability of each family 
of being the linked type (wi), it may be feasible to use 
the linked probes for genetic counselling in the families 
classified as of being the linked group by wi>a (Ott 1983, 
1985). This aspect is explored fully in the next section.
The identification of a subgroup of XLA families 
unlinked to Xq21.3-22 will be important in refining the
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classification of XLA so as to see whether there is any
difference in clinical features and prognosis between the
two groups. It may also facilitate the discovery of 
immunological differences between the subgroups of
families.
In diseases with non-allelic genetic heterogeneity, 
detecting linkage by traditional 2-point linkage analysis 
is much less effective in circumstances where the 
proportion of linked families (a) is small even though the 
recombination fraction, 0, of the linked probe used is 
small. It is because in the overall population, the 
chance that the probe will fail to cosegregate with the 
disease through a meiosis is the "apparent" recombination 
fraction 0 f=0a+l/2(1-a) (Lander and Botstein 1986). 
Therefore if one neglects to take account of even a modest 
degree of heterogeneity, linkage can be missed entirely. 
In the case of XLA, it is fortunate that the proportion of 
linked families is greater than 0.8 and theta for S21 is 
still zero, otherwise linkage with Xq21.3-q22 could be 
easily missed by the 2-point linkage analysis. Realising 
the weakness of 2-point linkage analysis in mapping 
heterogenous genetic traits, Lander and Botstein (1986) 
proposed two strategies, viz interval mapping and 
simultaneous search, which utilize a complete RFLP linkage 
map of the human genome. The construction of such a map 
has already been attempted (Donis-Keller et al 1987). 
Interval mapping involves testing whether a putative locus 
lies in an interval of known size between two adjacent
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markers. This is a more demanding hypothesis, and hence 
one easier to test, than whether the locus is linked to a 
single marker at an unknown distance. Simultaneous search 
involves testing several trait-causing loci simultaneouly, 
therefore in a heterogenous disease, at least one of the 
loci will appear to cosegregate with the disease in every 
family. By using these strategies, it is estimated only 
1/3 as many affected families are needed to map a 
heterogeneous trait and only 1/5 to 1/50 as many are 
needed to detect that genetic heterogeneity is present. 
(Lander and Botstein 1986).
4.4 GENETIC PREDICTION IN X-LINKED AGAMMAGLOBULINAEMIA 
USING S21 AND PXG12
Excluding the two unlinked families Z and 15, the
combined maximum lod score for S21 versus XLA locus in the
15 linked families published (4 families from Kwan et al
1986, family 66-8 from Mensink et at 1987a, 10 families 
from Malcolm et al 1987) is 10.5 at a recombination 
fraction 9 of 0 with 90-95% confidence intervals 0 to 0.04 
(Lau et al 1988b) as defined by taking the range of 0 at 
one less than the maximum lod score (Conneally et al 
1985). Since our original publications (Malcolm et al
1987, Lau et al 1988b), the maximum lod score for S21 for 
the 15 linked families above has been increased to 10.97 
at 0=0 with a 90-95% confidence intervals 0 to 0.02, due 
to increase in lod score in one of our families. The lod 
score value of 10.97 has not included the lod scores of 
several families from Ott et al (1986) which were shown to 
be linked to the locus of S21 by multi-point linkage
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analysis. In these 15 linked families, 
meioses were observed with no recombination between the 
XLA locus and S21. 22 informative meioses were observed
with no recombination with pXG12 in 11 XLA families in our 
original linkage study (Malcolm et al 1987). Since the 
recombination fraction between pXG12 and S21 was estimated 
to be 0.02 (Arveiler et al 1987a), we decided to use S21 
and pXG12 in genetic counselling of XLA families, quoting 
a recombination fraction of 0.04 (Lau et al 1988b). A 
method of risk calculation has also been developed to 
allow for non-allelic genetic heterogeneity.
4.4.1 METHOD OF ALLOWING FOR NON-ALLELIC GENETIC 
HETEROGENEITY
To allow for non-allelic genetic heterogeneity, a 
method of risk calculation has been developed which will 
incorporate the probability of linkage within each 
individual family as well as a specified proportion of 
unlinked families (Lau et al 1988b). As estimated by the 
admixture test above the proportion of unlinked families 
is likely to be between 10% and 20% on the present 
published evidence. The true figure for the proportion of 
unlinked families is uncertain but one can show what 
effect using figures between 10% and 30% have on final 
prediction in any particular family.
The formal calculations are as follows. For any 
individual the probaility of a specific XLA genotype, 
given the pedigree and marker (RELP) data, can be 
expressed as:
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Pr(genotype,pedigree)
Pr(genotype|pedigree) = ----------------------  ..(5)
Pr(pedigree)
If there is genetic heterogeneity the numerator and 
denominator in this expression (5) will be made up of two 
parts, depending on whether the pedigree is linked or 
unlinked, for example the numerator will be
Pr(linked).Pr(genotype,pedigree|linked) +
Pr(unlinked).Pr(genotype,pedigree|unlinked) ... (6)
In the first part of the above expression (6), the
prior probability that the disease segregating in that 
pedigree is in fact linked with the marker locus is 
multiplied by the probability of the specific genotype in 
the individual in question and the pedigree data given 
that the disease is linked to the marker (9=0.04). In the 
second part of the expression (6), it is assumed that the 
disease is not linked to the marker (i.e. 0=0.5).
Probability (5) can therefore be expressed as:
Pr(linked).Pr(genotype,pedigree|linked) +
Pr(unlinked).Pr(genotype, pedigree|unlinked) _  ... (7)
Pr(linked).Pr(pedigree|linked) +
Pr(unlinked).Pr(pedigree|unlinked)
Pr( pedigree | linked) is the probability of the
pedigree assuming the XLA genotype of the individual at 
risk is unknown and given that the disease is linked to 
the marker. These probabilities, together with their 
equivalents where the disease is unlinked to the marker, 
can be obtained from the computer programme LIPED (Ott
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1974), in which recent versions give specific instructions 
for risk calculation. Pr(unlinked) can be varied from 0 
to 1 to see its effect on final genetic risk of an 
individual in any particular family. A computer programme 
has been written to calculate the risk of an individual of 
being a specified genotype as Pr(unlinked) varies in 
expression (7) (Appendix 2). The input data for this 
programme are the values of the probabilities of the 
pedigrees in expression (7) which can be obtained from 
LIPED.
4.4.2 CARRIER DETECTION AND PREDICTION IN MALES
Out of 13 XLA families counselled (families 1-13), 11 
were studied previously (Malcolm et al 1987) and 
demonstrated linkage between the XLA locus and probes S21, 
pXG12 and 19-2. One of the other two families has only 
one affected male living, with an affected brother who 
died. One family (family 13) contains a single affected 
male with the mother originally planning for abortion of 
any male fetus but opted for prenatal exclusion when she 
learnt that it was feasible. The pedigrees and the 
segregation of the S21 and/or pXG12 alleles of these 13 
XLA families (families 1-13) are shown in figure 4-1. 
Table 6 lists all obligate and potential female carriers 
as well as a newborn male and a male fetus at risk from 
the 13 families, giving risk estimates and the possibility 
of prenatal diagnosis. The final risks combining pedigree
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Table 6
PREDICTION OF GENETIC RISKS IN XLA FAMILIES
Subj ects
Pedigree risk 
(%)
Pedigree + DNA risk 
(%) when proportion of 
unlinked families is:
0 0.1 0.3
Prenatal pre­
diction with 
S=S21/X=XG12
Family 1
1-1 100 (O.C.) i >45 years
1-12 100 (O.C.) >45 years
1-14 100 (O.C.) >45 years
1-6 27.27 24.17 24.23 24.38 >45 years
1-10 50 50 50 50 >45 years
II-l 50 95.98 95.08 92.71 ni
II-2 50 95.98 95.08 92.71 ni
II-5 9.09 1.48 1.62 2.01
II-7 25 48.13 47.69 46.53 S+X
II-8 25 48.13 47.69 46.53 S+X
11-12 33.33 2.05 2.64 4.22
11-13 50 95.99 95.12 92.8 X
11-14 20 1.04 1.34 2.16
III-l 25 48 47.57 46.4 ni
III-2 25 48 47.57 46.4 X
III-5 16.67 1.03 1.32 2.11
(continued next page)
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Dable 6 (continued)
Subj ects
Pedigree risk 
(%)
Pedigree + DNA risk 
(%) when proportion of 
unlinked families is:
0 0.1 0.3
Prenatal pre­
diction with 
S=S21,X=XG12
Family 2 
1-1 
1-2
I-4
II-5
100 (O.C.) 
100 (O.C.) 
33.35 
16.68
58.15 57.7 56.49 
55.82 55.11 53.21
>45 years 
>45 years 
>45 years 
ni
Family 3 
1-2
II-l
III-2*
100 (O.C.) 
20
16.67
92 89.29 82.55 
3.69 4.25 5.62
>45 years 
S
Family 4 
1-2 
II-l
II-4
III-4
27.28 
100 (O.C.) 
9.1 
4.57
10.32 11.5 14.1
3.46 3.85 4.71 
1.75 1.94 2.38
>45 years 
S+X
Family 5 
1-2 
II-2
33.34 
100 (O.C.)
0.02 1.52 5.14 >45 years 
X
(continued next page)
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Cable 6 (continued)
Subj ects
Pedigree risk 
(%)
Pedigree + DNA risk 
(%) when proportion of 
unlinked families is:
0 0.1 0.3
Prenatal pre­
diction with 
S=S21,X=XG12
Family 6 
1-2 
II-l 
II-3
20
100 (O.C.) 
10
63.86 62.7 59.69 
61.3 59.94 56.43
>45 years
X
X
Family 7 
II-l 
II-2 
II—3 
II-4
100 (O.C.) 
100 (O.C.) 
50
33.33
96 94.94 92.16 
92.31 90.95 87.39
>45 years 
>45 years 
>45 years 
>45 years
Family 8 
1-2 
II-l 
II-2
50
100 (O.C.) 
25
66.63 65.98 64.4 
5.15 5.92 7.82
>45 years 
S
Family 9 
1-2 
II—2
II-3
III-3
42.86 
100 (O.C.) 
14.3 
50
4.16 10.24 20.35
3.56 5.25 8.05 
88.65 82.58 72.49
>45 years 
S
S
(continued next page)
Page 95
Cable 6 (continued)
Subj ects
Pedigree risk 
(%)
Pedigree + DNA risk 
(%) when proportion of 
unlinked families is:
0 0.1 0.3
Prenatal pre­
diction with 
S=S21,X=XG12
Family 10 
1-2 
II-2 
II-6 
II-7
8.57 
100 (O.C.) 
2.87 
4.31
0.00 0.29 1.01
0.01 0.11 0.34 
0.02 0.17 0.53
X
Family 11 
1-2 
II-l
100 (O.C.) 
100 (O.C.)
>45 years 
X
Family 12 
1-2 
II-2
11.11 
100 (O.C.)
36.52 36.23 35.42 >45 years 
>45 years
Family 13 
1-2 
II-2 ~
66.67
33.33
66.67 66.67 66.67 
5.15 7.97 13.61
S
D.C. = obligate carrier 
ni = not informative
* = Newborn male at risk
= Male fetus at risk
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and DNA data are calculated assuming the proportion of 
unlinked families to be 0%, 10% and 30%. Of the 17
obligate carriers, 7 are under the age of 45 years and can 
all be offered prenatal diagnosis, using S21 in 2, pXG12 
in 4, and either probe in 1, Of the 34 females at risk of 
being carriers, 17 have their risks increased, 15 
decreased and 2 unchanged by the RFLP results. 11 of the 
17 women whose risks were increased are under 45 years and 
7 of them can be offered prenatal prediction.
The impact of varying the proportion of unlinked 
families in predicting low risks can also be assessed. Of 
the 15 women whose carrier risks were decreased, 3 were 
already below 5% and 7 were reduced to under 5% if the 
proportion of unlinked families is assumed to be 10%. Of 
these 7, 6 would still have a risk below 5% if a figure of 
30% unlinked families were used; the other would have a 
risk of 5.14% (Table 6).
In family 3, II-l was shown to be at high risk of 
being a carrier with both S21 and pXG12. She was 
heterozygous for S21 and hence prenatal diagnosis was 
possible. She was, however, well into the last trimester 
of her second pregnancy before the linkage study of XLA 
was completed. Pregnancy proceeded to term and a male 
infant (III-2) was born. RFLP analysis of cord blood 
indicated that he ran a low risk of being affected with 
XLA. With the family having 3 meioses supporting linkage 
with S21 and the posterior probability of this family 
being linked as 0.95, the risk to her son is 4.25-5.62%
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(assuming 10% or 30% unlinked families respectively). Ke 
was shown to have normal numbers of circulating B 
lymphocytes and normal immunoglobulin level and is 
clinically normal at the age of one year thereby 
confirming our prediction.
A woman (family 13) with only one son affected with 
XLA but no family history presented for prenatal exclusion 
at 9 weeks of pregnancy. She was shown to be heterozygous 
for S21 and the affected son inherited the 2.2kb allele. 
Chorionic villus sampling was performed and the fetus was 
shown to have 46XY karyotype and inherited the opposite 
2.0kb allele to the affected boy. A residual risk of 10% 
of the fetus being affected with XLA was quoted to the 
parents. This figure takes into account the possibility 
that the affected boy is a new mutation and that the 
mother is linkage phase unknown if she were a carrier. 
The calculated risk was 7.97, 10.79 and 13.6% according to 
whether 10,20 or 30% of families are unlinked. They 
accepted the risk and a male infant was born at term. 
Analysis of both cord blood at birth and peripheral blood 
at two weeks of age showed a normal number of B 
lymphocytes. As he is still under six months of age, 
serum immunoglobulins are mainly of maternal origin.
4.4.3 DISCUSSION
Until recently female carriers of XLA could not be 
detected, but once linkage to RFLPs was demonstrated it 
became possible to use gene tracking in genetic prediction
Genetic Studies of XLA Page 98
(Kwan et al 1986). In our study, of 34 potential 
carriers, gene tracking with S21 and pXG12 gave 
information that could be used in genetic counselling in 
32. Of a total of 19 obligate or potential carriers under 
the age of 45, prenatal prediction using these probes was 
possible in 15. However, the present sample is biased 
towards optimum family structure since most were selected 
for the original linkage study (Malcolm et al 1987). The 
combination of S21 (heterozygosity frequency 0.45) and 
pXG12 (heterozygosity frequency 0.48) can be expected to 
render about 70% of females in other families amenable to 
gene tracking. There is no evidence of linkage 
disequilibrium between S21 and pXG12, or between XLA and 
either probe. There are several potential unrelated 
sources of error in using linked probes. The problems of 
recombination, non-paternity and new mutation are well 
recognised (Pembrey 1986). Here the problem of non- 
allelic genetic heterogeneity has been addresed in 
particular. Until tests independent of linkage analysis 
can distinguish which gene locus is involved in any 
particular XLA family, non-allelic genetic heterogeneity 
must be incorporated into any genetic prediction.
It is demonstrated here how one can allow for the 
problem of non-allelic genetic heterogeneity in risk 
calculation. However, there is still a degree of 
uncertainty in risk prediction due to the fact that one 
cannot be sure about the true proportion of unlinked 
families, whether it is 10%, or perhaps 30%; though it is
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likely to be about 10% on present evidence. This degree 
of uncertainty (depending on whether unlinked families are 
10% or 30%) is less in a large family (family 1) with 
linkage data from many members than a smaller family 
(family 9) with little or no linkage data with the marker.
This difference in the degree of uncertainty can be 
illustrated by comparing 11-12 in family 1 with 1-2 in 
family 9 where the RFLP results favour a new mutation 
during spermatogenesis in 1-1. Both are potential 
carriers with pedigree risks between 33% and 43% which are 
reduced to under 5% with the RFLP results if all XLA 
mutations were linked to S21/pXG12. However, if one 
assumes 30% of families are unlinked, the risk of 1-2 in 
family 9 will be 20.35% while that of 11-12 in family 1 is 
still 4.22%. The change of these two women's carrier 
risks with the proportion of unlinked families is shown in 
figure 4-3.
It is also feasible, with the linkage data, to 
indicate where the mutation first started in a family, 
e.g. in families 5 and 10, the mutation most likely arose 
during spermatogenesis in the grandfathers. There are 
both practical and biological interests in determining 
whether the mutation rate in males and females is equal 
with respect to any X-linked disease (Winter 1980). 
However, the immediate practical benefit in pinpointing 
the mutation in a family is to exclude risks in all 
relatives except descendants of the carrier of the new 
mutation.
0.5_
(/>
t N C
cc
CC
UJ
EE
cc
<o
0.4L
0.3.
0.2.
0 .1.
0 j
I-2 Family 9
11-12 Family 1
0  0 . 2  0 . 4  0 . 6  0 . 8  1
Proportion of Unlinked Families
Figure 4 -3  Change of carrier risks with the proportion 
of unlinked families rising from 0% to 1 0 0% .
Carr ie r  risks ca lcu la ted  from expression (7 )  with  
LIPED and p ro g ram m e l is ted  in appendix 2.
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Another potential source of error in using linked 
probes for genetic prediction is that of non-paternity. 
In family 1, the prediction that the female 11-13 is a 
carrier which is based on the pXG12 linkage data is 
paternity dependent; that is if her biological father were 
another man, this prediction could be incorrect. However, 
a similar prediction that she (11-13) is a carrier, based 
on the S21 linkage data, is paternity independent. Using 
pXG12, she (11-13) can also be offered prenatal diagnosis. 
Therefore, pXG12 and S21 used together can get round the 
potential error of non-paternity and provide prenatal 
diagnosis, hence complementing each other in such 
circumstances.
A more powerful and universal strategy to confirm
family relationship is to use extremely polymorphic
A
minisatellite probe (Jeffreys et al 1985, Wong et al 
1986). A locus-specific minisatellite probe, p\g3, which 
detects at least 77 different alleles (Wong et al 1986) 
has been used to confirm paternity in some of our families 
where predictions are paternity-dependent. The chance of 
two randomly-selected individuals sharing a same allele 
>4kb was estimated to be only 0.016 (Wong et al 1986). The 
family relationship of family 15 was also checked and 
confirmed by using pXg3. Figure 4-4 shows the Southern 
blot of a family using pXG3. The parents have totally 
different alleles as they are not related; father has 
alleles a and b, mother c and d. Each of their four
Figure 4-
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Hinf1/pX G3
4 Autoradiograph showing the hypervariable DNA 
polymorphism detec ted  with a locus-specfic  
minisatell i te probe in checking family relationship.
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offsprings should have either ac, ad, be or bd.
A consensus opinion regarding screening for fetal and 
genetic abnormality has been reached by the King’s Fund 
forum (1987). The purpose of carrier detection should be 
to assist informed decision making before pregnancy. 
Accurate information on possible risks will allow some 
couples to avoid high risk pregnancies, while other 
couples may decide to embark on pregnancies that they 
would, without this knowledge, have avoided. The purpose 
of prenatal diagnosis is to provide the option of not 
continuing with an abnormal pregnancy, but should the 
mother wish to continue with an affected pregnancy the 
prenatal diagnosis would allow the family to prepare to 
care for an affected child or to attempt appropriate 
treatment as soon as possible after birth. This is 
particularly relevant for severe combined immunodeficiency 
where both matched and mismatched bone marrow transplants 
are curative and the success rate is about 90% for human 
leucocyte antigen (HLA) matched and 50-60% for HLA 
haploidentical transplants (Fischer et al 1986). 
Therefore, the specific goal of any genetic screening 
programme should not be of reducing the incidence of a 
disease, but of maximizing options available to couples at 
risk for an affected child (Rowley 1984).
4.5 X-LINKED HYPERIMMUNOGLOBULINAEMIA M IS NOT AN ALLELIC
GENETIC DISEASE WITH X-LINKED AGAMMAGLOBULINAEMIA
X-linked hyperimmunoglobulinaemia M (X-linked 
hyperIgM) shares certain similar clinical features with
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that of X-linked agammaglobulinaemia (XLA) (Chapter 1, 
this thesis), it is therefore conceivable that X-linked 
hyperlgM and XLA could be two allelic forms of the same 
genetic disease. However this hypothesis seems very 
unlikely from the linkage analysis of a family with X- 
linked hyperlgM (family 19). The pedigree is shown in 
figure 4-5, with the segregation of the alleles of 19.2, 
pXG12 and S21. At least two cross-overs were observed 
between the disease locus and the 3 DNA probes linked 
with XLA. One cross-over with known phase was observed 
with probes 19.2 and pXG12 as individual III-2 carries 
the same haplotype as his affected brother; S21 was 
uninformative in this case. Another cross-over was 
observed as a normal brother (II-2) has inherited the same 
haplotype as his two carrier sisters. As 1-1 is also 
informative for S21, the cross-over in this case does not 
lie between pXG12 and S21.
The results from this family clearly indicate^ a 
distinct localisation for the genetic defect in X-linked 
hyperlgM from that in X-linked agammaglobulinaemia. 
Mensink et al (1987b) has in fact mapped the gene locus 
for X-linked hyperlgM to Xq24-q27 with p43-15(DXS42) in
one family. Unfortunately our family is not informative
1-e.s
for the probe p43-15. Further linkage stud^ should 
however be done on many other X-linked hyperlgM families 
before decision can be made regarding clinical application 
of the linked RFLP in carrier detection and prenatal 
diagnosis.
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Chapter 5 GENETIC STUDIES OF X-LINKED SEVERE COMBINED 
IMMUNODEFICIENCY
5.1 INTRODUCTION
The underlying defect of X-linked severe combined 
immunodeficency (SCID) is still unclear but the primary 
cellular defect seems to be a block in early T cell 
differentiation (Griscelli et al 1978, Gelfand and Dosch 
1982, 1983). There is no immunological or biochemical
method to detect carriers (Chapter 1, this thesis). 
Female carriers can however be now identified by the 
pattern of non-random X-chromosome inactivation in their 
mature T cells (Goodship et al 1988). Prenatal diagnosis 
based on enumeration of fetal T cells and their response 
to phytohaemagglutinin has been successful but it involves 
mid-trimester fetal blood sampling (Linch et al 1984). 
Therefore, it would be desirable to localize the gene on 
the X-chromosome by linkage with RFLPs; it then renders 
carrier detection and first trimester prenatal diagnosis 
feasible by gene tracking (Pembrey 1986). The linkage 
analysis of 3 families with X-linked SCID is presented in 
this Chapter, which contributes to the mapping of the gene 
to Xqll-ql3 in a collaborative study with the French group 
headed by Professor C. Griscelli in Paris and Dr. J.L. 
Mandel in Strasbourg (de Saint Basile et al 1987).
5.2 LINKAGE ANALYSIS BETWEEN X-LINKED SEVERE COMBINED 
IMMUNODEFICIENCY AND DNA MARKERS FROM Xqll-ql3
The three families with X-linked SCID were chosen on 
the following two criteria. The diagnosis of SCID was
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ascertained by the demonstration of abscence of T cells, 
lack of mitogen-induced T cell proliferation as well as 
normal or increased numbers of B cells. (Rosen et al 
1983) The X-linked inheritance was established 
unequivocally as all 3 families (families 16-18) showed 
segregation of the disease in 3 generations (Figure 5-1). 
This is essential because children with the variety of 
autosomal recessive SCID may have identical immunological 
parameters in terms of T and B cell numbers and function 
as X-linked SCID. It follows that a family with two or 
more affected sons can either be of autosomal recessive or 
X-linked inheritance.
The RFLP data of these three families are shown in 
table 7 and the pedigrees with the cpX73 and 19.2 data are 
shown in figure 5-1. The two-point linkage analysis 
between the SCID locus and the loci defined by the four 
DNA markers, viz cpX73 (DXS159), 19.2(DXS3), pXG12(DXS94) 
and S21(DXS17) were performed with the LIPED programme 
(Ott 1974). The input and output files are included in 
appendix 6. The lod scores of these three families are 
shown in table 8; along with the combined results obtained 
from six more X-linked SCID families from the French group 
(de Saint Basile et al 1987).
The two-point linkage data suggested that the SCID 
gene locus is close to cpX73 marker, which defines the 
locus DXS159 in Xqll-ql3 (Arveiler et al 1987b). The 
marker cpX73 showed complete cosegregation with the
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Table 7
RFLP data of the 3 families with X-linked SCID
Family Individual cpX73 19.2 pXG12 S21
16 II-l 1 2 nd 1
II-2 (O.C.) 1/2 1,2 1 1,2
II-3 2 2 nd 1
II-4 1/2 1 1 1,2
II-5 1 1 nd 2
11-6(0.C.) 1,2 1,2 1 1,2
III-l 1 2 nd 1
III-2 1 1 nd 1
III-4 1,2 1,2 nd 1
III-5 1 1 nd 2
III-6 1 1 nd 1/2
III-7 1 1 nd 1
17 1-1 2 1 2 nd
1-2(O.C.) 1,2 1,2 1 1
II-l 2 2 2 nd
11-2(0.C.) 2 1 1/2 1
II-3 1 2 1 nd
II-4 1,2 1,2 1/2 1
II-7 1 2 1 1
III-l 2 1/2 1/2 1
(continued next page)
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Table 7 (continued)
Family Individual cpX73 19.2 pXG12 S21
18 1-1 1 2 nd nd
1-2 (O.C.) 1 1,2 1,2 1
II-3 2 2 nd nd
II-4 (O.C.) 1 1,2 2 1
II-5 1 2 1 nd
II-6 1 2 1 nd
III-2(O.C.) 1,2 1,2 2 1,2
III-6 1 2 nd nd
111-10(aff) 1 1 nd 1
H <3 l to 1 1 nd nd
O.C. = obligate carrier
aff. = affected
nd = not done
allele 1 = larger fragment
allele 2 = smaller fragment(s)
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Table 8
LOD SCORES FOR FAMILIES WITH X-LINKED SCID
LOD SCORES
LOCUS DXS159 DXS3 DXS94 DXS17
PROBE cpX73 19.2 pXG12 S21
©=0.00 1.48(5.27) -2.14(-INF) 0.62(-6.86) 0.48(-7.00)
©=0.01 1.45(5.16) 1.50(2.22) 0.61(-1.43) 0.48(-1.87)
©=0.05 1.30(4.70) 1.95(4.97) 0.55(0.59) 0.47(0.20)
©=0.10 1.12(4.11) 1.93(5.51) 0.48(1.29) 0.44(0.90)
©=0.15 0.93(3.50) 1.77(5.37) 0.40(1.51) 0.39(1.12)
©=0.20 0.75(2.90) 1.55(4.95) 0.32(1.52) 0.33(1.10)
©=0.30 0.39(1.71) 1.03(3.60) 0.17(1.18) 0.19(0.73)
jod scores for various recombination fractions (©) between SCID 
.ocus and the listed loci in the three SCID families (families 
.6, 17t 18). The lod scores in brackets are our results combined 
rith the results of the six French families (de Saint Basile et 
il 1987) .
NF=infinity.
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disease locus in all informative families analysed. The 
maximum lod score obtained with cpX73 was 5.27 at 
recombination fraction 0=0 in the collaborative study (de 
Saint Basile et al 1987). The 90% confidence limit for 
the recombination fraction between SCID and cpX73 was 
estimated to be 0.09. A maximum lod score of 5.51 at 0 
=0.11 was also obtained for the linkage between SCID and
19.2 (DXS3). The recombination fraction between cpX73 and
19.2 analysed in another study of larger set of families 
was estimated to be about 0.13 (Arveiler et al 1987a). 
This indeed suggests the SCID locus is very close to cpX73 
but it is not yet decided whether the disease locus lies 
distal or proximal to cpX73. The relatively high 
recombination fraction found between SCID and pXG12 or S21 
(0.18 and 0.17 respectively, see table 8) clearly shows 
that X-linked SCID is located in a different region from 
X-linked agammaglobulinaemia, which has been mapped very 
close to markers pXG12 and S21 (Chapter 4, this thesis).
In our three families, only one cross-over was 
observed in family 16; that between X-linked SCID and 
19.2. Individual III-l, an unaffected male, has inherited 
the opposite allele of 19.2 to that of his normal brother 
(III-2) and cousin (III-7).
The ethnic backgrounds of our three families are 
quite different from one another as well as from the 
French families. There was however no evidence for non­
allelic genetic heterogeneity since linkage with probes in
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the Xqll-q21 region was observed in all nine families (de 
Saint Basile et al 1987).
5.3 GENETIC PREDICTION
With the locus of X-linked SCID mapped to the region 
of Xqll-ql3 in nine families (de Saint Basile et al 1987) 
and the lod score of 5.27 with probe cpX73 obtained at 
recombination fraction 0=0 (90% confidence limit is 0.09), 
it is then possible to use cpX73 for genetic counselling 
in families with X-linked SCID. There are the usual 
potential sources of error in using linked probes in 
genetic prediction, viz recombinations and non-paternity. 
However there was no evidence for genetic heterogeneity in 
these nine families for X-linked SCID which may further 
confound the approach of gene tracking as in X-linked 
agammaglobulinaemia (Chapter 4, this thesis). Using cpX73 
one can make an earlier prenatal diagnosis in informative 
families than by using immunological methods on fetal 
blood (Linch et al 1984). However, because of the 
possibility of recombination, a control of the presence of 
T cells and normal mitogen-induced proliferation of T 
cells in fetal blood should still be performed if RFLP 
analysis suggests that a fetus has a low risk of being
affected. As for carrier detection, we have been able to
f>$szs<!j \h A
change the^genetic risk of being a carrier substantially 
in three potential female carriers in family 16 and one in 
family 17 using probe cpX73. It is however not possible 
to alter the risk of the other potential female carriers 
in families 17 and 18 since the key female carriers are
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not informative for cpX73. Several of the obligate female 
carriers can be offered prenatal diagnosis using cpX73.
Using cpX73 and assuming a recombination fraction of 
0.09 (the upper limit of 90% confidence intervals), the 
carrier risks were calculated as follows. For any 
individual the probability of a specific SCID genotype, 
given the pedigree and marker (RFLP) data, can be 
expressed as:
Pr(genotype,pedigree)
Pr(genotype|pedigree) = — ---------------------
Pr(pedigree)
where Pr(genotype,pedigree) is the probability of the 
specific SCID genotype in the individual in question and 
the pedigree data given that the disease is linked to the 
marker at 0=0.09. Pr(pedigree) is the probability of the 
pedigree assuming that the SCID genotype of the individual 
at risk is unknown and given that the disease is linked to 
the marker at 0=0.09. These probabilities can be obtained 
from the computer programme LIPED (Ott 1974). The results 
are shown in table 9.
5.4 DISCUSSION
Of the three potential female carriers whose risks 
were reduced (table 9), two were reduced to 5% and one to 
9%. These are not insignificant risks for a disease as^  X- 
linked SCID. Recently, we have established that DNA
Page 111
Table 9
PREDICTION OP CARRIER RISKS IN X-LINKED SCID FAMILIES
Subj ects
Pedigree risk 
(%)
Pedigree and 
DNA risk (%)
Family 16
II-4 33 60
III-4 17 5
III-6 50 9
Family 17
II-4 33 5
Carrier risks of females in SCID families as modified by 
RFLP results from cpX73 assuming a recombination fraction © 
=0.09.
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methylation analysis can be used for carrier detection in 
X-linked SCID (Goodship et al 1988). The principle of the 
method is as follows. The Lyon hypothesis states that 
permanent inactivation of one of the two X chromosomes 
occurs at random in every somatic cell in the female early 
in embryogenesis (Lyon 1961). The pattern of X chromosome 
inactivation is transmitted in stable fashion to all 
progeny cells. In cells requiring the mutant gene for 
development, cells with the normal X active will have a 
selective advantage, so although the initial inactivation 
was random, the mature cell population will show a non- 
random pattern of X inactivation. Goodship et al (1988) 
demonstrated non-random X chromosome inactivation pattern 
in the mature T lymphocytes of two obligate female 
carriers of X-linked SCID; while in normal females, the T 
lymphocytes showed random X chromosome inactivation 
pattern. This method of determining carrier status will 
be applicable to at least 50% of Caucasian females who are 
informative for the probes from the 5' end of the 
hypoxanthine phosphoribosyltransferase (HPRT) and phospho- 
glycerate kinase (PGK) genes. These probes detect both a 
RFLP which is used to distinguish the paternal X 
chromosome from the maternal X chromosome and also a 
difference in methylation between the active and inactive 
X chromosome. One endonuclease is used to demonstrate the 
RFLP and a methylation-sensitive endonuclease to 
demonstrate the methylation pattern. The methylation of 
the CpG-rich islands (Hpa II tiny fragments islands) 
situated at the 51 end of most vertebrate genes is
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associated with inactivation of that gene (Bird 1986). 
This method of carrier detection will obviously be 
preferred in informative females to that of gene tracking 
using linked probes because it will give an absolute 
prediction while the latter approach only gives a 
probability. In fact, II-4 in family 17 has been found to 
have the pattern of random X chromosome inactivation in 
her T cells with this approach (Goodship et al 1988); 
hence confirming the prediction that she is not a carrier 
using the linked probe cpX73> Nevertheless the gene 
tracking approach is technically much easier and is 
therefore used first in informative families with clear 
cut X-linked pedigrees. DNA methylation analysis can also 
distinguish the X-linked form of SCID from recessive form 
in families with only two or more affected sons. This in 
turn can help to ascertain more X-linked families for 
refining the linkage data in this disease.
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Chapter 6 FUNCTIONAL STUDIES OF B CELLS FROM PATIENTS 
WITH X-LINKED AGAMMAGLOBULINAEMIA AND WISKOTT- 
ALDRICH SYNDROME
6.1 INTRODUCTION
The development of B lymphocytes can be divided into 
two main phases, an initial antigen-independent phase 
(stem cell to pre-B cell to mature B lymphocyte) and an 
antigen dependent phase (B lymphocyte to antibody 
secreting plasma cell). Inherited primary immuno­
deficiency diseases involving the B cell may result from 
developmental blocks at certain points in either of the 
two phases. Therefore, the understanding of the normal 
development and differentiation of B cells is 
indispensable in the analysis of the possible B cell 
defects in X-linked agammaglobulinaemia and Wiskott- 
Aldrich syndrome.
6.1.1. DEVELOPMENT OF PRE-B CELL TO B LYMPHOCYTE
The earliest B cell precusors are identified in the 
fetal liver during the eigth or ninth week of gestation 
when the pluripotent haemopoeitic stem cells first migrate 
from the yolk sac to the fetal liver; the bone marrow is 
then similarly populated (Cooper 1981). Pre-B cells and 
their B cell progeny are subsequently generated in the 
bone marrow throughout life. Two biological processes are 
essential in the generation of a large population of B 
cells which are clonally diverse with respect to their 
antibody receptors. The first is the rearrangement of the 
immunoglobulin variable-region genes and the second is 
polyclonal proliferation (Cooper 1987). Antigens play no
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part in this process since pre-B cells lack cell-surface 
antibodies.
The immunoglobulin heavy-chain genes are on 
chromosome 14, kappa-light-chain genes on chromosome 2 and 
lambda-light-chain genes on chromosome 22. Each gene 
family consists of multiple exons separated by noncoding 
introns. A complex but orderly rearrangement of the exons 
of the variable (V), diversity (D) and joining (J) genes 
of the heavy-chain has to be executed correctly before 
transcription can begin (Tonegawa 1983). When the VDJ- 
constant mu transcript is further processed by RNA 
splicing, the processed message is translated into mu- 
heavy-chain products (Tonegawa 1983). The cytoplasmic 
expression of mu chains is the first easily identifiable 
marker of the pre-B cell stage. The next step is the 
rearrangement of variable (V) and joining (J) genes of the 
kappa or lambda light-chain gene families in the small 
postmitotic cytoplasmic-mu positive pre-B cells. If the 
VJ rearrangement is correct, the RNA transcript can be 
processed to form messenger RNA for light-chain 
production. The light chains are assembled with the mu 
chains to form the complete IgM molecules which are then 
transported through the Golgi region to the cell surface. 
The expression of the surface IgM marks the end of the 
pre-B cell stage and the beginning of the B lymphocyte. 
The surface IgM positive B cells then produce a long 
nuclear transcript, VDJ-Cu-Cd, which is differentially 
spliced into VDJ-Cu and VDJ-Cd messenger RNAs; these are
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subsequently translated to generate mu and delta chains 
(Cooper 1987). Mature B cells can thus express both IgM 
and IgD antibody receptors with the same specificity.
The regulatory mechanism of the complex 
differentiation of the pre-B cells to B lymphocytes 
remains largely unknown. Stromal cells in the bone marrow 
appear to promote pre-B cell differentiation, possibly via 
direct cell contact and by secretion of soluble factors 
(Dorshkind 1987, Collins and Dorshkind 1987). Conditioned 
medium from a stromal cell line, S17, has been shown to 
act as growth factor for murine pre-B cells (Landreth and 
Dorshkind 1988). Landreth et al (1985b) identified in the 
urine of a patient with cyclic neutropenia a lymphopoeitic 
activity that acts as a growth factor for human pre-B 
cells. Recently, a murine lymphopoeitic growth factor 
designated lymphopoeitin 1 has been purified to a single 
25 kilodaltons species from the culture supernatant of an 
adherent stromal cell line (Namen et al 1988). It is 
capable of stimulating the proliferation and extended 
maintenance of precursor cells of the B cell lineage and 
has been shown to be distinct from IL-1, IL-2, IL-3, IL-4, 
IL-5, GM-CSF, G-CSF, CSF-1 and IFN (Namen et al 1988).
6.1.2 ACTIVATION, GROWTH A m  DIFFERENTIATION OF B 
LYMPHOCYTES
The generation of millions of B-cell clones to the 
surface IgM/IgD positive stage as described above and 
their migration from bone marrow to the spleen and other 
peripheral lymphoid tissues are all antigen-independent
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events. B cells that encounter antigens complementary to 
their surface immunoglobulin receptors and those that 
receive T-cell help will undergo phases of activation, 
proliferation and differentiation into antibody-secreting 
plasma cells or long-lived memory cells. The mechanism 
of isotype switching involves cutting of repetitive DNA 
sequences in a switch (s) region upstream of the Cu gene 
and splicing with a complementary s region in front of the 
next constant-heavy gene to be expressed (Cooper 1987). 
The molecular basis of T-cell help has been clarified in 
the last few years (Gordon and Guy 1987) and it is now 
apparent that the various B-cell factors are not B-cell 
specific but can act on many other cell types; when they 
act on the B cells, the factors are not stage-specific, 
and B-cell factors can be derived from non-T cells as well 
(O'Garra et al 1988). Hence the control of the B-cell 
programme must reside in levels other than those operating 
through the direction of single factors.
These soluble factors were originally divided into 
two functional groups: B cell growth factors (BCGF),
thought to be involved in B cell activation and 
replication, and B cell differentiation factors (BCDF), 
responsible for maturation of activated B cells into 
plasma cells (Kishimoto et al 1984). This strict 
classification based on function has to be reviewed as 
recombinant B cell factors (interleukins: IL-4, IL-5, IL- 
6) are now available and shown to be pleiotropic (O’Garra 
et al 1988). Other lymphokines originally shown to be
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effective on target cells other than B cells have also 
been shown to affect B-cell physiology (IL-1, IL-2 and 
gamma-interferon). The functions of these factors on B
cells are reviewed as follows:
6.1.3 INTERLEUKIN 4
Human interleukin 4 (IL-4) or B-cell stimulatory 
factor 1 (BSF-1) has been isolated and characterised by 
molecular cloning of a human cDNA based on homology with a 
mouse IL-4 cDNA (Yokota et al 1986). The DNA sequences of 
human and murine IL-4 are 70% homologous and the two 
factors mediate several similar activities, such as 
inducing IgE secretion by activated B cells, low-affinity 
receptors for the Fc portion of IgE (CD23) on resting B 
cells (DeFrance et al 1987a), the proliferation of anti- 
IgM stimulated B cells and the growth of helper T-cell 
clones (Yokota et al 1986, DeFrance et al 1987b). Murine 
IL-4 has also been shown to be IgGl inducing factor and to 
induce the expression of class II major histocompatibility 
complex molecules on resting B cells (Snapper and Paul 
1987, O ’Garra et al 1988).
6.1.4 INTERLEUKIN 5
Human interleukin 5 (IL-5) or eosinophil differentiat­
ing factor (EDF) or T-cell replacing factor (TRF) has also 
been identified by molecular cloning of a cDNA from T 
cells, based upon its homology with murine IL-5 cDNA 
(Yokota et al 1987). Human IL-5 has been shown to enhance 
IgA production by unstimulated and Staphylococcus aureus
B-cell Studies of XLR and WAS Page 119
Cowan 1 (SAC)-activated enriched peripheral blood B cell 
preparations (Yokota et al 1987). In many standard human 
B cell growth factor assays, human IL-5 has however been 
shown to have no activity on human B cells at all 
(Clutterbuck et al 1987). The difference is probably due 
to the source of the B cell target population and the 
levels of contaminating accessory cells. The principal 
activity of human IL-5 is on the differentiation of 
eosinophils.
6.1.5 INTERLEUKIN 6
Human interleukin 6 (IL-6) or B-cell stimulatory
factor 2 (BSF2) was purified and identified by its ability 
to induce antibody secretion by preactivated normal and 
Epstein-Barr virus-transformed human B cells (Hirano et al
1985). The cDNA of IL-6 was subsequently cloned by Hirano 
et al (1986) by probing the cDNA libraries of a human T- 
cell line, which constitutively produced large amounts of 
BSF-2/IL-6, with synthetic oligonucleoties corresponding 
to fragments of amino acid sequences of the purified IL-6. 
Human IL-6 was initially thought to be a pure 
differentiation factor with no growth effect on B cells 
(Hirano et al 1985). IL-6 is however now known to be the 
same as plasmacytoma/hybridoma growth factor and has been 
shown to be produced by human multiple myelomas as an 
autocrine growth factor (Kawano et al 1988). IL-6 is also 
identical to interferon-beta 2 (Billiau 1987). IL-6 has 
in addition been shown to induce acute phase proteins by 
hepatocytes (Gauldie et al 1987). IL-6 is therefore not
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just a B cell differentiation factor as previously thought 
and its action on pre-B cell development remains to be 
elucidated (O'Garra et al 1988).
6.1.6 LOW MOLECULAR WEIGHT B CELL GROWTH FACTOR
Low molecular weight B cell growth factor (BCGF-low) 
has been purified from lectin-stimulated, peripheral blood 
mononuclear cell-conditioned medium (Mehta et al 1985) and 
was shown to be a heat and protease sensitive protein 
with a molecular weight of 12 to 14 kilodaltons. BCGF-low 
co-stimulates with anti-Ig to induce DNA synthesis in 
normal human B cells? long-term BCGF-low dependent B cell 
culture has also been established as an assay for BCGF-low 
(Maizel et al 1983). A commercially available preparation 
of BCGF-low (Cellular Products, Inc) has been shown to 
increase DNA synthesis and immunoglobulin secretion in 
several human B cell lines (Shields et al 1987). Sharma 
et al (1987) have isolated and expressed a cDNA in E. coli 
which appears to encode BCGF-low, but this recombinant 
molecule has not yet been shown to induce the effects 
attributed to the commercial BCGF-low. The commercial 
BCGF-low also contains traces of other contaminating 
lymphokines, such as IL-1, IL-2, interferon-gamma and 
tumour necrosis factor (O’Garra et al 1988), which may 
complicate interpretation of experiments using this 
commercial preparation.
6.1.7 B-CELL FACTORS FROM NON-LYMPHOID AND LYMPHOID CELL 
LINES
T24, a bladder carcinoma cell line, has been shown to
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produce a molecule with IL-6/BSF-2 activity (Rawle et al
1986). Cardiac myxoma cells also produce high levels of a 
molecule with IL-6 activity which was specifically 
absorbed by the anti-IL-6 antibody (Hirano et al 1987). 
Northern blot analysis has established that the IL-6 mRNA 
was transcribed in both T24 cells and cardiac myxoma cells 
at a much higher level than activated lymphocytes (Hirano 
et al 1986). It is therefore feasible to use such cell 
lines as sources of IL-6.
KG-la, a promyelocytic cell line, has been shown to 
secrete a BCGF-like factor which is not the same as IL-4 
(Callard et al 1987, Shields et al unpublished), but this 
factor has not been characterised.
An Epstein-Barr virus (EBV)-transformed B cell line, 
has been shown to secrete a BCGF which appears to be 
distinct from IL-1, IL-2, IL-4, IL-5 and interferon-gamma 
(Muraguchi et al 1986). This factor induces proliferation 
of activated B cells that has been stimulated with 
Staphylococcus aureus Cowan Strain I for 3 days. Normal 
activated B cells also secrete this BCGF, but at a lower 
level. It has been postulated the constitutive production 
of an autostimulatory BCGF serves as part of the crucial 
events in the immortalisation of these cells (Gordon et al
1984). A low molecular weight BCGF (16Kilodaltons) 
derived from an EBV-transformed B cell line has also been 
purified (Buck et al 1987). A high molecular weight BCGF 
(50 kilodaltons) has also been generated from an IL-2- 
dependent helper T cell clone, this was found to be
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synergistic with the BCGF-low, generated from 
phytohaemagglutinin-stimulated T cells, on the 
proliferation of anti-IgM stimulated B cells (Yoshizaki et 
al 1983). Another high molecular BCDF-like factor (40-60 
Kilodaltons) from various human T and B cell lines has 
been described (Kanowith-Klein et al 1987). Its 
relationship to IL-6 (21 kilodaltons) has not been 
elucidated however.
6.1.8 INTERLEUKIN 1, INTERLEUKIN 2, INTERFERON-GAMMA
Monocyte-derived interleukin 1 (IL-1) has been shown 
to support the proliferation of EBV-transformed B cell 
lines but not resting B cells costimulated with anti-IgM 
(Gordon et al 1986a); Falkoff et al (1983) however 
demonstrated synergy between purified IL-1 and a low 
concentration of anti-IgM in the proliferation of B cells.
Purified IL-1 alone did not induce immunoglobulin
secretion by activated B cells (Falkoff et al 1984).
Transformed B cells also secrete an IL-1 like factor which 
promotes B cell proliferation (Rimsky et al 1986) and EBV- 
transformed B cell lines have been shown to possess 
receptors for IL-1 alpha/beta (Matsushima et al 1986). 
The importance of interleukin 2 (IL-2) and interferon- 
gramma in B-cell proliferation and differentiation is 
still being elucidated. It is however clear that IL-2 can 
promote proliferation and differentiation of
staphylococcus aureus Cowan Strain I activated B cells 
(Jelinek et al 1986). Interferon-gamma delivers an 
enhancing signal during initial activation that permits
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subsequent growth and differentiation of activated B cells 
in response to IL-2 (Jelinek et al 1986). Interferon- 
gamma also specifically inhibits the IL-4 mediated 
induction of the low-affinity receptor for IgE (CD23) on B 
lymphocytes (DeFrance et al 1987a). In contrast, 
interferon-gamma was found to enhance the IL-4-induced 
proliferation of anti-IgM-preactivated B cells (DeFrance 
et al 1987b).
The activity of the various interleukins on human B 
cells is summarised in the table 10.
6.1.9 THE ROLE OF B-CELL SURFACE ANTIGENS IN B-CELL 
DIFFERENTIATION
In the third international workshop on human 
leucocyte differentiation antigens in Oxford, twelve 
cluster differentiation (CD) surface markers of B cells 
have been delineated (Ling et al 1987). Various 
functional roles have been ascribed to several of these 
cell surface antigens (Golay 1986, Zola 1987). Ajrt£^CD19 
antibody blocks the DNA synthesis of B cells induced by 
anti-IgM (Pezzutto et al 1987a) and partially inhibits the 
growth of long-term EBV-transformed cell lines (Golay and 
Crawford 1987) while CD20 antigen is involved in the 
activation of B cells (Golay et al 1985). Ani:i-CD22 
antibody was costimulatory with anti-IgM in inducing 
small, dense tonsillar B cells to proliferate (Pezzutto et
al 1987b). Monoclonal antibody to CD21, which is the
h
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Table 10
EFFECTS OF LYMPHOKINES ON HUMAN B CELLS
FACTORS EFFECTS ON B CELLS
Interleukin 1
Interleukin 2
Interleukin 4
Interleukin 5
Interleukin 6
Interferon-
gamma
induces proliferation of EBV-transformed B cell 
lines (Gordon et al 1986a).
induces proliferation and differentiation of
staphylococcus aureus Cowan I (SAC) activated B 
cells (Jelinek et al 1986).
induces low-affinity receptors for the Fc portion 
of IgE (CD23) on resting B cells;
induces proliferation and IgE secretion of
activated B cells (DeFrance et al 1987 a&b).
induces IgA production by SAC activated B cells 
(Yokota et al 1987).
induces Ig secretion by EBV-transformed B cell 
lines (Hirano et al 1985);
induces growth of multiple myelomas (Kawano et al 
1988) and EBV-transformed B cell lines (Tosato et 
al 1988).
enhances the growth and differenatiation of
activated B cells in response to IL-2 (Jelinek et 
al 1986); inhibits the IL-4 induction of CD23 on B 
cells but enhances the IL-4-induced proliferation 
of activated B cells (DeFrance et al 1987 a&b).
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receptor for both Epstein-Barr virus and complement C3d 
(CR2) (Frade et al 1985), is able to trigger human B cells 
to divide and differentiate in the presence of T cells 
(Nemerow et al 1985). Anti-CDw40 antibody provides a very 
potent co-stimulation in B cell activation as long as the 
signal transmitted through this CDw40 is delivered 
concomitantly or shortly after the initial stimulus (Clark
and Ledbetter 1986). IL-4 and anti-CDW40 have been shown/
to synergise in promoting DNA synthesis of B cells in a 
restimulation assay (Gordon et al 1987).
CD23, the low-affinity receptor for IgE (45 kDa), is 
expressed on activated but not on resting B cells. IL-4 
has been shown to induce the expression of CD23 on resting 
B cells (DeFrance et al 1987a). Epstein-Barr virus also 
induces CD23 rapidly on a large number of B cells (Wang et 
al 1987), the expression of which is essential for 
transformation to proceed (Thorley-Lawson and Mann 1985). 
It has been suggested CD23 acts as a central focus for 
growth-promoting signals delivered to the activated B 
cells (Gordon and Guy 1987). Apr£i-CD23 monoclonal 
antibody can promote DNA synthesis in phorbol ester 
activated B cells (Gordon et al 1986b) and it has been 
suggested that there is an association between CD23 and 
the receptor for BCGF-low (Gordon et al 1986c). Moreover, 
the binding of the anti^-CD23 antibody to the 45 kDa CD23 
causes the release of a 25 kDa form of the CD23 into the 
extracellular medium (Guy and Gordon 1987); this effect
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is mimicked by the binding of BCGF-low to the activated B- 
cell surface. Shed CD-23 is associated with autocrine 
growth factor activity (Swendeman and Thorley-Lawson
1987). Furthermore, IgE has been shown to augment both 
BCGF-low and anti-CD23 in promoting B-cell growth, by 
enhancing CD23 expression (Guy and Gordon 1987). This 
then leads to the generation of more cleaved CD23 by BCGF- 
low and anti-CD23 antibody and thus provide greater 
autocrine activity.
The various functions mediated through the B cell 
surface markers are summarised in table 11.
6.1.10 FUNCTIONAL STUDIES ON EPSTEIN-BARR VIRUS 
TRANSFORMED B CELL LINES FROM PATIENTS WITH XLA 
AND WAS: RATIONALE AND HYPOTHESIS
As the normal development of the B lymphocytes is 
subject to such a complex network of regulatory mechanisms 
involving many exogenous and endogenous growth and 
differentiation factors which mediate their functions 
through binding onto their specific B-cell surface 
receptors, it is conceivable either a lack of factors or 
failure to respond to factors may lead to a developmental 
arrest of the B lymphocytes. In both X-linked 
agammaglobulinaemia (XLA) and Wiskott-Aldrich syndrome 
(WAS), B lymphocytes are thought to be intrinsically 
defective from both immunological and genetic evidence 
(Chapter 1). In XLA, there is a relative developmental
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Table 11
EFFECTS OF MONOCLONAL ANTIBODIES 
AGAINST B CELL SURFACE MARKERS ON HUMAN B CELLS
ANTIBODY TO SURFACE 
BARKERS ON B CELLS
EFFECTS ON B CELLS
AH^i-CD19 blocks DNA synthesis of B cell induced by 
anti-IgM (Pezzutto et al 1987a); partially 
inhibits growth of EBV-transformed B cell 
lines (Golay and Crawford 1987).
Ap'lfl“CD2 0 activates B cells (Golay et al 1985).
Aptl-CD21 (Receptor 
for EBV/C3d)
induces proliferation and differentiation of B 
cells (Nemerow et al 1985).
Ai*£j.-CD22 costimulates with anti-IgM in inducing B cells 
to proliferate (Pezzutto et al 1987b).
Al^ta-CD23 promotes DNA synthesis in phorbol ester 
activated B cells (Gordon et al 1986b).
Aiytfl-CDw40 augments the proliferation of activated B 
cells (Clark and Ledbetter 1986).
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arrest from pre-B cells to B lymphocytes. In WAS, the B 
lymphocytes bear striking resemblance to the immature B 
cell system of the newborn, viz inability to respond to 
polysaccharide antigens (Blaese et al 1968, Cooper et al
1986). We therefore hypothesize that the B lymphocytes 
from these patients may respond abnormally to the B-cell 
factors, leading to the disease phenotype. A subsidary 
hypothesis is that these patients1 B lymphocytes do not 
secrete autocrine growth and differentiation factors, 
which may be important in allowing clonal expansion.
To test the above hypothesis, we have chosen Epstein- 
Barr virus (EBV)-transformed B cell lines from these 
patients as an experimental model. Receptors for EBV 
occur on mature and immature B cells; pre-B cells and even 
cells of B lineage prior to immunoglobulin gene 
rearrangement can also be transformed by EBV (Fu et al 
1980, Katamine et al 1984). The frequency of B-lymphocyte 
transformation by EBV depends on stages of cell cycle of 
the B cells and experimental conditions of the 
transformation (Chan et al 1986) and it varies from 1% to 
30%. The validity of the EBV-transformed B cell lines as 
a model partly depends on the evidence that in a female 
carrier with either XLA or WAS, B cells manifest non- 
random X-inactivation pattern, hence B cells bearing the 
defective gene which is not inactivated do not mature in 
the female carrier (Fearon et al 1987, M. Blaese, personal 
communication). It is therefore most likely that all B 
cells in the patients with XLA or WAS will be affected by
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their respective basic defects, hence transformation of a 
fraction of these patients1 B lymphocytes by EBV should 
still give a valid model to study their underlying 
defects.
EBV-transformed B cell lines secrete and respond to 
various B cell growth and differentiation factors. These 
include B cell derived BCGF (Gordon et al 1984, Muraguchi 
et al 1986), monocyte derived IL-1 (Gordon et al 1986a), B 
cell derived IL-1 (Rimsky et al 1986), T cell derived IL-6 
(Hirano et al 1985) and the soluble CD23 (Swendeman and 
Thorley-Lawson 1987). Such cell lines may not be 
representative of the normal B cell population, but their 
range of responses to B cell growth and differentiation 
factors, and availability in large numbers free of other 
cell types makes them suitable for studies of some aspects 
of B cell physiology. It is difficult to obtain enough 
purified peripheral blood B cells from children for 
measuring responses to B cell growth and differentiation 
factors, especially from patients with XLA. In such 
cases, the use of EBV-transformed B cell lines for 
experiments is the only viable option. The EBV- 
transformed B cell lines used in the following study were 
grown for a short period only (8-12 weeks) in bulk culture 
to avoid overgrowth by dominant clones.
6.2 PRELIMINARY STUDY
A series of preliminary experiments were done on 
several normal EBV-transformed B cell lines to determine
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the optimum conditions for eliciting responses in 
increasing DNA synthesis and immunoglobulin secretion of 
these cell lines to T24-BCDF, KGl-a supernatant and BCGF- 
low. In later experiments, recombinant human IL-4 (rhlL- 
4) and IL-6 (rhIL-6) were used.
The basic methodology of these experiments are 
detailed in Chapter 3.
6.2.1 EFFECT OF VARYING CELL NUMBERS PER WELL
q
A range of cell concentrations (2.5 to 20 x 10 
cells/well) were tested to ascertain at what range of cell 
concentrations these EBV-transformed B cell lines would 
give the optimum response to various factors added. 
Figures 6-1 and 6-2 show the responses of a normal EBV- 
transformed B cell line to BCGF-low in increasing DNA 
synthesis and to T24-BCDF in increasing IgG secretion at 
different cell concentrations. At 2.5x10^ cells/well, 
there was no response in growth or differentiation 
probably because EBV-transformed B cell lines need a 
minimum cell density to survive even in the presence of 
growth factors. At 5 and 10x10° cells/well, there were 
some increases in DNA synthesis and IgG secretion in
q
response to factors. At 20x10 cells/well, the magnitude 
of responses increased but the control values also 
increased dramatically because at a high cell density, the 
EBV-transformed B cell lines are able to sustain its own 
growth via the autocrine stimulatory mechanism (Gordon et 
al 1984). Hence, it is critical to use a suitable range 
of cell concentrations in order to test whether the EBV-
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transformed B cell lines respond to factors or not. In
q
subsequent experiments, a range of 5 to 20x10° cells/well 
were normally used.
6.2.2 EFFECT OF VARYING NUMBER OF DAYS OF CULTURE
Several time-course experiments were done to 
ascertain how many days of culture would give the best 
response in DNA synthesis and immunoglobulin secretion of 
normal EBV-transformed B cell lines. DNA synthesis as 
measured by incorporation of tritiated thymidine is only 
indicative of the DNA synthesized in the last 8 hours of 
the cultured period and not of the total cell growth and 
survival at the end of the culture. Measurement of 
immunoglobulins in the supernatant at the end of the 
cultured period represents the cumulative secretion over 
the whole period. Figure 6-3 shows the kinetics of 
response of a normal EBV-transformed B cell line to BCGF- 
low and KGl-a supernatant in DNA synthesis from day 2 to 
day 6. The maximum response was seen on day 3. BCGF-low 
was able to sustain DNA synthesis at a much higher level 
and over a longer period than KGl-a supernatant. In 
subsequent experiments, 3 days of culture was used in 
assaying DNA synthesis. Figure 6-4 shows that after 5 to 
7 days of culture, the accumulation of immunoglobulin 
secretion of a normal EBV-transformed B cell line in 
response to T24-BCDF had probably reached a maximum. 
Hence, 5 or 6 days of culture was used in assaying 
immunoglobulin secretion.
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6.2.3 EFFECT OF VARYING CONCENTRATION OF FACTORS
Since T24-BCDF and KGl-a supernatant were generated 
from cell lines in our laboratory, it is essential to test 
each batch of supernatants to ensure the presumed 
activities are present. Figure 6-5 shows the dose- 
response curves of IgG secretion of a normal EBV- 
transformed B cell line to T24-BCDF and KGl-a supernatant. 
25% of either factor elicited appreciable response and 
this concentration was used throughout all subsequent 
experiments. The same batches of T24-BCDF and KGl-a 
supernatants were used in all experiments.
A commercial source of BCGF-low (Cellular Products, 
Inc) was used. Figure 6-6 shows a dose-response curve of 
IgM secretion of a normal EBV-transformed B cell line to 
BCGF-low. 5% of BCGF-low elicited appreciable response 
and was used in all experiments for differentiation 
subsequently, while 10% of BCGF-low was used for growth 
assay.
Recombinant human interleukins, rhIL-4 and rhIL-6, 
were used at various concentrations as indicated in 
separate experiments.
6.3 PROLIFERATIVE RESPONSES TO KG1-A SUPERNATANT, BCGF- 
LOW AND rhIL-4
EBV-transformed B cell lines from 7 normal subjects, 
3 XLA and 6 WAS patients were tested for their 
proliferative responses to KGl-a supernatant, BCFG-low and 
rhIL-4. rhIL-4 was in the form of supernatant from COS-7 
cells transfected with plasmids bearing the human IL-4
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gene and was used at a concentration of 1%. All cell 
lines were tested in at least two separate experiments at 
a range of cell concentrations (5 to 20x10 cells/well). 
The results observed with the optimal cell concentration 
for each cell line are presented in Table 12. All of the 
normal, XLA and WAS B cell lines responded significantly 
to BCGF-low. rhIL-4 induced a small but significant 
increase in proliferation in some normal (EG and JR) and 
WAS (GB and RF) B cell lines. None of the 3 XLA B cell 
lines proliferated in response to rhIL-4. KGl-a 
supernatant induced significant proliferative response in 
all normal and WAS B cell lines, but neither of the 2 XLA 
B cell lines tested has shown any significant response to 
KGl-a supernatant.
6.4 RESPONSES OF IMMUNOGLOBULIN SECRETION TO KG1-A 
SUPERNATANT, BCGF-LOW, T24-BCDF AND rhIL-4
The same EBV-transformed B cell lines shown in Table 
12 were tested for their responses in increasing IgG and 
IgM secretion to KGl-a supernatant, BCGF-low, T24-BCDF and 
rhIL-4. The results from the optimal cell concentration 
in at least two separate experiments for each cell line 
are resented in tables 13 and 14. KGl-a supernatant,
BCGF-low and T24-BCDF induced significant increase 
in IgM secretion from all normal, XLA and WAS B
cell lines. Five out of six normal and four out of six
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Table 12
PROLIFERATION OF EBV-TRANSFORMED B CELL LINES
IN THE ABSENCE AND PRESENCE OF KG1-A, BCGF-LOW AND IL-4
TRITIATED THYMIDINE INCORPORATION
(10 dpm/WELL)
CELL NO.
(10 3/WELL) MEDIUM KG1-A BCGF-LOW IL4
Normal
SH 10 23.5+2.6* 7 0.4+1.4 109.3+9.4 21.1±0.8
VR 10 5.5+0.5 15.9+1.9 28.9+9.8 6.1+1.0
JS 10 5.2+0.9 15.2+0.6 18.9+2.6 6.6+0.7
EG 10 3.1±0.2 2 8.8+1.7 60.6+5.6 16.3+3.2
BJ 20 19.1+2.6 46.3+1.2 134.5+7.4 3 0.3+3.2
JR 10 19.9+0.9 46.3+4.2 68.8+9.8 45.8+4.3
DB 20 3 0.1±7 .8 7 9.2+7.1 123.7+31.9 24.5+1.1
XLA
BW 10 9.8±3.1 13.1+3.9 28.0+11.9 7.6+1.6
RH 10 6.1±0.5 nd 249.3+1.9 9.4+1.9
MH 10 12.9+2.2 17.8+0.9 75.8+6.0 2.4+0.4
WAS
GB 20 13.7+1.1 49.4+4.5 208.1+61.7 29.3+1.8
DR 20 44.7+6.1 76.1+1.5 9 2.5+7.7 34.8+1.8
PM 10 38.3+0.7 158.9±6.3 236.9+4.8 34.2+2.7
RF 10 15.9+1.4 46.9+0.5 208.6+10.7 31.3+2.8
SS 20 7.5+1.3 15.3±0.9 25.3+10.7 17.7+5.0
MC 20 22.3+3.4 68.8+5.5 97.7+5.5 32.8+7.2
* = mean of triplicate cultures +1S.D.
nd = not done
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Table 13
IgM SECRETION OF EBV-TRANSFORMED B CELL LINES IN THE ABSENCE
AND PRESENCE OF KG1-A SUPERNATANT, BCGF-LOW, T24-BCDF AND IL4
IgM (microgram/ml)
Cell No.
(xl0“3)/well Medium KGl-a BCGF-low T24-BCDF IL4
Normal
SH 5 <0.06 0.4+0.1* 1.7+0.1 0.8+0.2 nd
VR 5 0.9+0.2 7.6+0.7 8.1+0.2 11.3+0.0 0.5+0.4
JS 10 0.8+0.0 5.4+0.5 2 4.0+4.5 8.1+0.8 2.0+0.3
EG 5 0.5+0.2 3.6+0.4 11.8+1.4 9.5+1.4 0.6+0.2
BJ 20 1.3+0.2 4.1+0.9 9.9+0.8 5.8+1.4 3.1±0.5
JR 5 1.2+0.5 5.6+1.4 16.8+8.9 6.7+3.9 8.1+3.3
DB 5 0.5+0.1 3.2+0.4 18.8+2.7 9 . 8+1.5 0.5+0.1
XLA
BW 5 0.5+0.2 1.4+0.5 4.8+1.2 1.8+0.4 0.3+0.0
RH 5 1.3+0.2 nd 36.5+3.0 16.8+1.4 0.5+0.0
MH 10 0.7+0.2 3.4+0.9 4.2+0.8 4.0+0.4 1.2+0.1
WAS
GB 20 17.4+4.4 31.8+2.8 94.5+26.8 62.7+10.4 35.3+7.7
DR 20 8.0+0.7 14.0+2.8 21.0+6.1 16.8+2.7 8.1+1.1
PM 20 0.4+0.2 1.3+0.1 3.5+0.3 4.1±0.6 0.9+0.6
RF 10 0.3+0.0 3.3+1.5 24.3+0.6 9.9+3.8 0.5+0.2
SS 5 0.5+0.4 2.3+0.5 3.2+1.2 8.9+4.2 2.9+1.1
MC 5 6.8+0.7 15.6+1.1 2 8.5+9.6 49.7+4.1 72.7+47.3
* = mean of triplicate cultures +1S.D.
nd= not done
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Table 14
IgG SECRETION OF EBV-TRANSFORMED B CELL LINES IN THE ABSENCE
AND PRESENCE OF KG1-A SUPERNATANT, BCGF-LOW, T24-BCDF AND IL4
IgG (ng/ml)
Cell No. 
(xlO 3/well) Medium KGl-a BCGF-lOW T24-BCDF IL4
Normal
SH 5 441+45 1059+381 1430+420 2031+516 678+180
VR 5 249+33 1089±120 1439+399 1539+420 183+ 12
JS 5 6+ 3 81+ 36 513+ 72 69+ 12 15+ 3
EG 10 24+ 3 138+ 6 581+174 273+ 57 69+ 48
BJ 20 9+ 3 27+ 12 69+ 15 57+ 21 30+ 6
JR 20 57+12 252+ 57 459+108 477+ 18 153+ 39
DB 10 <3 <3 <3 <3 <3
XLA
BW 20 <3 <3 <3 <3 <3
RH 10 <3 nd <3 <3 <3
MH 10 <3 <3 <3 <3 <3
WAS
GB 20 81+ 3 291+ 45 1215+567 366+123 396+ 96
DR 20 <3 <3 <3 <3 <3
PM 20 87+30 843+267 >3000 >3000 102+ 9
RF 10 27+ 9 246+ 54 408+23 0 426+ 45 54+ 39
SS 5 912+174 1197+231 1635+591 2337+606 984+141
MC 5 <9 <9 <9 <9 <9
* = mean of triplicate cultures +1S.D.
nd= not done
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WAS B cell lines also increased IgG secretion in response 
to KGl-a supernatant, BCGF-low and T24-BCDF. None of the 
3 XLA B cell lines secreted IgG constitutively or in 
response to any of the factors.
rhIL-4 unexpectedly induced some increase in IgM and 
IgG secretion in several normal B cell lines (BJ, JS and 
JR) and one WAS B cell line (GB). Two other WAS B cell 
lines (SS and MC) also increased the IgM secretion in 
response to rhIL-4. None of the 3 XLA B cell lines 
responded to rhIL-4.
6.5 RESPONSES OF IMMUNOGLOBULIN SECRETION TO COMBINATION 
OF FACTORS
Several cell lines which were examined above were 
also tested for their responses in increasing immuno­
globulin secretion to a combination of two factors. The 
non-IgG secreting cell lines were included to see whether 
a combination of rhIL-4 & BCGF-low, rhIL-4 & T24-BCDF or 
BCFG-low & T24-BCDF would switch these cell lines into IgG 
secretion. The results from the optimal cell
concentration for each cell line tested are presented in 
tables 15 and 16.
The various combination of factors did not switch on 
IgG secretion in the non-IgG secreting cell lines, whether
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Table 15
IgM SECRETION OF EBV-TRANSFORMED B CELL LINES
IN THE ABSENCE AND PRESENCE OF COMBINATIONS OF FACTORS
IgM (microgram/ml)
Cell lines
Normal
JR DB
XLA
BW
WAS
DR RF
Cell No. 
(xlO-3/well) 5 5 20 5 5
Medium 0.9+0.2* 0.6+0.1 3.8+0.8 2.5±0.9 0.6+0.2
IL4 1.7+0.1 0.9+0.2 4.3+0.4 10.9+4.5 1.2+0.2
BCGF-low 2.7+0.1 1.9+0.2 19.4+6.4 4.9+0.6 1. 9+0.2
T24 2.9+0.6 2.3+0.4 13.3+4.4 19.3+7.0 4.1±1.1
IL4+BCGF-low 6.2+0.3 2.9+0.4 27.6+3.4 12.9+5.0 2.6+0.7
IL4+T24 5.9+1.0 2.9+0.2 13.9+5.6 48.8+21.9 3.8+0.7
BCGF-10W+T24 5.6+0.5 3.7+0.2 26.2+4.6 16.4+3.8 8.3+3.0
* = mean of triplicate cultures +1S.D.
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Table 16
IgG SECRETION OF EBV-TRANSFORMED B CELL LINES
IN THE ABSENCE AND PRESENCE OF COMBINATIONS OF FACTORS
IgG (ng/ml)
Cell lines
Normal
JR DB
XLA
BW DR
WAS
RF
Cell No. 
(xlO VweH) 5 5 20 5 5
Medium 27+ 3* <3 <3 <3 27+ 9
IL4 45+12 <3 <3 <3 54+39
BCGF-low 141+ 6 <3 <3 <3 408+23
T24 132+15 <3 <3 <3 426+45
IL4+BCGF-low 198+15 <3 <3 <3 nd
IL4+T24 156+3 0 <3 <3 <3 nd
BCGF-10W+T24 237+15 <3 <3 <3 nd
* = mean of triplicate cultures +1S.D. 
nd= not done
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they are normal, XLA or WAS B cell lines. However, the 
combination of factors did have some additive effects on 
increasing either IgM or IgG secretion in cell lines 
already secreting IgM/IgG constitutively. No significant 
difference was observed in this response among the 2 
normal, 1 XLA and 2 WAS B cell lines tested.
6.6 B CELL LINES FROM NORMAL AND XLA PATIENTS SECRETE 
B CELL GROWTH AND DIFFERENTIATION FACTORS
A hypogammaglobulinaemic patient has been reported to 
be deficient in the production of B cell differentiation 
factor by his peripheral blood mononuclear cells (Matheson 
and Green 1987). Supernatants from normal and XLA EBV- 
transformed B cell lines were hence assayed for B cell 
growth and differentiation factors using B cell indicator 
cell lines L4, HFB-1 and CESS (Shields et al 1987, Hunter 
et al 1982, Olsson et al 1983, Muraguchi et al 1981). 
These supernatants were used at a final concentration of 
25%. The results from the optimal cell concentration for 
each cell line are presented in tables 17 and 18.
Both normal and XLA B cell lines secreted B cell 
growth factor(s) which increased the proliferation of two 
indicator B cell lines, L4 and HFB-1 (Table 17). 
Similarly, they also secreted factor(s) which increased 
IgG secretion by L4 and CESS (Table 18).
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Table 17
BC6F ACTIVITY IN THE SUPERNATANTS 
OF NORMAL AND XLA EBV-TRANSFORMED B CELL LINES
TRITIATED THYMIDINE INCORPORATION
(10-3dpm/well)
L4
(10xl03cells/well)
HFB1
(5X103cells/well)
Medium 4.5+ 0.2 6.8+ 2.0
BCGF-low 148.7+10.0 74.3+16.1
Normal supernatant 56.0+ 3.7 150.6± 4.2
XLA supernatant 199.4± 7.4 179.9± 8.6
Table 18
BCDF ACTIVITY IN THE SUPERNATANTS 
OF NORMAL AND XLA EBV-TRANSFORMED B CELL LINES
IgG (ng/ml)
L4
(20xl03cells/well)
CESS
(2.5X103cells/well)
Medium <9 39+ 18
T24 180+21* 966+129
Normal supernatant 118+21 507+141
XLA supernatant 258+ 6 216+ 45
Using L4, HFB1 and CESS as indicator B cell lines to assay BCGF 
and BCDF activities in the supernatants of normal and XLA EBV- 
transformed B cell lines.
* = mean of triplicate cultures +1S.D.
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6.7 CELL SURFACE PHENOTYPES OF NORMAL AND XLA B CELL 
LINES
Since the EBV-transformed B cell lines from patients 
with XLA differed in certain aspects in their responses to 
the factors investigated above from the normal control B 
cell lines, it is conceivable that the XLA B cell lines 
may have differences in their cell surface phenotypes from 
the normal. EBV-transformed B cell lines from two 
patients with XLA and two normal control were therefore 
typed with a panel of B cell surface markers (Table 19). 
Monoclonal antibodies used for surface phenotype analysis 
were 8EBI (CD19), B1(CD20), BL13/10B1(CD21), MHM6(CD23),
and G28-10 (CD39) as described in the third international 
workshop on human leucocyte differentiation antigens (Ling 
et al 1987). No significant differences were seen between 
the cell surface phenotypes of XLA and normal B cell 
lines.
6.8 PROLIFERATIVE RESPONSES OF NORMAL AND XLA B CELL 
LINES TO rhIL-6
Recombinant human IL-6 became available towards the 
end of the tenure of my research fellowship and with the 
realisation that it may also be a growth promoting factor 
for B cells (Kawano et al 1988) rather than just a pure 
differentiation factor as previously thought (Hirano et al
1985), EBV-transformed B cell lines from the three XLA 
patients and three normal control were tested for their 
proliferative responses to rhIL-6. Two sources of rhIL-6, 
from Immunex Corporation, Seattle, USA and Dr T.
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Table 19
PHENOTYPES OF EBV-TRANSFORMED B CELL LINES 
FROM PATIENTS WITH XLA AND NORMAL CONTROL
(JS)
NORMAL
(BJ)
XLA
(MH) (RH)
CD19 + ++ ++ +
CD20 + ++ ++ ++
CD21 + + + +
CD23 ++ ++ +++ ++
CD39 ++ +++ +++ nd
nd = not done
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Kishimoto, Japan, were used at two final concentrations of
0.1 unit/ml and 1 unit/ml. All three XLA cell lines were 
tested at least in two separate experiments at a range of 
cell concentrations (2.5 to 20xl03 cells/well). BCGF-low 
at 5% final concentrations was used as a positive control 
in these experiments. No significant difference was 
observed between the responses to the two different 
sources of rhIL-6 or to the two different concentrations. 
Therefore, only the results with rhIL-6 from Immunex at 1 
unit/ml are presented. The results observed with the 
optimal cell concentration for each cell line are 
presented in Table 20. There were no consistent and 
significant proliferative responses to rhIL-6 in either 
normal or XLA B cell lines as they did to BCGF-low. 
However, there were minor proliferative responses in one 
normal (SS) and two XLA (MH, RH) EBV-transformed B cell 
lines.
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Table 20
PROLIFERATIVE RESPONSES OF EBV-TRANSFORMED 
B CELL LINES TO rhIL-6 AND BCGF-LOW
TRITIATED THYMIDINE INCORPORATION
(dpm/well)
CELL
(xl0“
NUMBER
3/well) MEDIUM BCGF-LOW rhIL-6
NORMAL 
S.S. 10 10269+1047* 277942+ 6217 22240+2833
M.B. 20 13729+2020 69206+ 7008 18125+1235
V.R. 20 12104+4494 262983+11676 19283+3697
XLA
B.W. 20 14079+4301 41866+ 1988 12003+1809
M.H. 20 28396+6851 155859+28048 49263+ 676
R.H. 10 6125+ 472 249266+ 1942 54078+3830
* = Mean of triplicate cultures +1S.D.
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6.9 DISCUSSION
EBV-transformed B cell lines from both XLA and WAS 
patients proliferated in response to BCGF-low (Table 12). 
In each case, the response was not appreciably different 
from that of normal EBV-transformed B cell lines. However 
there were differences in proliferative responses to both 
KGl-a supernatant and rhIL-4. EBV-transformed B cell 
lines from both normal control and WAS patients showed 
significant proliferative responses to KGl-a supernatant 
but none of the XLA B cell lines showed any significant 
response (Table 12). KGl-a is a promyelocytic cell line 
derived from a human acute myelogenous leukaemia cell line 
(Koeffler et al 1980); it has been shown to produce B cell 
growth and differentiation factors, which are not IL-1, 
IL-2, IL-4, or interferon-gamma (Shields et al
unpublished observation). The nature of the B cell growth 
factor in KGl-a supernatant is not clear but its activity 
is similar to that of BCGF-low in that it can promote DNA 
synthesis in indicator B cell lines L4 and HFB1, as well 
as TPA (12-0-tetradecanoylphorbol 13-acetate) activated 
tonsillar E negative cells (non sheep red blood cells- 
rosette forming cells) (Shields et al 1987 and unpublished 
observations). However, it is likely that the BCGF 
activity in KGl-a supernatant is not the same as BCGF-low 
since the EBV-transformed B cell lines from XLA patients 
proliferated in response to BCGF-low but not to KGl-a 
supernatant (Table 12). It will be important to 
characterise the BCGF activity in the KGl-a supernatant in
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order to investigate further the difference in 
proliferative response between the XLA and normal EBV- 
transformed B cell lines.
Unexpectedly, rhIL-4 promoted DNA synthesis in some 
normal and WAS EBV-transformed B cell lines, but had no 
effect on the XLA EBV-transformed B cell lines (Table 12). 
rhIL-4 is a BCGF in costimulation assay with anti-IgM for 
normal B cells (DeFrance et al 1987b) but does not usually 
induce proliferation of other B cell lines (Shields et al 
1987). It is not clear why some normal and WAS EBV- 
transformed B cell lines proliferate in response to rhlL- 
4. It may be a property of B cell subpopulations 
transformed by EBV, or of B cells at a particular stage of 
differentiation represented by these lines, or EBV cell 
lines transformed relatively recently.
In the differentiation assay, both normal and WAS 
EBV-transformed B cell lines increased secretion of IgM 
and IgG in response to BCGF-low, T24-BCDF and KGl-a 
supernatant (Tables 13 and 14). Both BCGF-low and KGl-a 
supernatant have been shown to increase immunoglobulin 
secretion by B cell lines (Shields et al 1987 and 
unpublished obervation); T24, a bladder carcinoma cell 
line, is known to secrete IL-6 (Rawle et al 1986, Hirano 
et al 1986) which is a BCDF for EBV-transformed B cell 
line such as CESS (Hirano et al 1985). Unexpectedly, some 
normal and WAS EBV-transformed B cell lines also increased 
secretion of IgM and IgG in response to rhIL-4. (Tables 
13 and 14). Murine IL-4 has been shown to induce IgGl
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secretion (Snapper and Paul 1987) and it will be of 
interest to investigate further whether the IgG response 
of these EBV-transformed B cell lines, which showed 
increase in total IgG secretion in response to rhIL-4, are 
of any particular IgG subclass.
In contrast to the EBV-transformed B cell lines from 
normal control and WAS patients, those obtained from XLA 
patients responded quite differently in the 
differentiation assays. Although the XLA lines did 
increase IgM secretion in response to BCGF-low, T24-BCDF 
and KGl-a supernatant, they did not secrete IgG 
constitutively or in response to any of the factors 
(Tables 13 and 14). This is consistent with earlier 
findings that XLA EBV-transformed B cell lines can secrete 
IgM without being stimulated (Levitt et al 1984). None of 
the XLA EBV-transformed B cell lines responded to rhIL-4. 
(Tables 13 and 14).
Patients with. XLA do have low levels of serum IgG. 
The lack of IgG secretion by the XLA EBV-transformed B 
cell lines may, therefore, be due to an inability to 
transform pre-committed IgG precursors with EBV (Stein et 
al 1983), or a failure to switch from IgM to IgG 
secretion. Various combinations of factors (IL-4 + BCGF- 
low, IL-4 + T24-BCDF, and BCGF-low + T24-BCDF) were tried 
in an attempt to induce switching of the IgM producing 
EBV-transformed B cell lines from the XLA patients and the 
one normal and two WAS EBV-transformed B cell lines which
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did not secrete detectable IgG, but without success (Table 
16).
These results suggest that the non-IgG secreting XLA 
EBV-transformed B cell lines probably result from the much 
lower frequency of pre-committed IgG precursors which are 
transformable with EBV in patients with XLA as compared 
with normal control and patients with WAS. The question 
of IgG, IgM, IgA precursor frequencies in normal control 
and various disease states can be investigated by limiting 
dilution analysis, but these experiments have not been 
performed. The combination of two factors however did have 
at least an additive effect in most cases in increasing 
IgM and/or IgG secretion by B cell lines which were 
secreting IgM and/or IgG constitutively (Tables 15 and 
16).
B cells are known to secrete and respond to growth 
and differentiation factors (Gordon et al 1984, Muraguchi 
et al 1986, Rimsky et al 1986, Buck et al 1987). EBV- 
transformed B cell lines depend on an autocrine growth 
factor for continuous proliferation (Gordon et al 1984) 
and it is conceivable that autostimulation is also 
sustained briefly for rapid expansion of normal B cells in 
areas of high B-cell density (Gordon and Guy 1987). It 
was, therefore, of interest to determine B cells derived 
from our patients were able to produce autocrine factors. 
Using the indicator B cell lines L4, HFBl and CESS, for 
assaying B cell growth and differentiation factors, 
supernatants from XLA EBV-transformed B cell lines were
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shown to contain BCGF and BCDF (Tables 17 and 18). 
Several B cell derived factors were reported to be 
involved in autocrine proliferation (Buck et al 1987, 
Swendeman and Thorley-Lawson 1987, Muraguchi et al 1986). 
The nature of the factors secreted by the XLA B cell lines 
has however not been investigated further.
There are immunodeficiency syndromes resulting from 
defective expression of cell surface antigens which have 
vital immunological functions, viz leucocyte adherence 
defect and bare lymphocyte syndrome (Lisowska-Grospierre 
et al 1985, 1986). It was, therefore, of interest to
determine whether the surface phenotypes of XLA EBV- 
transformed B cell lines differed from that of normal. 
Using a panel of B cell monoclonal antibodies, no 
significant difference was found (Table 19).
Although rhIL-6 has been shown to be a growth 
promoting factor for a range of B cells, such as hybridoma 
and multiple myeloma (Billiau 1987, Kawano et al 1988), 
it was previously thought to be purely a B cell 
differentiation factor (Hirano et al 1985). It has, in 
addition, been shown recently that rhIL-6 can promote the 
proliferation of EBV-transformed B cell lines (Tosato et 
al 1988). Two XLA and one normal EBV-transformed B cell 
lines showed some proliferative response to rhIL-6 (Table 
20). The reason why not all cell lines proliferated in 
response to rhIL-6 could be that the concentration of 
rhIL-6 used was suboptimal since Tosato et al (1988) used
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100 units/ml of rhIL-6 while only 1 unit/ml was used here.
In conclusion, the EBV transformed B cells from the 
patients with WAS did not differ from the normal control 
in any of the functional assays I have tested. However 
differences were found in the B cells from the patients 
with XLA. XLA EBV-transformed B cell lines did not 
proliferate in response to KGl-a supernatant; they did not 
produce IgG in the presence or absence of various B cell 
growth and differentiation factors.
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Chapter 7 CONCLUSION
7.1 EXPERIMENTS OF NATURE
The incidence of primary immunodeficiency diseases is 
comparatively low (Chapter 1) but their importance as 
"experiments of nature" extends far beyond the immediate 
problems faced by these relatively low number of patients 
and the physicians caring for them. Ever since Bruton 
(1952) described the first case of agammaglobulinaemia and 
the subsequent description of many other forms of human 
immunodeficiency, a deeper understanding of how the 
various arms of immune system cooperate and function has 
been achieved by the detailed investigation and inter­
pretation of these nature's experiments, coupled with the 
development and study of experimental models (Good 1976).
The present study is mainly concerned with the 
lymphoid system which, through nature's experiments, has 
deviated from normality and resulted in diseases such as 
X-linked agammaglobulinaemia (XLA), X-linked severe 
combined immunodeficiency (X-linked SCID) and Wiskott- 
Aldrich syndrome (WAS). The elucidation of the underlying 
defects of these diseases will no doubt throw a ray of 
light into the understanding of the normal physiology of 
the lymphoid system, and may perhaps lead to better 
management of these patients and their families. Two 
approaches of investigation are feasible in any genetic 
diseases of Mendelian inheritance. One is to identify the 
mutant gene and the other is to pinpoint the underlying 
biochemical abnormality. The former approach depends
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firstly on genetic mapping to give the genomic position, 
and secondly on molecular techniques to identify coding 
sequences corresponding to the locus. This strategy has 
been coined reverse genetics (Orkin 1986a) and it has 
been successfully applied in the isolation and cloning of 
the gene of X-linked chronic granulomatous disease (X- 
linked CGD) (Baehner et al 1986, Royer-Pokora et al 1986). 
The latter approach depends firstly on identifying which 
cell types are intrinsically defective in function, and 
secondly on biochemical and biophysical techniques to 
characterise the biochemical defect which leads to the 
dysfunction of the cell types involved. This strategy has 
also been successful in elucidating the biochemical defect 
in the neutrophils of X-linked CGD (Segal et al 1983). 
The two approaches finally converged in establishing the 
basic defect in X-linked CGD as that in the beta-chain of 
cytochrome b complex (Teahan et al 1987, Dinauer et al 
1987).
7.2 THE APPROACH OF MOLECULAR BIOLOGY - CLONING THE GENE 
This present study has been able to achieve the first 
step in the approach of isolating the mutant genes 
responsible for XLA and X-linked SCID (Chapters 4 and 5), 
viz mapping their gene loci to Xq21.3-q22 and Xqll-ql3 
respectively. For XLA, we have confirmed the linkage with 
S21 (DXS17) and 19.2 (DXS3) (Kwan et al 1986); and
extended the linkage with another probe, pXG12 (DXS94) 
(Malcolm et al 1987). Evidence for non-allelic genetic 
heterogeneity in XLA soon emerged and has complicated the
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approach of gene tracking in carrier detection and 
prenatal diagnosis (Mensink et al 1986a, 1987a, Ott et al
1986). Further evidence of non-allelic genetic hetero­
geneity in XLA was presented in this thesis and the 
percentage of XLA families unlinked to Xq21.3-q22 was 
estimated (Chapter 4). A method of risk calculation to 
allow for non-allelic genetic heterogeneity was developed 
and applied in the genetic counselling of thirteen XLA 
families (Lau et al 1988b). The genetic locus of X-linked
hyperlgM was also shown to be distinct from that of XLA
(Chapter 4). The next step should be finer mapping of 
this region of the X chromosome using more probes in 
larger number of families (Arveiler et al 1987a) or in 
isolated patients with chromosomal duplication or deletion 
(Cremers et al 1987, Schwartz 1988); and establishing 
closely linked probes which flank the disease locus. This 
will not only improve the certainty of genetic prediction 
but also the chance of cloning the gene. Future progress
in isolating the gene however depends on recent advances
in techniques for cloning long segments of DNA, such as 
the chromosome hopping procedure (Collins et al 1987); as 
well as the breakthrough in the ability to display and 
isolate large DNA fragments up to several megabase pairs 
by pulsed-field gel electrophoresis (Schwartz and Cantor 
1984, Weissman 1987). In the past, the successful cloning 
of disease genes without the benefit of these novel 
techniques has always depended on exploitation of isolated 
patients with chromosomal deletions, such as that found in
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association with X-linked chronic granulomatous disease 
(Baehner et al 1986, Royer-Pokora et al 1986). For both 
XLA and X-linked SCID, no patients have been described 
with the corresponding chromosomal deletion or trans­
location to allow for a strategy of rapid cloning of the 
defective genes. One has to rely on the recently 
established molecular genetic techniques of mapping the 
human genome (Weissman 1987).
Pulsed-field gel electrophoresis subjects DNA after 
cleavage by rare-cutting endonucleases to non-uniform (or 
uniform) field pulses applied at an angle greater than 90° 
to each other; the DNA size range separable by this 
technique extends from 0.005 Mbp (megabase pairs) to more 
than 9.0 Mbp (Barlow and Lehrach 1987). This technique 
has enabled one to generate physical long-range 
restriction maps covering several million basepairs by 
single and double enzyme digests, as well as deliberate 
partial digests showing the physical distances separating 
genetically linked markers (Burmeister and Lehrach 1986). 
If the two linked markers are known from linkage analysis 
to flank the disease gene and the physical distance 
between them is within the capacity of cloning technique 
available, the DNA fragment separated by pulsed-field gel 
electrophoresis which is recognised by the two linked 
markers can be excised from preparative low melting point 
agarose gels, and after a second digestion used to 
generate fragments that can be cloned into lambda vectors 
(Barlow and Lehrach 1987). The library hence generated
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will provide enriched sources of DNA from around the 
disease locus. A further step of purification is possible 
by cleavage of the DNA contained in the excised agarose 
strip with a second rare-cutting endonuclease that changes 
the fragment length and re-electrophoresis on a pulsed- 
field gel, before cloning into vectors (Barlow and Lehrach 
1987).
The construction of long-range restriction maps also 
allows the genetic distances deduced from linkage analysis 
to be compared with the physical length in kilobase pairs; 
thereby identifying regions with high and low 
recombinations and may lead to understanding the 
regulation of recombination frequency. (Barlow and Lehrach 
1987).
All the rare-cutting endonucleases used for pulsed- 
field gel electrophoresis (except Sfi I) contain one or 
more CpG dinucleotides in their recognition site (Weissman
1987), and because their ability to cleave genomic DNA is 
inhibited by methylation of the cytosine residue, a 
cleaved rare-cutter site identifies a methylation-free 
CpG-containing region. Clusters of unmethylated CpG 
dinucleotides (Hpa II tiny fragments or HTF islands) were 
thought to be associated with the 5 1 end of most 
vertebrate genes (Bird 1986, Burmeister and Lehrach 1986). 
HTF islands can be readily identified by pulsed-field gel 
electrophoresis as a cluster of several different rare- 
cutter sites (Brown and Bird 1986, Burmeister and Lehrach 
1986) in the long-range restriction map and may lead in
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turn to the associated gene.
The novel techniques of molecular biology will 
certainly accelerate the pace of identifying the genetic 
defects of XLA and X-linked SCID. The eventual 
identification of the gene may not necessarily lead to 
better treatment of the disease but at least open up the 
futuristic option of gene therapy, which is however more 
feasible in genetic diseases due to enzymatic defects such 
as adenosine deaminase deficiency (Orkin 1986b).
7.3 THE APPROACH OF CELL BIOLOGY - DEFINING THE CELLULAR 
AND BIOCHEMICAL DEFECT
The present study has also followed the second 
approach in investigating XLA and Wiskott-Aldrich syndrome 
(WAS), viz attempting to elucidate the functional defects 
of the B lymphocytes which are known from both clinical 
and genetic evidence to be affected in both XLA and WAS 
(Chapter 6). Epstein-Barr virus (EBV)-transformed B cell 
lines were established and characterised as an 
experimental system for testing B cell function in vitro 
for normal subjects and then extended to patients with XLA 
and WAS. The differences detected in the XLA EBV- 
transformed B cell lines were that they did not 
proliferate in response to KGl-a supernatant and did not 
secrete IgG in the absence or presence of the various B 
cell growth and differentiation factors. No abnormalities 
were detected in the EBV-transformed B cell lines from 
patients with WAS in terms of their responses to various 
B cell growth and differentiation factors. XLA EBV-
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transformed B cell lines were also shown to secrete B cell 
growth and differentiation factors and have similar 
surface phenotypes as normal B cell lines.
With the availability of recombinant lymphokines 
(rhIL-4, rhIL-6) recently, it was discovered that factors 
originally thought to act only on B cells are, in fact, 
pleiotropic, i.e. acting on many other cell types (O'Garra 
et al 1988). In addition, each factor mediates multiple 
effects on a single target cell population. Therefore, it 
seems unlikely that the defect in response to and/or 
production of these factors will account for the 
underlying defect in XLA, which seems to affect the B 
cells only. For WAS, it is still conceivable that a 
defect in response to such a pleiotropic factor could lead 
to functional impairment in B cells, T cells and 
platelets. It is easier to interpret an experiment if 
recombinant lymphokines are used rather than factors- 
containing supernatants from cell lines or activated T 
cells; and such recombinant lymphokines were only 
available near the end of my research fellowship. 
However, it is interesting to note that one consistent 
functional difference identified in this study is the 
failure of XLA EBV-transformed B cell lines to proliferate 
in response to KGl-a supernatant, which no doubt contains 
a mixture of active factors. Since XLA EBV-transformed B 
cell lines increased IgM secretion in response to KGl-a 
supernatant as the normal B cell lines, the growth- 
promoting factor in KGl-a supernatant would seem to be
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different from that which increased immunoglobulin 
secretion. Moreover, the growth-promoting factor in KGl-a 
supernatant is not BCGF-low as XLA EBV-transformed B cell 
lines proliferated in response to BCGF-low but not to KG1- 
a supernatant. It is important to confirm this finding in 
more XLA B cell lines before attempting to isolate and 
purify this growth-promoting factor in KGl-a supernatant 
which has so far failed to stimulate two XLA EBV- 
transformed B cell lines to proliferate but stimulated all 
normal and WAS B cell lines to proliferate. This factor 
may be important in the further elucidation of the the 
underlying defect of XLA.
Another experimental model which may throw some light 
in the early events of pre-B cell development, which is 
defective in XLA, is long-term culture of bone marrow pre- 
B cells, which can then be investigated for their 
requirements of growth and differentiation. Some advances 
in this direction have been made in the mouse system 
recently (Landreth and Dorshkind 1988, Namen et al 1988) 
and a purified murine pre-B cell growth factor of 25 
kilodaltons has been reported (Namen et al 1988). It is 
important to set up parallel human system to identify 
human pre-B cell growth and differentiation factor(s) and 
investigate their possible role in the pathogenesis of 
XLA. This may be more fruitful as the intrinsic defect of 
XLA seems to be somewhere along the developmental pathway 
between pre-B cell and mature B cell; and the 
understanding of regulation of this phase of B cell
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development lags much behind that from mature B cells to 
plasma cells.
For WAS, the present study has not identified any 
functional abnormality in the EBV-transformed B cell lines 
from six patients. It could be the measurement of total 
IgG and IgM was too crude to detect the abnormalities in 
WAS. It will be interesting therefore to see whether the 
ability and inability to mount antibody response to 
polysaccharide antigens in normal subjects and patients 
with WAS respectively (Blaese et al 1968) are also 
reflected in their EBV-transformed B cell lines; if so, it 
will be important to test whether any B cell growth and 
differentiation factor may influence the magnitude and/or 
ability to mount antibody response to polysaccharide 
antigens in the normal and WAS EBV-transformed B cell 
lines. It will also be interesting to see the IgG 
subclass profile in the antibody responses since IgG 
antibodies to polysaccharides are predominantly restricted 
to IgG2 subclass in man, although it has been shown 
patients with WAS have normal IgG2 levels (Nahm et al 
1986).
7.4 THE INTEGRATION
The complementary nature of the two approaches above 
has been instrumental in the success of determining the 
underlying defect of X-linked CGD (Teahan et al 1987, 
Dinauer et al 1987) and will no doubt be successful for 
the other X-linked immunodeficiencies in the near future. 
Similarly, the integration of clinical medicine and
Conclusion Page 161
vigorous scientific experimentation has been the hallmark 
of many successes.
I would like to end this dissertation with a quote 
from Robert A. Good in his presidential address to the 
American Association of Immunologists on April 13, 1976;
"the very great strengths of immunology, from its
very beginning..... , is that this discipline originated
and has been maintained by the interaction between the 
clinic and effective scientific investigation."
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APPENDIX 1 MATERIALS
A. CULTURE MEDIUM AND ADDITIVES
Culture medium used for in vitro experiments with 
human B cells is RPMI 1640 supplemented with 25mM Hepes, 
2mM glutamine and fetal calf serum (Gibco, Paisley, 
Scotland). Gentamicin at 50 microgram/ml has been used to 
inhibit bacterial growth in long term culture.
B. SALT SOLUTIONS
Stock solutions were prepared as follows:
1. 1M Tris
Dissolve 121.1 g Tris base in 800 ml of water. 
Adjust the pH to the desired value by adding 
concentrated hydrochloric acid. Then make up the 
volume of the solution to 1 litre.
2. 0.5M Ethylenediamine tetraacetate (EDTA)
Add 186.1 g of disodium ethylenediamine tetra­
acetate. 2H2O to 800 ml of water. Stir vigorously on a 
magnetic stirrer. Adjust pH to 8.0 with sodium 
hydroxide pellets.
3. 5M Sodium Chloride (NaCl)
Dissolve 292.2 g of NaCl in 800ml of water. 
Adjust volume to 1 litre.
4. 3M Sodium Acetate (ph5.2)
Dissolve 408.1 g of sodium acetate.3 ^ 0  in 800 
ml of water. Adjust pH to 5.2 with glacial acetic 
acid. Adjust volume to 1 litre.
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5. 10% Sodium Dodecyl Sulphate (SDS)
Dissolve 100 g of electrophoresis-grade SDS in 
900 ml of water. Heat to 68°C to assist dissolution. 
Adjust pH to 7.2 by concentrated hydrochloric acid. 
Adjust volume to 1 litre.
6. 20x Sodium Chloride and Sodium Citrate (SSC)
Dissolve 175.3 g of sodium chloride and 88.2 g
of sodium citrate in 800 ml of water. Adjust pH to 
7.0 with 10N solution of sodium hydroxide. Adjust 
volume to 1 litre.
7. Ethidium Bromide (lOmg/ml)
Add 1 g of ethidium bromide to 100 ml of water. 
Stir on a magnetic stirrer for several hours to 
ensure that the dye has dissolved. Wrap the 
container in aluminum foil and store at 4° C.
8. 1M Magnesium Chloride (MgC^)
Dissolve 203.3 g of MgCl2»6H20 in 800 ml of 
water. Adjust volume to 1 litre.
9. TE solution
A solution of lOmM Tris and ImM EDTA.
10. 10% Bovine Serum Albumin (BSA)
Dissolve 1 g of BSA in 10 ml of water.
11. 50x Denhardt's Solution
5 g of ficoll, 5 g of polyvinylpyrrolidone and 
5 g of bovine serum albumin (BSA) to 500 ml of
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water. Filter and dispense into 25ml aliquots and
store at -20°C.
12. Beta-Mercaptoethanol (BME)
Usually obtained as a 14.4M solution. Store in 
a dark bottle at 4°C.
13. TM Solution
A solution of 250mM Tris (pH8), 25mM MgCl2 and 
50mM BME.
14. DTM Solution
A solution of 100 microM of dATP, dGTP and TTP 
in TM solution.
15. OL Solution
To 250 microlitres of 90 units/ml of oligo­
nucleotide (17-base),add 1 microlitre of 0.25M EDTA 
and 1 microlitre of 0.25M Tris (pH7.5).
16. LS Solution
A solution of 25 parts of 1M Hepes (pH 
6.6), 25 parts of DTM and 7 parts of OL solution.
17. Prehybridization Solution
A solution of lOx Denhardt’s, 4xSSC, 0.1% SDS, 
10 micrograms/ml polyA and 50 micrograms/ml herring 
sperum. Herring sperm should be boiled for 5 minutes 
and the SDS to be added last.
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18. lOx Tris E Buffer
Dissolve 193.6 g of Tris, 65.6 g sodium acetate 
and 29.6 g EDTA in 3 litres of water. Adjust pH to 
7.7 with glacial acetic acid. Make final volume to 4 
litres.
19. Denaturing Solution
A solution of 0.5M sodium hydroxide and 0.5M 
sodium chloride.
20. Neutralising Solution
Dissolve 242 g of Tris, 700 g of sodium chloride 
and 353 g of sodium citrate in 3 litres of water. 
Adj ust pH to 5.5 with concentrated hydrochloric acid. 
Make final volume to 4 litres.
21. Bicarbonate Buffer (pH9.6)
Dissolve 1.59 g of sodium carbonate, 2.93 g of 
sodium hydrogen carbonate and 0.20 g of sodium azide 
in 1 litre of distilled water.
22. Phosphate Citrate Buffer (pH5.0)
28.4 g of sodium hydrogen phosphate in 1 litre 
of distilled buffer (pH5.0) water. 21.0 g of citric 
acid in 1 litre of distilled water. Mix equal 
volumes of each just prior to use.
23. Saline/Tween 20
Dissolve 45 g of NaCl in 5 litres of 
distilled water and add 2.5 ml of Tween 20.
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C. B CELL GROWTH AND DIFFERENTIATION FACTORS
Partially purified low molecular weight BCGF (BCGF-
low) prepared by Cellular Products was purchased from Sera 
Lab, Crawley Down, UK (Mehta et al 1985). Recombinant 1L4 
was kindly provided by Dr.J. Banchereau, UNICET, France as 
supernatants from COS 7 cells transfected with cDNA 
encoding human 1L-4 (Yokota et al 1986). Supernatants 
from the bladder carcinoma cell line, T24 and 
promyelocytic cell line, KGl-a were prepared by seeding 
2.5x10^ cells/ml in medium supplemented with 5% FCS, and 
incubated at 37°C for 5 days. Cells were removed by 
centrifugation and the supernatants then filtered through 
an 0.22 micron filter, aliquoted and stored at -70°C 
(Rawle et al 1986, Callard et al 1986) Recombinant 1L--6 
was kindly provided by both Immunex and Dr. Kishimoto, 
Japan.
D. CELL LINES
Indicator B cell lines for assaying B cell growth and 
differentiation factors are HFB1, L4 and CESS (Shields et 
al 1987, Hunter et al 1982, Olsson et al 1983, Muraguchi 
et al 1981). L4 and HFB1 are mycoplasma free as shown by 
repeated testing with orcein acetate staining and culture 
on PPLO agar. DNA dot blots with a mycoplasma specfic 
probe have also shown these lines to be mycoplasma free. 
CESS, however, does contain mycoplasma. An EBV producing 
marmoset B cell line, B95-8, was used to generate EBV 
containing supernatants for human B cell transformation 
(Miller et al 1972). All these B cell lines were
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maintained in cultures in Hepes buffered RPMI 1640 
supplemented with 2mM glutamine and 10% FCS.
E. RESTRICTION ENDONUCLEASES, POLYMERASE AND DNA PROBES 
Restriction endonucleases, Taql, Pstl, Hind III,
Alul, Mspl and Hinfl, were purchased from either Pharmacia 
or Northumbria Biologicals Ltd, Cramlington, England. DNA 
polymerase 1 Klenow fragment was purchased from Pharmacia. 
Various DNA probes used with their polymorphisms and 
allele frequency are listed in table 21.
F. OTHER MATERIALS
Reagents used in the ELISA assay for IgG and IgM were 
purchased from Sigma, viz horseradish peroxidase (HRP) 
conjugated affinity goat anti-human IgG/IgM, o-phenylene- 
diamine (OPD) and affinity purified goat anti-human 
IgG/IgM.
Other materials used in the Southern blotting include
q?
nitrocellulose or nylon filters and [ P] dCTP purchased 
from Du Point or Amersham, fast film (XAR-5) from Kodak, 
and electrophoresis-grade agarose powder from Betheseda 
Research Lab.
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Table 21
DNA probes used in the linkage studies
CHROMOSOME
REGION
PROBE(LOCUS) ENZYME CONSTANT
BAND
ALLELE 
LENGTH(kb)
FREQUENCY
Xqll-ql3 cpX73(DXS159) Pst 1 - 5.5 .67
1.6 .33
Xq21.3-q22 19.2(DXS3) Taq 1 - 5.1 .38
2.95,2.15 .62
Xq21.3-q22 pXG12(DXS94) Pst 1 - 7.2 .40
6.5 .60
Xq21.3-q22 S21(DXS17) Taq 1 4.0,1.0 2.2 .65
2.0 .35
cpX73 (Arveiler et al 1987);
19.2 (Aldridge et al 1984, Menlove et al 1985); 
pXG12 (Davatelis et al 1985);
S21 (Drayna and White 1985).
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Appendix 2 COMPUTER PROGRAMME FOR CALCULATING THE
VARIATION OF THE CARRIER RISK OF AN 
INDIVIDUAL WITH VARYING PROPORTION OF 
UNLINKED FAMILIES
program xla(input, output);
{
XLA CALCULATION
Function :
This program calculates the carrier risk of an 
individual depending on the proportion of the 
unlinked families.
The data can be either entered from a data file or 
keyed-in interactively. The data required are as 
follows :-
1) Family name
2) Patient name
3) Aa (probability of being a carrier when the
probe is linked with the disease locus)
4) Aa1 (probability of being a carrier when the
probe is unlinked with the disease locus)
5) aa (probability of being a normal genotype
when the probe is linked with the disease 
locus)
6) aa1 (probability of being a normal genotype
when the probe is unlinked with the 
disease locus)
7) AA (probability of being affected when the
probe is linked with the disease locus)
8) AA' (probability of being affected when the
probe is unlinked with the disease locus)
(If data file is used, each parameter must be in 
a new line)
The result of the XLA calculation is outputed to a 
file named 'XLA.OUT1.
Date ; July 1987
Version : 1
Language ; Turbo Pascal
To be run on : IBM PC and compatible using MSDOS operating
}
var
family : string[50]; 
patient : string[50]; 
in_file_name ; string[30]; 
in_file_var ; text; 
out_file_name : string[30]; 
out_file_var : text; 
d_in, d_out : text; 
from_data_file, error : boolean;
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al, a2, a3, a4, a5, a6 : real; 
bl, b2, b3, b4, b5, b6 : real;
procedure GetlnFile; 
var
io_ok : boolean; 
begin
error ;= false;
from_data_file := false;
in_file_name := ' ';
write(1 Enter data filename (ret = from keyboard) : '); 
readln(input, in_file_name); 
if (in_file_name <> 11) then begin 
assign(in_file_var, in_file_name);
{$1-} reset(in_file_var); {$1+} 
io_ok := (IOresult = 0); 
if not io_ok then begin
writeln('Input data file not found1); 
error := true; 
end else begin
from_data_file := true; 
readln(in_file_var, family); 
readln(in_file_var, patient); 
readln(in_file_var, al); 
readln(in_file_var, a2); 
readln(in_file_var, a3); 
readln(in_file_var, a4); 
readln(in_file_var, a5); 
readln(in_file_var, a6); 
close(in_file_var); 
end; 
end; 
end;
procedure GetName(var d_in, d_out : text); 
begin
write(d_out,' Enter family : ’); 
readln(d_in, family); 
write(d_out, ' Enter Patient ; ' ); 
readln(d_in, patient); 
end;
procedure PrName(var d_out : text); 
begin
writeln(d_out);
writeln(d_out, 1 FAMILY ; ', family);
writeln(d_out, ' PATIENT ; ', patient);
end;
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function power(y : real) : real; 
begin
if (y <= -38.0) then 
power := 0.0 
else
power ;= exp(y * ln(10));
end;
procedure anti_log(var al, a2, a3, a4, a5, a6 : real); 
begin
al ;= power(al); 
a2 := power(a2); 
a3 ;= power(a3); 
a4 := power(a4); 
a5 := power(a5); 
a6 ;= power(a6); 
end;
procedure GetPar(var d_in, d_out : text;
var al, a2, a3, a4, a5, a6 ; real);
begin
write(d_out, f Enter Aa : ' );
readln(d_in, al);
write(d_out, 'Enter Aa" : ');
readln(d_in, a2);
write(d_out, ’Enter aa : ’);
readln(d_in, a3);
write(d_out, 1 Enter aa" : ');
readln(d_in, a4);
write(d_out, 1 Enter AA ; f );
readln(d_in, a5);
write(d_out, ’Enter AA" : ' );
readln(d_in, a6);
end;
procedure PrProbs(var d_out : text;
al, a2, a3, a4, a5,
begin
writeln(d_out); 
writeln(d_out, 
writeln(d_out, 
writeln(d_out, 
writeln(d_out, 
writeln(d_out, 
writeln(d_out, 
writeln(d_out); 
end;
a6 : real);
1 Aa ’, bl : 10:6, I / prob(Aa ) “ /
' Aa" = ’, b2:10:6, I / prob(Aa") " /
’ aa ', b3:10:6, I r prob(aa ) ■“ /
’ aa" = ', b4:10:6, f / prob(aa") "  r
? AA = ?, b5 : 10:6 , I / prob(AA ) "  f
1 AA" = 1, b6:10:6, f r prob(AA") “ /
al:25:20) 
a2:25:20) 
a3:25:20) 
a4:25:20) 
a5:25:20) 
a6:25:20)
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function CalcXLA(al, a2, a3, a4, a5, a6, alpha : real) : real; 
var
xl, x2, x3, x4 : real; 
begin
xl := (1 - alpha) * al;
x2 := alpha * a2;
x3 := (1 - alpha) * (al + a3 + a5);
x4 := alpha * (a2 + a4 + a6);
CalcXLA ;= (xl + x2) / (x3 + x4); 
end;
procedure LoopXLA(var d_out : text;
al, a2, a3, a4, a5, a6 : real);
var
i : integer;
alpha, step, result : real; 
begin
alpha := 0.0; 
step := 0.1;
for i := 1 to 11 do begin
result ;= CalcXLA(al, a2, a3, a4, a5, a6, alpha) * 100.0; 
writeln(d_out, f Unlinked family = ’, alpha:4:l,
f, Risk = ', result;7:2); 
alpha := alpha + step; 
end; 
end;
procedure OpenOutFile; 
begin
out_file_name := f xla.out’; 
assign(out_file_var, out_file_name); 
rewrite(out_file_var); 
end;
procedure CloseOutFile; 
begin
close(out_file_var); 
end;
procedure save_input;
begin
bl = al;
b2 = a2;
b3 = a3;
b4 = a4;
b5 = a5;
b6 = a6;
end;
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begin { MAIN } 
writeln;
writeln(’XLA Calculation'); 
writeln('===============');
writeln;
GetlnFile;
if not error then begin
if from_data_file = false then begin 
GetName(input, output);
GetPar(input, output, al, a2, a3, a4, a5, a6); 
end;
save_input;
anti_log(al, a2, a3, a4, a5, a6);
OpenOutFile;
PrName(output);
PrProbs(output, al, a2, a3, a4, a5, a6);
LoopXLA(output, al, a2, a3, a4, a5, a6);
PrName(out_file_var);
PrProbs(out_file_var, al, a2, a3, a4, a5, a6); 
LoopXLA(out_file_var, al, a2, a3, a4, a5, a6);
CloseOutFile; 
writeln;
writeln('Output in XLA.OUT.'); 
end;
end. { MAIN }
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Appendix 3 INPUT AND OUTPUT FILES OF LIPED FOR THE 
ANALYSIS OF S21, pXG21 AND 19.2 DATA IN 
THE FAMILIES WITH XLA
1 0010 0.00001 XLA Linkage Study (S21)
(20A4)
(2A4,10F2.0)
(20A4)
m
2 2 
2 3 
0-1
9
0000 0000
0010 0010 
0100 0100 
0200 0200 
0300 0300 
0400 0400 
0500 0500 
0600 0600 
0700 0700 
0800 0800 
0900 0900 
1000 1000 
1500 1500 
2000 2000 
2500 2500 
3000 3000 
3500 3500 
4000 4000 
4500 4500
60000
XLA A a aff n.a
0001 9999
A A 1 0
A a 0 1
a a 0 1
S21 U L UU UL LL
6500 3500
U U 1 0  0
U L 0 1 0
L L 0 0 1
5 0Fox/Berryman(family
1.1 m n.a
1.2 f n.a UU
2.1 m n.a
2.2 1.1 1.2 f n.a UU
3.1 2.1 2.2 m aff UU
7000
5 0Parry(family 10)
1.1 m n.a
1.2 f n.a UU
2.1 1.1 1.2 m aff
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2.2
2.3
7000
8
1.1 1.2
1.1 1.2
m aff 
m aff
ORushin/Graham/Golder(family 3)
1.1 m n.a UU
1.2 f n.a UL
2.1 1.1 1.2 m n.a UU
2.2 1.1 1.2 m aff LL
2.3 1.1 1.2 m n.a UU
2.4 1.1 1.2 f n.a UL
2.5 m n.a
3.1
in•<N 2.4 m n.a UU
7000
5 0Barton(family 5)
1.1 m n.a
1.2 f n.a UU
2.1 1.1 1.2 m aff
2.2 1.1 1.2 m n.a
2.3 1.1 1.2 m aff
7000
4
1.1
1.2
2.1
2.2
7000
11
0Williams(family 6) 
m n.a 
f n.a UU
1.1 1.2 m aff
1.1 1.2 m aff
OPatterson/Williamson/Carse(family 7)
1.1 m n.a
1.2 f n.a UL
2.1 m n.a
2.2 1.1 1.2 f n.a UU
2.3 m n.a
2.4 1.1 1.2 f n.a UU
2.5 1.1 1.2 m n.a LL
3.1 2.1 2.2 m aff UU
3.2 2.1 2.2 m n.a UU
3.3 2.3 2.4 m aff UU
3.4 2.3 2.4 m aff UU
7000
12 0King/Pomfrett(family 1)
1.1 m n.a
1.2 f n.a
2.1 m n.a
2.2 1.1 1.2 f n.a UL
2.3 1.1 1.2 m n.a UU
2.4 m n.a
2.5 1.1 1.2 f n.a UL
2.6 1.1 1.2 f n.a UL
2.7 1.1 1.2 f n.a UL
2.8 1.1 1.2 f n.a UL
3.1 2.1 2.2 m aff UU
3.2 2.4 2.5 m aff UU
7000
4 0Kirsopp(family 4
1.1 m n.a
1.2 f n.a UL
2.1 1.1 1.2 m aff LL
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2.2 1.1 1.2 m aff LL
4 OCox
1.1 m n.a
1.2 f n.a UL
2.1 1.1 1.2 m aff LL
2.2 1.1 1.2 m aff LL
7000
9 0Lucken/Gach(fami!
1.1 m n.a
1.2 f n.a
2.1 m n.a
2.2 1.1 1.2 f n.a UL
2.3 m n.a
2.4 1.1 1.2 f n.a UL
3.1 2.1 2.2 m n.a LL
3.2 2.1 2.2 m aff UU
3.3 2.3 2.4 m aff UU
7000
6 0Gerrard( family l:
1.1 m n.a
1.2 f n.a UL
2.1 1.1 1.2 m n.a UU
2.2 1.1 1.2 m aff LL
2.3 1.1 1.2 m aff LL
2.4 1.1 1.2 m aff LL
7000
9 0Chaperon(French :
1.1 m n.a LL
1.2 f n.a UU
2.1 1.1 1.2 m n.a UU
2.2 m n.a
2.3 1.1 1.2 f n.a UL
2.4 1.1 1.2 m aff UU
2.5 1.1 1.2 m n.a UU
2.6 1.1 1.2 m aff UU
3.1 2.2 2.3 m aff UU
7000
7 0Gatte(French 2)
1.1 m n.a
1.2 f n.a UL
2.1 m n.a
2.2 1.1 1.2 f n.a LL
2.3 1.1 1.2 m aff LL
3.1 2.1 2.2 m aff LL
3.2 2.1 2.2 m n.a LL
7000
9 0Joliton(French 3
1.1 m n.a LL
1.2 f n.a UL
2.1 m n.a
2.2 1.1 1.2 f n.a LL
2.3 m n.a
2.4 1.1 1.2 f n.a LL
3.1 2.1 2.2 m n.a LL
3.2 2.1 2.2 m aff LL
3.3 2.3 2.4 m aff LL
9000
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Program LIPED Version for IBM PC March 1987 J. Ott
PROBLEM 1 XLA Linkage Study 
**********
PEDIGREE 1 Fox/Berryman
5 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
GENE FREQUENCIES FOR 0 XLA .0001 .9999
GENE FREQUENCIES FOR 1 S21 .6500 .3500
R MALE R FEM. L0G10(L(R)) LOD-SCORE
.5000 .5000 -4.71629 .00000
.0000 .0000 -4.71629 .00000
.0010 .0010 -4.71629 .00000
.0100 .0100 -4.71629 .00000
.0200 .0200 -4.71629 .00000
.0300 .0300 -4.71629 .00000
.0400 .0400 -4.71629 .00000
.0500 .0500 -4.71629 .00000
.0600 .0600 -4.71629 .00000
.0700 .0700 -4.71629 .00000
.0800 .0800 -4.71629 .00000
.0900 .0900 -4.71629 .00000
.1000 .1000 -4.71629 .00000
.1500 .1500 -4.71629 .00000
.2000 .2000 -4.71629 .00000
.2500 .2500 -4.71629 .00000
.3000 .3000 -4.71629 .00000
.3500 .3500 -4.71629 .00000
.4000 .4000 -4.71629 .00000
.4500 .4500 -4.71629 .00000
PEDIGREE 2 Parry
5 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -4.97631 .00000
.0000 .0000 -4.97631 .00000
Appendix 3 Page 178
0010 .0010 -4.97631 .00000
0100 .0100 -4.97631 .00000
0200 .0200 -4.97631 .00000
0300 .0300 -4.97631 .00000
0400 .0400 -4.97631 .00000
0500 .0500 -4.97631 .00000
0600 .0600 -4.97631 .00000
0700 .0700 -4.97631 .00000
0800 .0800 -4.97631 .00000
0900 .0900 -4.97631 .00000
1000 .1000 -4.97631 .00000
1500 .1500 -4.97631 .00000
2000 .2000 -4.97631 .00000
2500 .2500 -4.97631 .00000
3000 .3000 -4.97631 .00000
3500 .3500 -4.97631 .00000
4000 .4000 -4.97631 .00000
4500 .4500 -4.97631 .00000
PEDIGREE 3 Rushin/Graham/Golder
8 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.57575 .00000
.0000 .0000 -5.99298 .58276
.0010 .0010 -5.99456 .58118
.0100 .0100 -6.00879 .56696
.0200 .0200 -6.02461 .55114
.0300 .0300 -6.04044 .53531
.0400 .0400 -6.05628 .51947
.0500 .0500 -6.07211 .50363
.0600 .0600 -6.08795 .48780
.0700 .0700 -6.10377 .47198
.0800 .0800 -6.11957 .45618
.0900 .0900 -6.13534 .44041
.1000 .1000 -6.15107 .42468
.1500 .1500 -6.22879 .34695
.2000 .2000 -6.30379 .27196
.2500 .2500 -6.37406 .20168
.3000 .3000 -6.43719 .13856
.3500 .3500 -6.49060 .08515
.4000 .4000 -6.53207 .04368
.4500 .4500 -6.56036 .01539
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PEDIGREE 4 Barton
5 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
lutation rate at current main locus = . 1
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -4.97631 .00000
.0000 .0000 -4.97631 .00000
.0010 .0010 -4.97631 .00000
.0100 .0100 -4.97631 .00000
.0200 .0200 -4.97631 .00000
.0300 .0300 -4.97631 .00000
.0400 .0400 -4.97631 .00000
.0500 .0500 -4.97631 .00000
.0600 .0600 -4.97631 .00000
.0700 .0700 -4.97631 .00000
.0800 .0800 -4.97631 .00000
.0900 .0900 -4.97631 .00000
.1000 .1000 -4.97631 .00000
.1500 .1500 -4.97631 .00000
.2000 .2000 -4.97631 .00000
.2500 .2500 -4.97631 .00000
.3000 .3000 -4.97631 .00000
.3500 .3500 -4.97631 .00000
.4000 .4000 -4.97631 .00000
.4500 .4500 -4.97631 .00000
PEDIGREE 5 Williams
4 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -4.67528 .00000
.0000 .0000 -4.67528 .00000
.0010 .0010 -4.67528 .00000
.0100 .0100 -4.67528 .00000
.0200 .0200 -4.67528 .00000
.0300 .0300 -4.67528 .00000
.0400 .0400 -4.67528 .00000
.0500 .0500 -4.67528 .00000
.0600 .0600 -4.67528 .00000
.0700 .0700 -4.67528 .00000
.0800 .0800 -4.67528 .00000
.0900 .0900 -4.67528 .00000
.1000 .1000 -4.67528 .00000
.1500 .1500 -4.67528 .00000
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2000 .2000 -4.67528 .00000
2500 .2500 -4.67528 .00000
3000 .3000 -4.67528 .00000
3500 .3500 -4.67528 .00000
4000 .4000 -4.67528 .00000
4500 .4500 -4.67528 .00000
PEDIGREE 6 Patterson/Williamson/Carse
11 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -7.23847 .00000
.0000 .0000 -6.63646 .60201
.0010 .0010 -6.63776 .60071
.0100 .0100 -6.64955 .58892
.0200 .0200 -6.66278 .57569
.0300 .0300 -6.67613 .56234
.0400 .0400 -6.68961 .54886
.0500 .0500 -6.70322 .53525
.0600 .0600 -6.71696 .52151
.0700 .0700 -6.73082 .50765
.0800 .0800 -6.74480 .49366
.0900 .0900 -6.75891 .47956
.1000 .1000 -6.77313 .46534
.1500 .1500 -6.84581 .39266
.2000 .2000 -6.92044 .31803
.2500 .2500 -6.99546 .24301
.3000 .3000 -7.06823 .17024
.3500 .3500 -7.13468 .10379
.4000 .4000 -7.18926 .04921
.4500 .4500 -7.22563 .01284
PEDIGREE 7 King/Pomfrett
12 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.61601 .00000
.0000 .0000 -6.03439 .58162
.0010 .0010 -6.03523 .58078
.0100 .0100 -6.04283 .57319
.0200 .0200 -6.05135 .56467
.0300 .0300 -6.05995 .55606
.0400 .0400 -6.06865 .54737
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0500 .0500 -6.07743 .53858
0600 .0600 -6.08631 .52971
0700 .0700 -6.09528 .52073
0800 .0800 -6.10435 .51166
0900 .0900 -6.11352 .50249
1000 .1000 -6.12280 .49322
1500 .1500 -6.17080 .44521
2000 .2000 -6.22181 .39421
2500 .2500 -6.27621 .33980
3000 .3000 -6.33446 .28155
3500 .3500 -6.39705 .21897
4000 .4000 -6.46450 .15151
4500 .4500 -6.53735 .07867
PEDIGREE 8 Kirsopp
4 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -5.24516 .00000
.0000 .0000 -4.94414 .30102
.0010 .0010 -4.94500 .30015
.0100 .0100 -4.95282 .29234
.0200 .0200 -4.96150 .28365
.0300 .0300 -4.97018 .27498
.0400 .0400 -4.97884 .26632
.0500 .0500 -4.98749 .25767
.0600 .0600 -4.99611 .24904
.0700 .0700 -5.00471 .24044
.0800 .0800 -5.01329 .23187
.0900 .0900 -5.02182 .22333
.1000 .1000 -5.03032 .21484
.1500 .1500 -5.07198 .17318
.2000 .2000 -5.11162 .13353
.2500 .2500 -5.14825 .09691
.3000 .3000 -5.18070 .06446
.3500 .3500 -5.20773 .03743
.4000 .4000 -5.22812 .01703
.4500 .4500 -5.24083 .00432
PEDIGREE 9 Cox
4 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
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5000 .5000 -5.24516 .00000
0000 .0000 -4.94414 .30102
0010 .0010 -4.94500 .30015
0100 .0100 -4.95282 .29234
0200 .0200 -4.96150 .28365
0300 .0300 -4.97018 .27498
0400 .0400 -4.97884 .26632
0500 .0500 -4.98749 .25767
0600 .0600 -4.99611 .24904
0700 .0700 -5.00471 .24044
0800 .0800 -5.01329 .23187
0900 .0900 -5.02182 .22333
1000 .1000 -5.03032 .21484
1500 .1500 -5.07198 .17318
2000 .2000 -5.11162 .13353
2500 .2500 -5.14825 .09691
3000 .3000 -5.18070 .06446
3500 .3500 -5.20773 .03743
4000 .4000 -5.22812 .01703
4500 .4500 -5.24083 .00432
PEDIGREE 10 Lucken/Gach
9 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.57425 .00000
.0000 .0000 -5.84731 .72694
.0010 .0010 -5.84892 .72533
.0100 .0100 -5.86342 .71083
.0200 .0200 -5.87963 .69463
.0300 .0300 -5.89592 .67833
.0400 .0400 -5.91230 .66196
.0500 .0500 -5.92876 .64549
.0600 .0600 -5.94531 .62894
.0700 .0700 -5.96193 .61232
.0800 .0800 -5.97864 .59561
.0900 .0900 -5.99542 .57883
.1000 .1000 -6.01227 .56198
.1500 .1500 -6.09746 .47679
.2000 .2000 -6.18360 .39065
.2500 .2500 -6.26943 .30482
.3000 .3000 -6.35283 .22142
.3500 .3500 -6.43049 .14376
.4000 .4000 -6.49751 .07674
.4500 .4500 -6.54763 .02662
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PEDIGREE 11 Gerrard
6 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
Mutation rate at current main locus = .1
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.44928 .00000
.0000 .0000 -5.54620 .90308
.0010 .0010 -5.54794 .90134
.0100 .0100 -5.56366 .88562
.0200 .0200 -5.58130 .86798
.0300 .0300 -5.59911 .85016
.0400 .0400 -5.61711 .83216
.0500 .0500 -5.63530 .81398
.0600 .0600 -5.65368 .79560
.0700 .0700 -5.67225 .77702
.0800 .0800 -5.69102 .75825
.0900 .0900 -5.70999 .73929
.1000 .1000 -5.72916 .72011
.1500 .1500 -5.82810 .62118
.2000 .2000 -5.93214 .51713
.2500 .2500 -6.04062 .40866
.3000 .3000 -6.15139 .29789
.3500 .3500 -6.25948 .18979
.4000 .4000 -6.35530 .09398
.4500 .4500 -6.42393 .02535
PEDIGREE 12 Chaperon
9 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.63640 .00000
.0000 .0000 -6.33538 .30102
.0010 .0010 -6.33582 .30058
.0100 .0100 -6.33975 .29665
.0200 .0200 -6.34415 .29224
.0300 .0300 -6.34861 .28779
.0400 .0400 -6.35311 .28329
.0500 .0500 -6.35766 .27874
.0600 .0600 -6.36225 .27415
.0700 .0700 -6.36690 .26950
.0800 .0800 -6.37159 .26481
.0900 .0900 -6.37634 .26006
.1000 .1000 -6.38114 .25526
.1500 .1500 -6.40596 .23044
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2000 .2000 -6.43229 .20411
2500 .2500 -6.46032 .17608
3000 .3000 -6.49028 .14612
3500 .3500 -6.52246 .11394
4000 .4000 -6.55722 .07918
4500 .4500 -6.59501 .04139
PEDIGREE 13 Gatte
7 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
lutation rate at current main locus = . I
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.30317 .00000
.0000 .0000 -6.00217 .30100
.0010 .0010 -6.00304 .30013
.0100 .0100 -6.01086 .29231
.0200 .0200 -6.01954 .28363
.0300 .0300 -6.02821 .27496
.0400 .0400 -6.03687 .26630
.0500 .0500 -6.04552 .25765
.0600 .0600 -6.05415 .24902
.0700 .0700 -6.06275 .24042
.0800 .0800 -6.07132 .23185
.0900 .0900 -6.07986 .22331
.1000 .1000 -6.08835 .21482
.1500 .1500 -6.13000 .17316
. 2000 .2000 -6.16965 .13352
.2500 .2500 -6.20627 .09690
.3000 .3000 -6.23872 .06445
.3500 .3500 -6.26575 .03742
.4000 .4000 -6.28614 .01703
.4500 .4500 -6.29885 .00432
PEDIGREE 14 Joliton
9 PERSONS
LOCUS 0 XLA VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.60421 .00000
.0000 .0000 -6.30324 .30098
.0010 .0010 -6.30411 .30011
.0100 .0100 -6.31192 .29229
.0200 .0200 -6.32060 .28361
.0300 .0300 -6.32928 .27494
.0400 .0400 -6.33794 .26628
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0500
0600
0700
0800
0900
1000
1500
2000
2500
3000
3500
4000
4500
.0500
.0600
.0700
.0800
.0900
.1000
.1500
.2000
.2500
.3000
.3500
.4000
.4500
-6.34658 
-6.35521 
-6.36381 
-6.37238 
-6.38092 
-6.38941 
-6.43106 
-6.47070 
-6.50733 
-6.53977 
-6.56680 
-6.58719 
-6.59989
SUMMARY
R MALE R FEM. SUM OF LODS
.0000 .0000 4.90144
.0010 .0010 4.89047
.0100 .0100 4.79144
.0200 .0200 4.68090
.0300 .0300 4.56986
.0400 .0400 4.45831
.0500 .0500 4.34629
.0600 .0600 4.23382
.0700 .0700 4.12091
.0800 .0800 4.00760
.0900 .0900 3.89391
.1000 .1000 3.77988
.1500 .1500 3.20590
.2000 .2000 2.63019
.2500 .2500 2.06166
.3000 .3000 1.51357
.3500 .3500 1.00509
.4000 .4000 .56242
.4500 .4500 .21753
.25763
.24900
.24040
.23183
.22330
.21480
.17315
.13351
.09689
.06444
.03742
.01703
.00432
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1 0010 0.00001 XLA Linkage Study (pXG12) 
(20A4)
(2A4,10F2.0)
(20A4)
m
2 2 
2 3 
0-1
9
0000 0000
0010 0010 
0100 0100 
0200 0200 
0300 0300 
0400 0400 
0500 0500 
0600 0600 
0700 0700 
0800 0800 
0900 0900 
1000 1000 
1500 1500 
2000 2000 
2500 2500 
3000 3000 
3500 3500 
4000 4000 
4500 4500
60000
XLA A a aff n.a
0001 9999
A A 1 0
A a 0 1
a a 0 1
XG12 U L UU UL
4000 6000
U U 1 0 0
U L 0 1 0
L L 0 0 1
5 0Fox/Berryman(family 11)
1.1 m n. a UU
1.2 f n.a UL
2.1 m n.a
2.2 1.1 1.2 f n.a UL
3.1 2.1 2.2 m aff LL
7000
5 0Parry(family 10)
1.1 m n.a
1.2 f n.a UL
2.1 1.1 1.2 m aff UU
2.2 1.1 1.2 m aff UU
2.3 1.1 1.2 m aff UU
7000
5 ORushin/Graham/Golder(family 3)
1.1 m n. a UU
1.2 f n.a UL
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2.1 1.1 1.2 m n.a LL
2.2 1.1 1.2 m aff UU
2.3 1.1 1.2 m n.a LL
7000
5 OBarton( family 5)
1.1 m n.a
1.2 f n.a UL
2.1 1.1 1.2 m aff LL
2.2 1.1 1.2 m n.a UU
2.3 1.1 1.2 m aff LL
7000
4
1.1
1.2
2.1
2.2
7000
11
OWilliams(family 6) 
m n.a 
f n.a UL
1.1 1.2 m aff LL
1.1 1.2 m aff LL
OPatterson/Williamson/Carse(family 7)
1.1 m n.a
1.2 f n.a UL
2.1 m n.a
2.2 1.1 1.2 f n.a LL
2.3 m n.a
2.4 1.1 1.2 f n.a LL
2.5 1.1 1.2 m n.a UU
3.1 2.1 2.2 m aff LL
3.2 2.1 2.2 m n.a LL
3.3 2.3 2.4 m aff LL
3.4 2.3 2.4 m aff LL
7000
12 OKing/Pomfrett(family 1)
1.1 m n.a UU
1.2 f n.a LL
2.1 m n.a
2.2 1.1 1.2 f n.a UL
2.3 1.1 1.2 m n.a LL
2.4 m n.a
2.5 1.1 1.2 f n.a UL
2.6 1.1 1.2 f n.a UL
2.7 1.1 1.2 f n.a UL
2.8 1.1 1.2 f n.a UL
3.1 2.1 2.2 m aff LL
3.2 2.4 2.5 m aff LL
7000
4 OKirsopp(family 4
1.1 m n.a
1.2 f n.a UL
2.1 1.1 1.2 m aff UU
2.2 1.1 1.2 m aff UU
4 OCox(family 8)
1.1 m n.a
1.2 f n.a LL
2.1 1.1 1.2 m aff LL
2.2 1.1 1.2 m aff LL
7000
9 OChaperon(French :
1.1 m n.a UU
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1.2 f n.a UL
2.1 1.1 1.2 m n.a UU
2.2 m n.a
2.3 1.1 1.2 f n.a UL
2.4 1.1 1.2 m aff LL
2.5 1.1 1.2 m n.a UU
2.6 1.1 1.2 m aff LL
3.1 2.2 2.3 m aff LL
7000
7 0Gatte(French 2)
1.1 m n.a UU
1.2 f n.a LL
2.1 m n.a
2.2 1.1 1.2 f n.a UL
2.3 1.1 1.2 m aff LL
3.1 2.1 2.2 m aff LL
3.2 2.1 2.2 m n.a UU
7000
9 0Joliton(French 3)
1.1 m n.a UU
1.2 f n.a LL
2.1 m n.a
2.2 1.1 1.2 f n.a UL
2.3 m n.a
2.4 1.1 1.2 f n.a UL
3.1 2.1 2.2 m n.a UU
3.2 2.1 2.2 m aff LL
3.3 2.3 2.4 m aff LL
9000
Appendix 3
Program LIPED Version for IBM PC March 1987
PROBLEM 1 XLA Linkage Study 
* * * * * * * * * *
PEDIGREE 1 Fox/Berryman
5 PERSONS
LOCUS 0 XLA VS. LOCUS 1 XG12
Mutation rate at current main locus = .000010000000
GENE FREQUENCIES FOR 0 XLA .0001 .9999
GENE FREQUENCIES FOR 1 XG12 .4000 .6000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -5.47379 .00000
.0000 .0000 -5.23971 .23408
.0010 .0010 -5.24007 .23372
.0100 .0100 -5.24335 .23045
.0200 .0200 -5.24701 .22678
.0300 .0300 -5.25071 .22308
.0400 .0400 -5.25444 .21936
.0500 .0500 -5.25820 .21560
.0600 .0600 -5.26199 .21180
.0700 .0700 -5.26581 .20798
.0800 .0800 -5.26967 .20412
.0900 .0900 -5.27357 .20022
.1000 .1000 -5.27750 .19629
.1500 .1500 -5.29770 .17609
.2000 .2000 -5.31889 .15490
.2500 .2500 -5.34117 .13262
.3000 .3000 -5.36465 .10914
.3500 .3500 -5.38947 .08432
.4000 .4000 -5.41580 .05799
.4500 .4500 -5.44383 .02996
PEDIGREE 2 Parry
5 PERSONS
LOCUS 0 XLA VS. LOCUS 1 XG12
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -5.82398 .00000
.0000 .0000 -5.22194 .60205
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0010 .0010 -5.22324 .60074
0100 .0100 -5.23503 .58895
0200 .0200 -5.24825 .57573
0300 .0300 -5.26161 .56238
0400 .0400 -5.27509 .54889
0500 .0500 -5.28870 .53528
0600 .0600 -5.30244 .52154
0700 .0700 -5.31630 .50768
0800 .0800 -5.33029 .49370
0900 .0900 -5.34439 .47959
1000 .1000 -5.35861 .46537
1500 .1500 -5.43130 .39269
2000 .2000 -5.50593 .31805
2500 .2500 -5.58095 .24303
3000 .3000 -5.65373 .17026
3500 .3500 -5.72018 .10380
4000 .4000 -5.77477 .04922
4500 .4500 -5.81115 .01284
PEDIGREE 3 Rushin/Graham/Golder
5 PERSONS
LOCUS 0 XLA VS. LOCUS 1 XG12
lutation rate at current main locus = . I
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.07583 .00000
.0000 .0000 -5.57850 .49733
.0010 .0010 -5.57968 .49615
.0100 .0100 -5.59038 .48544
.0200 .0200 -5.60235 .47347
.0300 .0300 -5.61441 .46142
.0400 .0400 -5.62654 .44929
.0500 .0500 -5.63875 .43708
.0600 .0600 -5.65103 .42479
.0700 .0700 -5.66338 .41244
.0800 .0800 -5.67580 .40002
.0900 .0900 -5.68828 .38755
.1000 .1000 -5.70081 .37501
.1500 .1500 -5.76407 .31176
.2000 .2000 -5.82750 .24833
.2500 .2500 -5.88951 .18631
.3000 .3000 -5.94779 .12803
.3500 .3500 -5.99924 .07659
.4000 .4000 -6.04011 .03572
.4500 .4500 -6.06662 .00921
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PEDIGREE 4 Barton
5 PERSONS
LOCUS 0 XLA VS. LOCUS 1 XG12
lutation rate at current main locus = J
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -5.82399 .00000
.0000 .0000 -5.22194 .60205
.0010 .0010 -5.22324 .60075
.0100 .0100 -5.23503 .58896
.0200 .0200 -5.24826 .57573
.0300 .0300 -5.26161 .56238
.0400 .0400 -5.27509 .54890
.0500 .0500 -5.28870 .53528
.0600 .0600 -5.30244 .52155
.0700 .0700 -5.31630 .50768
.0800 .0800 -5.33029 .49370
.0900 .0900 -5.34439 .47960
.1000 .1000 -5.35862 .46537
.1500 .1500 -5.43130 .39269
.2000 .2000 -5.50593 .31806
.2500 .2500 -5.58096 .24303
.3000 .3000 -5.65373 .17026
.3500 .3500 -5.72019 .10380
.4000 .4000 -5.77477 .04922
.4500 .4500 -5.81115 .01284
PEDIGREE 5 Williams
4 PERSONS
LOCUS 0 XLA VS. LOCUS 1 XG12
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -5.22193 .00000
.0000 .0000 -4.92091 .30102
.0010 .0010 -4.92177 .30015
.0100 .0100 -4.92959 .29234
.0200 .0200 -4.93827 .28365
.0300 .0300 -4.94695 .27498
.0400 .0400 -4.95561 .26632
.0500 .0500 -4.96426 .25767
.0600 .0600 -4.97288 .24904
.0700 .0700 -4.98148 .24044
.0800 .0800 -4.99006 .23187
.0900 .0900 -4.99859 .22333
.1000 .1000 -5.00709 .21484
.1500 .1500 -5.04875 .17318
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2000 .2000 -5.08839 .13353
2500 .2500 -5.12502 .09691
3000 .3000 -5.15747 .06446
3500 .3500 -5.18450 .03743
4000 .4000 -5.20489 .01703
4500 .4500 -5.21760 .00432
PEDIGREE 6 Patterson/Williamson/Carse
11 PERSONS
LOCUS 0 XLA VS. LOCUS XG12
lutation rate at current main locus = . 1
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -7.25000 .00000
.0000 .0000 -6.64799 .60201
.0010 .0010 -6.64929 .60071
.0100 .0100 -6.66108 .58892
.0200 .0200 -6.67431 .57569
.0300 .0300 -6.68766 .56234
.0400 .0400 -6.70114 .54886
.0500 .0500 -6.71475 .53525
.0600 .0600 -6.72849 .52151
.0700 .0700 -6.74235 .50765
.0800 .0800 -6.75634 .49366
.0900 .0900 -6.77044 .47956
.1000 .1000 -6.78466 .46534
.1500 .1500 -6.85734 .39266
.2000 .2000 -6.93197 .31803
.2500 .2500 -7.00699 .24301
.3000 .3000 -7.07976 .17024
.3500 .3500 -7.14621 .10379
.4000 .4000 -7.20079 .04921
.4500 .4500 -7.23716 .01284
000010000000
PEDIGREE King/Pomfrett 
12 PERSONS
LOCUS 0 XLA VS. LOCUS XG12
Mutation rate at current main locus = .0 0 0 0 1 0 0 0 0 0 0 0
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.64794 .00000
.0000 .0000 -6.04593 .60201
.0010 .0010 -6.04680 .60114
.0100 .0100 -6.05466 .59328
.0200 .0200 -6.06347 .58447
.0300 .0300 -6.07238 .57556
.0400 .0400 -6.08138 .56656
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0500 .0500 -6.09048 .55746
0600 .0600 -6.09967 .54827
0700 .0700 -6.10896 .53898
0800 .0800 -6.11835 .52959
0900 .0900 -6.12784 .52010
1000 .1000 -6.13744 .51050
1500 .1500 -6.18708 .46086
2000 .2000 -6.23974 .40820
2500 .2500 -6.29579 .35215
3000 .3000 -6.35571 .29223
3500 .3500 -6.42008 .22786
4000 .4000 -6.48959 .15835
4500 .4500 -6.56516 .08278
PEDIGREE 8 Kirsopp
4 PERSONS
LOCUS 0 XLA VS. LOCUS 1 XG12
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -5.22193 .00000
.0000 .0000 -4.92091 .30102
.0010 .0010 -4.92177 .30015
.0100 .0100 -4.92959 .29234
.0200 .0200 -4.93827 .28365
.0300 .0300 -4.94695 .27498
.0400 .0400 -4.95561 .26632
.0500 .0500 -4.96426 .25767
.0600 .0600 -4.97288 .24904
.0700 .0700 -4.98148 .24044
.0800 .0800 -4.99006 .23187
.0900 .0900 -4.99859 .22333
.1000 .1000 -5.00709 .21484
.1500 .1500 -5.04875 .17318
.2000 .2000 -5.08839 .13353
.2500 .2500 -5.12502 .09691
.3000 .3000 -5.15747 .06446
.3500 .3500 -5.18450 .03743
.4000 .4000 -5.20489 .01703
.4500 .4500 -5.21760 .00432
PEDIGREE 9 Cox
4 PERSONS
LOCUS 0 XLA VS. LOCUS 1 XG12
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
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5000 .5000 -4.74480 .00000
0000 .0000 -4.74480 .00000
0010 .0010 -4.74480 .00000
0100 .0100 -4.74480 .00000
0200 .0200 -4.74480 .00000
0300 .0300 -4.74480 .00000
0400 .0400 -4.74480 .00000
0500 .0500 -4.74480 .00000
0600 .0600 -4.74480 .00000
0700 .0700 -4.74480 .00000
0800 .0800 -4.74480 .00000
0900 .0900 -4.74480 .00000
1000 .1000 -4.74480 .00000
1500 .1500 -4.74480 .00000
2000 .2000 -4.74480 .00000
2500 .2500 -4.74480 .00000
3000 .3000 -4.74480 .00000
3500 .3500 -4.74480 .00000
4000 .4000 -4.74480 .00000
4500 .4500 -4.74480 .00000
PEDIGREE 10 Chaperon
9 PERSONS
LOCUS 0 XLA VS. LOCUS 1 XG12
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -8.02814 .00000
.0000 .0000 -6.52302 1.50512
.0010 .0010 -6.52563 1.50251
.0100 .0100 -6.54921 1.47893
.0200 .0200 -6.57566 1.45248
.0300 .0300 -6.60239 1.42575
.0400 .0400 -6.62939 1.39875
.0500 .0500 -6.65668 1.37146
.0600 .0600 -6.68425 1.34389
.0700 .0700 -6.71212 1.31602
.0800 .0800 -6.74029 1.28785
.0900 .0900 -6.76877 1.25937
.1000 .1000 -6.79756 1.23059
.1500 .1500 -6.94643 1.08171
.2000 .2000 -7.10405 .92409
.2500 .2500 -7.27086 .75728
.3000 .3000 -7.44619 .58195
.3500 .3500 -7.62630 .40184
.4000 .4000 -7.80037 .22777
.4500 .4500 -7.94516 .08298
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PEDIGREE 11 Gatte
7 PERSONS
LOCUS 0 XLA VS. LOCUS 1 XG12
lutation rate at current main locus = .1
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.34689 .00000
.0000 .0000 -5.74485 .60204
.0010 .0010 -5.74572 .60117
.0100 .0100 -5.75358 .59331
.0200 .0200 -5.76240 .58449
.0300 .0300 -5.77131 .57558
.0400 .0400 -5.78031 .56658
.0500 .0500 -5.78940 .55748
.0600 .0600 -5.79859 .54829
.0700 .0700 -5.80788 .53900
.0800 .0800 -5.81727 .52961
.0900 .0900 -5.82677 .52012
.1000 .1000 -5.83636 .51052
.1500 .1500 -5.88601 .46088
.2000 .2000 -5.93867 .40822
.2500 .2500 -5.99472 .35216
.3000 .3000 -6.05465 .29224
.3500 .3500 -6.11901 .22787
.4000 .4000 -6.18853 .15835
.4500 .4500 -6.26411 .08278
PEDIGREE 12 Joliton
9 PERSONS
LOCUS 0 XLA VS. LOCUS 1 XG12
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.94896 .00000
.0000 .0000 -6.04592 .90304
.0010 .0010 -6.04723 .90173
.0100 .0100 -6.05902 .88994
.0200 .0200 -6.07224 .87672
.0300 .0300 -6.08561 .86335
.0400 .0400 -6.09911 .84985
.0500 .0500 -6.11275 .83621
.0600 .0600 -6.12654 .82242
.0700 .0700 -6.14047 .80849
.0800 .0800 -6.15456 .79440
.0900 .0900 -6.16880 .78017
.1000 .1000 -6.18319 .76577
.1500 .1500 -6.25766 .69130
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2000
2500
3000
3500
4000
4500
.2000
.2500
.3000
.3500
.4000
.4500
-6.33664
-6.42073
-6.51061
-6.60716
-6.71144
-6.82480
SUMMARY
R MALE R FEM. SUM OF LODS
.0000 .0000 6.75176
.0010 .0010 6.73892
.0100 .0100 6.62285
.0200 .0200 6.49286
.0300 .0300 6.36180
.0400 .0400 6.22966
.0500 .0500 6.09645
.0600 .0600 5.96216
.0700 .0700 5.82681
.0800 .0800 5.69040
.0900 .0900 5.55294
.1000 .1000 5.41444
.1500 .1500 4.70699
.2000 .2000 3.97727
.2500 .2500 3.23165
.3000 .3000 2.48161
.3500 .3500 1.74653
.4000 .4000 1.05741
.4500 .4500 .45902
.61232
.52823
.43835
.34180
.23752
.12417
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1 0010 0.00001 XLA Linkage Study 
(20A4)
(2A4,10F2.0)
(20A4)
m
2 2 
2 3 
0-1
9
0000 0000
0010 0010 
0100 0100 
0200 0200 
0300 0300 
0400 0400 
0500 0500 
0600 0600 
1000 1000 
1400 1400 
1500 1500 
1600 1600 
1900 1900 
2000 2000 
2500 2500 
3000 3000 
3500 3500 
4000 4000 
4500 4500
60000
XLA A a aff n.a
0001 9999
A A 1 0
A a 0 1
a a 0 1
19-2 U L UU UL
3800 6200
U U 1 0 0
U L 0 1 0
L L 0 0 1
5 0Fox/Berryman(family 11)
1.1 m n.a
1.2 f n.a UU
2.1 m n.a
2.2 1.1 1.2 f n.a UU
3.1 2.1 2.2 m aff UU
7000
5 0Parry(family 10)
1.1 m n.a
1.2 f n.a UL
2.1 1.1 1.2 m aff LL
2.2 1.1 1.2 m aff LL
2.3 1.1 1.2 m aff LL
7000
9 ORushin/Graham/Golder(family 3)
1.1 m n.a
1.2 f n.a LL
(19.2)
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2.1 1.1 1.2 m n.a LL
2.2 1.1 1.2 m aff LL
2.3 1.1 1.2 m n.a LL
2.4 1.1 1.2 f n.a UL
2.5 m n.a
3.1 2.4 2.5 m aff
3.2 2.4 2.5 m aff
7000
5 0Barton( family 5)
1.1
1.2
2.1
2.2
2.3
7000
4
1.1
1.2
2.1
2.2
7000
11
1.1 1.2
1.1 1.2
1.1 1.2
m n.a 
f n.a 
m aff 
m n.a 
m aff
UL
LL
UU
LL
0Williams(family 6) 
m n.a 
f n.a UL
1.1 1.2 m aff UU
1.1 1.2 m aff UU
OPatterson/Williamson/Carse(family 7)
1.1 m n.a
1.2 f n.a LL
2.1 m n.a
2.2 1.1 1.2 f n.a LL
2.3 m n.a
2.4 1.1 1.2 f n.a LL
2.5 1.1 1.2 m n.a LL
3.1 2.1 2.2 m aff
3.2 2.1 2.2 m n.a
3.3 2.3 2.4 m aff
3.4 2.3 2.4 m aff
7000
12 0King/Pomfrett(family 1)
1.1 m n.a
1.2 f n.a
2.1 m n.a
2.2 1.1 1.2 f n.a UL
2.3 1.1 1.2 m n.a UU
2.4 m n.a
2.5 1.1 1.2 f n.a UL
2.6 1.1 1.2 f n.a UL
2.7 1.1 1.2 f n.a UL
2.8 1.1 1.2 f n.a UL
3.1 2.1 2.2 m aff UU
3.2 2.4 2.5 m aff UU
7000
4
1.1
1.2
2.1
2.2
7000
4
1.1
1.2
0Kirsopp(family 4) 
m n.a 
f n.a LL
1.1 1.2 m aff
1.1 1.2 m aff
0Cox(family 8) 
m n.a 
f n.a LL
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2.1 1.1 1.2 m aff LL
2.2 1.1 1.2 m aff LL
7000
9 0Lucken/Gach(family 2)
1.1 m n.a
1.2 f n.a
2.1 m n.a
2.2 1.1 1.2 f n.a UL
2.3 m n.a
2.4 1.1 1.2 f n.a UL
3.1 2.1 2.2 m n.a LL
3.2 2.1 2.2 m aff UU
3.3 2.3 2.4 m aff UU
7000
6 OGerrard(family 12)
1.1 m n.a
1.2 f n.a LL
2.1 1.1 1.2 m n.a
2.2 1.1 1.2 m aff
2.3 1.1 1.2 m aff
2.4 1.1 1.2 m aff
7000
5 OMann(family 14)
1.1 m n.a
1.2 f n.a UL
2.1 1.1 1.2 m aff LL
2.2 1.1 1.2 m aff UU
2.3 1.1 1.2 m aff UU
7000
9 OChaperon(French 1)
1.1 m n.a UU
1.2 f n.a
2.1 1.1 1.2 m n.a LL
2.2 m n.a
2.3 1.1 1.2 f n.a UL
2.4 1.1 1.2 m aff LL
2.5 1.1 1.2 m n.a LL
2.6 1.1 1.2 m aff LL
3.1 2.2 2.3 m aff LL
7000
7 OGatte(French 2)
1.1 m n.a LL
1.2 f n.a UU
2.1 m n.a
2.2 1.1 1.2 f n.a UL
2.3 1.1 1.2 m aff UU
3.1 2.1 2.2 m aff UU
3.2 2.1 2.2 m n.a LL
7000
9 0Joliton(French 3)
1.1 m n.a LL
1.2 f n.a UL
2.1 m n.a
2.2 1.1 1.2 f n.a UL
2.3 m n.a
2.4 1.1 1.2 f n.a UL
3.1 2.1 2.2 m n.a LL
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3.2 2.1 2.2 m aff UU
3.3 2.3 2.4 m aff UU
9000
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Program LIPED Version for IBM PC March 1987 J. Ott
PROBLEM 1 XLA Linkage Study 
* * * * * * * * * *
PEDIGREE 1 Fox/Berryman
5 PERSONS
LOCUS 0 XLA VS. LOCUS 1 19-2
Mutation rate at current main locus = .000010000000
GENE FREQUENCIES FOR 0 XLA .0001 .9999
GENE FREQUENCIES FOR 1 19-2 .3800 .6200
R MALE R FEM. L0G10(L(R)) LOD-SCORE
.5000 .5000 -5.41568 .00000
.0000 .0000 -5.41568 .00000
.0010 .0010 -5.41568 .00000
.0100 .0100 -5.41568 .00000
.0200 .0200 -5.41568 .00000
.0300 .0300 -5.41568 .00000
.0400 .0400 -5.41568 .00000
.0500 .0500 -5.41568 .00000
.0600 .0600 -5.41568 .00000
.1000 .1000 -5.41568 .00000
.1400 .1400 -5.41568 .00000
.1500 .1500 -5.41568 .00000
.1600 .1600 -5.41568 .00000
.1900 .1900 -5.41568 .00000
.2000 .2000 -5.41568 .00000
.2500 .2500 -5.41568 .00000
.3000 .3000 -5.41568 .00000
.3500 .3500 -5.41568 .00000
.4000 .4000 -5.41568 .00000
.4500 .4500 -5.41568 .00000
PEDIGREE 2 Parry
5 PERSONS
LOCUS 0 XLA VS. LOCUS 1 19-2
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -5.83202 .00000
.0000 .0000 -5.22997 .60205
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.0010 .0010 -5.23128 .60074
.0100 .0100 -5.24307 .58895
.0200 .0200 -5.25629 .57573
.0300 .0300 -5.26964 .56238
.0400 .0400 -5.28313 .54889
.0500 .0500 -5.29674 .53528
.0600 .0600 -5.31047 .52154
.1000 .1000 -5.36665 .46537
.1400 .1400 -5.42460 .40741
.1500 .1500 -5.43933 .39269
.1600 .1600 -5.45414 .37788
.1900 .1900 -5.49894 .33308
.2000 .2000 -5.51396 .31805
.2500 .2500 -5.58899 .24303
.3000 .3000 -5.66176 .17026
.3500 .3500 -5.72822 .10380
.4000 .4000 -5.78280 .04922
.4500 .4500 -5.81918 .01284
PEDIGREE 3 Rushin/Graham/Golder 
9 PERSONS
LOCUS 0 XLA VS. LOCUS 1 19
Mutation rate at current main locus = . 1
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.34070 .00000
.0000 .0000 -6.34070 .00000
.0010 .0010 -6.34070 .00000
.0100 .0100 -6.34070 .00000
.0200 .0200 -6.34070 .00000
.0300 .0300 -6.34070 .00000
.0400 .0400 -6.34070 .00000
.0500 .0500 -6.34070 .00000
.0600 .0600 -6.34070 .00000
.1000 .1000 -6.34070 .00000
.1400 .1400 -6.34070 .00000
.1500 .1500 -6.34070 .00000
.1600 .1600 -6.34070 .00000
.1900 .1900 -6.34070 .00000
.2000 .2000 -6.34070 .00000
.2500 .2500 -6.34070 .00000
.3000 .3000 -6.34070 .00000
.3500 .3500 -6.34070 .00000
.4000 .4000 -6.34070 .00000
.4500 .4500 -6.34070 .00000
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PEDIGREE 4 Barton
5 PERSONS
LOCUS 0 XLA VS. LOCUS 19-2
lutation rate at current main locus = . I
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -5.83203 .00000
.0000 .0000 -5.22998 .60205
.0010 .0010 -5.23128 .60075
.0100 .0100 -5.24307 .58896
.0200 .0200 -5.25629 .57573
.0300 .0300 -5.26965 .56238
.0400 .0400 -5.28313 .54890
.0500 .0500 -5.29674 .53528
.0600 .0600 -5.31048 .52155
.1000 .1000 -5.36665 .46537
.1400 .1400 -5.42461 .40742
.1500 .1500 -5.43934 .39269
.1600 .1600 -5.45414 .37788
.1900 .1900 -5.49895 .33308
.2000 .2000 -5.51397 .31806
.2500 .2500 -5.58899 .24303
.3000 .3000 -5.66177 .17026
.3500 .3500 -5.72822 .10380
.4000 .4000 -5.78281 .04922
.4500 .4500 -5.81919 .01284
000010000000
PEDIGREE 5 Williams
4 PERSONS
LOCUS 0 XLA VS. LOCUS 19-2
Mutation rate at current main locus = .0 0 0 0 1 0 0 0 0 0 0 0
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -5.22996 .00000
.0000 .0000 -4.92894 .30102
.0010 .0010 -4.92981 .30015
.0100 .0100 -4.93763 .29234
.0200 .0200 -4.94631 .28365
.0300 .0300 -4.95498 .27498
.0400 .0400 -4.96364 .26632
.0500 .0500 -4.97229 .25767
.0600 .0600 -4.98092 .24904
.1000 .1000 -5.01513 .21484
.1400 .1400 -5.04858 .18138
.1500 .1500 -5.05678 .17318
.1600 .1600 -5.06490 .16506
.1900 .1900 -5.08871 .14126
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2000 .2000 -5.09643 .13353
2500 .2500 -5.13306 .09691
3000 .3000 -5.16551 .06446
3500 .3500 -5.19254 .03743
4000 .4000 -5.21293 .01703
4500 .4500 -5.22564 .00432
PEDIGREE 6 Patterson/Williamson/Carse
11 PERSONS
LOCUS 0 XLA VS. LOCUS 19-2
lutation rate at current main locus = J
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.42913 .00000
.0000 .0000 -6.42913 .00000
.0010 .0010 -6.42913 .00000
.0100 .0100 -6.42913 .00000
.0200 .0200 -6.42913 .00000
.0300 .0300 -6.42913 .00000
.0400 .0400 -6.42913 .00000
.0500 .0500 -6.42913 .00000
.0600 .0600 -6.42913 .00000
.1000 .1000 -6.42913 .00000
.1400 .1400 -6.42913 .00000
.1500 .1500 -6.42913 .00000
.1600 .1600 -6.42913 .00000
.1900 .1900 -6.42913 .00000
.2000 .2000 -6.42913 .00000
.2500 .2500 -6.42913 .00000
.3000 .3000 -6.42913 .00000
.3500 .3500 -6.42913 .00000
.4000 .4000 -6.42913 .00000
.4500 .4500 -6.42913 .00000
.000010000000
PEDIGREE King/Pomfrett 
12 PERSONS
LOCUS 0 XLA VS. LOCUS 19-2
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.82002 .00000
.0000 .0000 -6.25233 .56769
.0010 .0010 -6.25311 .56691
.0100 .0100 -6.26018 .55984
.0200 .0200 -6.26812 .55190
.0300 .0300 -6.27617 .54385
.0400 .0400 -6.28432 .53571
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.0500 .0500 -6.29257 .52745
.0600 .0600 -6.30092 .51910
.1000 .1000 -6.33546 .48456
.1400 .1400 -6.37189 .44813
.1500 .1500 -6.38132 .43870
.1600 .1600 -6.39088 .42914
.1900 .1900 -6.42037 .39965
.2000 .2000 -6.43049 .38953
.2500 .2500 -6.48336 .33666
.3000 .3000 -6.54038 .27964
.3500 .3500 -6.60203 .21799
.4000 .4000 -6.66885 .15117
.4500 .4500 -6.74136 .07866
PEDIGREE 8 Kirsopp
4 PERSONS
LOCUS 0 XLA VS. LOCUS 1 19
Mutation rate at current main locus = . 1
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -4.71632 .00000
.0000 .0000 -4.71632 .00000
.0010 .0010 -4.71632 .00000
.0100 .0100 -4.71632 .00000
.0200 .0200 -4.71632 .00000
.0300 .0300 -4.71632 .00000
.0400 .0400 -4.71632 .00000
.0500 .0500 -4.71632 .00000
.0600 .0600 -4.71632 .00000
.1000 .1000 -4.71632 .00000
.1400 .1400 -4.71632 .00000
.1500 .1500 -4.71632 .00000
.1600 .1600 -4.71632 .00000
.1900 .1900 -4.71632 .00000
.2000 .2000 -4.71632 .00000
.2500 .2500 -4.71632 .00000
.3000 .3000 -4.71632 .00000
.3500 .3500 -4.71632 .00000
.4000 .4000 -4.71632 .00000
.4500 .4500 -4.71632 .00000
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PEDIGREE Cox
4 PERSONS
LOCUS 0 XLA VS. LOCUS 19-2
lutation rate at current main locus = . 1
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -4.71632 .00000
.0000 .0000 -4.71632 .00000
.0010 .0010 -4.71632 .00000
.0100 .0100 -4.71632 .00000
.0200 .0200 -4.71632 .00000
.0300 .0300 -4.71632 .00000
.0400 .0400 -4.71632 .00000
.0500 .0500 -4.71632 .00000
.0600 .0600 -4.71632 .00000
.1000 .1000 -4.71632 .00000
.1400 .1400 -4.71632 .00000
.1500 .1500 -4.71632 .00000
.1600 .1600 -4.71632 .00000
.1900 .1900 -4.71632 .00000
.2000 .2000 -4.71632 .00000
.2500 .2500 -4.71632 .00000
.3000 .3000 -4.71632 .00000
.3500 .3500 -4.71632 .00000
.4000 .4000 -4.71632 .00000
.4500 .4500 -4.71632 .00000
000010000000
PEDIGREE 10 Lucken/Gach
9 PERSONS
LOCUS 0 XLA VS. LOCUS 19-2
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.55906 .00000
.0000 .0000 -5.83212 .72694
.0010 .0010 -5.83396 .72510
.0100 .0100 -5.85058 .70848
.0200 .0200 -5.86912 .68994
.0300 .0300 -5.88775 .67131
.0400 .0400 -5.90646 .65260
.0500 .0500 -5.92524 .63381
.0600 .0600 -5.94410 .61495
.1000 .1000 -6.02015 .53891
.1400 .1400 -6.09684 .46222
.1500 .1500 -6.11604 .44302
.1600 .1600 -6.13522 .42384
.1900 .1900 -6.19253 .36652
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2000 .2000 -6.21150 .34756
2500 .2500 -6.30422 .25484
3000 .3000 -6.39059 .16847
3500 .3500 -6.46544 .09362
4000 .4000 -6.52234 .03672
4500 .4500 -6.55491 .00415
PEDIGREE 11 Gerrard
6 PERSONS
LOCUS 0 XLA VS. LOCUS 1 19-2
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -5.31838 .00000
.0000 .0000 -5.31838 .00000
.0010 .0010 -5.31838 .00000
.0100 .0100 -5.31838 .00000
.0200 .0200 -5.31838 .00000
.0300 .0300 -5.31838 .00000
.0400 .0400 -5.31838 .00000
.0500 .0500 -5.31838 .00000
.0600 .0600 -5.31838 .00000
.1000 .1000 -5.31838 .00000
.1400 .1400 -5.31838 .00000
.1500 .1500 -5.31838 .00000
.1600 .1600 -5.31838 .00000
.1900 .1900 -5.31838 .00000
.2000 .2000 -5.31838 .00000
.2500 .2500 -5.31838 .00000
.3000 .3000 -5.31838 .00000
.3500 .3500 -5.31838 .00000
.4000 .4000 -5.31838 .00000
.4500 .4500 -5.31838 .00000
PEDIGREE 12 Mann
5 PERSONS
LOCUS 0 XLA VS. LOCUS 1 19-2
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -5.83202 .00000
.0000 .0000 -10.22997 -4.39795
.0010 .0010 -8.22608 -2.39407
.0100 .0100 -7.23390 -1.40188
.0200 .0200 -6.93750 -1.10548
.0300 .0300 -6.76593 -.93392
.0400 .0400 -6.64553 -.81351
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.0500 .0500 -6.55319 -.72117
.0600 .0600 -6.47862 -.64660
.1000 .1000 -6.27569 -.44367
.1400 .1400 -6.14931 -.31730
.1500 .1500 -6.12443 -.29241
.1600 .1600 -6.10154 -.26953
.1900 .1900 -6.04271 -.21069
.2000 .2000 -6.02583 -.19381
.2500 .2500 -5.95695 -.12493
.3000 .3000 -5.90774 -.07572
.3500 .3500 -5.87298 -.04096
.4000 .4000 -5.84975 -.01773
.4500 .4500 -5.83638 -.00436
PEDIGREE 13 Chaperon
9 PERSONS
LOCUS 0 XLA VS. LOCUS 1 19
Mutation rate at current main locus = .<
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.62540 .00000
.0000 .0000 -6.34071 .28469
.0010 .0010 -6.34114 .28426
.0100 .0100 -6.34505 .28035
.0200 .0200 -6.34938 .27602
.0300 .0300 -6.35371 .27169
.0400 .0400 -6.35805 .26736
.0500 .0500 -6.36238 .26302
.0600 .0600 -6.36673 .25867
.1000 .1000 -6.38431 .24109
.1400 .1400 -6.40237 .22303
.1500 .1500 -6.40698 .21842
.1600 .1600 -6.41165 .21376
.1900 .1900 -6.42596 .19944
.2000 .2000 -6.43085 .19455
.2500 .2500 -6.45638 .16902
.3000 .3000 -6.48402 .14138
.3500 .3500 -6.51423 .11117
.4000 .4000 -6.54748 .07792
.4500 .4500 -6.58433 .04107
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PEDIGREE 14 Gatte
7 PERSONS
LOCUS 0 XLA VS. LOCUS 1 19-2
lutation rate at current main locus = J
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.55329 .00000
.0000 .0000 -5.95126 .60203
.0010 .0010 -5.95212 .60117
.0100 .0100 -5.95998 .59331
.0200 .0200 -5.96880 .58449
.0300 .0300 -5.97771 .57558
.0400 .0400 -5.98671 .56658
.0500 .0500 -5.99581 .55748
.0600 .0600 -6.00500 .54829
.1000 . 1000 -6.04277 .51052
.1400 .1400 -6.08226 .47103
.1500 .1500 -6.09241 .46088
.1600 .1600 -6.10269 .45060
.1900 .1900 -6.13428 .41901
.2000 .2000 -6.14507 .40822
.2500 .2500 -6.20113 .35216
.3000 .3000 -6.26105 .29224
.3500 .3500 -6.32542 .22787
.4000 .4000 -6.39494 .15835
.4500 .4500 -6.47051 .08278
PEDIGREE 15 Joliton
9 PERSONS
LOCUS 0 XLA VS. LOCUS 1 19-2
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -7.24379 .00000
.0000 .0000 -6.03974 1.20405
.0010 .0010 -6.04191 1.20188
.0100 .0100 -6.06152 1.18227
.0200 .0200 -6.08343 1.16036
.0300 .0300 -6.10546 1.13832
.0400 .0400 -6.12763 1.11616
.0500 .0500 -6.14992 1.09387
.0600 .0600 -6.17233 1.07146
. 1000 .1000 -6.26319 .98060
.1400 .1400 -6.35588 .88791
.1500 .1500 -6.37931 .86447
.1600 .1600 -6.40285 .84093
.1900 .1900 -6.47404 .76975
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.2000
.2500
.3000
.3500
.4000
.4500
.2000
.2500
.3000
.3500
.4000
.4500
-6.49794
-6.61865
-6.74099
-6.86457
-6.98923
-7.11530
SUMMARY
R MALE R FEM. SUM OF LODS
.0000 .0000 .49257
.0010 .0010 2.48688
.0100 .0100 3.39261
.0200 .0200 3.59234
.0300 .0300 3.66657
.0400 .0400 3.68899
.0500 .0500 3.68270
.0600 .0600 3.65800
.1000 .1000 3.45758
.1400 .1400 3.17124
.1500 .1500 3.09163
.1600 .1600 3.00956
.1900 .1900 2.75109
.2000 .2000 2.66153
.2500 .2500 2.19585
.3000 .3000 1.71378
.3500 .3500 1.23395
.4000 .4000 .77645
.4500 .4500 .36077
.74584
.62513
.50280
.37922
.25455
.12849
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Appendix 4 INPUT AND OUTPUT FILES OF LIPED FOR THE 
ANALYSIS OF S21 AND 19.2 DATA IN FAMILY 15
1 0010 0.00001 
(20A4)
(2A4,10F2.0) 
(20A4)
XLA Linkage Study (S21)
m
2 2 
2 3 
0-1
9
0000 0000
0010 0010 
0100 0100 
0200 0200 
0300 0300 
0400 0400 
0500 0500 
0600 0600 
0700 0700 
0800 0800 
0900 0900 
1000 1000 
1500 1500 
2000 2000 
2500 2500 
3000 3000 
3500 3500 
4000 4000 
4500 4500
60000 
XLA A
0001 
A A 1
A a 0
a a 0
S21 U
6500
a aff n.a 
9999
0
1
1
L UU UL LL 
3500
u U 1 0 0
u L 0 1 0
L L 0 0 1
14 015
1.1 m n.a UU
1.2 f n.a UL
2.1 m n.a
2.2 1.1 1.2 f n.a UL
2.3 1.1 1.2 f n.a UU
2.4 m n.a
2.5 1.1 1.2 m aff
2.6 1.1 1.2 m aff
2.7 1.1 1.2 m aff
3.1 2.1 2.2 m n.a LL
3.2 2.1 2.2 m aff
3.3 2.1 2.2 m aff
3.4 2.3 2.4 m aff
3.5 2.3 2.4 m aff
9000
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Program LIPED Version for IBM PC March 1987 J. Ott
PROBLEM 1 XLA Linkage Study 
**********
PEDIGREE 1 15
14 PERSONS
LOCUS 0 XLA VS. LOCUS S21
Mutation rate at current main locus = . I
GENE FREQUENCIES FOR 0 XLA .0001
GENE FREQUENCIES FOR 1 S21 .6500
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -8.14157 .00000
.0000 .0000 -12.53951 -4.39794
.0010 .0010 -12.46041 -4.31884
.0100 .0100 -11.22147 -3.07990
.0200 .0200 -10.63972 -2.49814
.0300 .0300 -10.29501 -2.15344
.0400 .0400 -10.05070 -1.90913
.0500 .0500 -9.86193 -1.72036
.0600 .0600 -9.70843 -1.56686
.0700 .0700 -9.57935 -1.43778
.0800 .0800 -9.46817 -1.32660
.0900 .0900 -9.37068 -1.22911
.1000 .1000 -9.28402 -1.14245
.1500 .1500 -8.95679 -.81522
.2000 .2000 -8.73329 -.59171
.2500 .2500 -8.56752 -.42594
.3000 .3000 -8.43913 -.29755
.3500 .3500 -8.33743 -.19585
.4000 .4000 -8.25621 -.11464
.4500 .4500 -8.19170 -.05012
000010000000
SUMMARY
R MALE R FEM. SUM OF L(3dS
.0000 .0000 -4.39794
.0010 .0010 -4.31884
.0100 .0100 -3.07990
.0200 .0200 -2.49814
.0300 .0300 -2.15344
.0400 .0400 -1.90913
.0500 .0500 -1.72036
.0600 .0600 -1.56686
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0700 .0700
0800 .0800
0900 .0900
1000 .1000
1500 .1500
2000 .2000
2500 .2500
3000 .3000
3500 .3500
4000 .4000
4500 .4500
1.43778
1.32660
1.22911
1.14245
-.81522
-.59171
-.42594
-.29755
-.19585
-.11464
-.05012
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1 0010 0.00001 XLA Linkage Study 
(20A4)
(2A4,10F2.0)
(20A4)
m
2 2 
2 3 
0-1
9
0000 0000
0010 0010 
0100 0100 
0200 0200 
0300 0300 
0400 0400 
0500 0500 
0600 0600 
0700 0700 
0800 0800 
0900 0900 
1000 1000 
1500 1500 
2000 2000 
2500 2500 
3000 3000 
3500 3500 
4000 4000 
4500 4500
60000
[LA A a aff n. a
0001 9999
A A 1 0
A a 0 1
a a 0 1
.9.2 U L UU UL LL
6500 3500
U U 1 0 0
U L 0 1 0
L L 0 0 1
14 015
1.1 m n. a UU
1.2 f n. a LL
2.1 m n. a
2.2 1.1 1.2 f n. a UL
2.3 1.1 1.2 f n. a UL
2.4 m n. a
2.5 1.1 1.2 m aff
2.6 1.1 1.2 m aff
2.7 1.1 1.2 m aff
3.1 2.1 2.2 m n.a LL
3.2 2.1 2.2 m aff
3.3 2.1 2.2 m aff
3.4 2.3 2.4 m aff
3.5 2.3 2.4 m aff LL
9000
(19.2)
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Program LIPED Version for IBM PC March 1987 J. Ott
PROBLEM 1 XLA Linkage Study 
**********
PEDIGREE 1 15
14 PERSONS
LOCUS 0 XLA VS. LOCUS 1 19.2
Mutation rate at current main locus = .000010000000
GENE FREQUENCIES FOR 0 XLA .0001 .9999
GENE FREQUENCIES FOR 1 19.2 .6500 .3500
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -8.41042 .00000
.0000 .0000 -12.80836 -4.39794
.0010 .0010 -10.80449 -2.39407
.0100 .0100 -9.81231 -1.40189
.0200 .0200 -9.51590 -1.10548
.0300 .0300 -9.34434 -.93392
.0400 .0400 -9.22394 -.81352
.0500 .0500 -9.13160 -.72118
.0600 .0600 -9.05702 -.64661
.0700 .0700 -8.99473 -.58431
.0800 .0800 -8.94144 -.53102
.0900 .0900 -8.89504 -.48462
.1000 .1000 -8.85409 -.44367
.1500 .1500 -8.70284 -.29242
.2000 .2000 -8.60423 -.19381
.2500 .2500 -8.53536 -.12494
.3000 .3000 -8.48614 -.07572
.3500 .3500 -8.45138 -.04096
.4000 .4000 -8.42815 -.01773
.4500 .4500 -8.41479 -.00437
SUMMARY
R MALE R FEM. SUM OF LODS
.0000 .0000 -4.39794
.0010 .0010 -2.39407
.0100 .0100 -1.40189
.0200 .0200 -1.10548
.0300 .0300 -.93392
.0400 .0400 -.81352
.0500 .0500 -.72118
.0600 .0600 -.64661
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.0700 .0700
.0800 .0800 
.0900 .0900
.1000 .1000 
.1500 .1500
.2000 .2000 
.2500 .2500
.3000 .3000
.3500 .3500
.4000 .4000
.4500 .4500
.58431
.53102
.48462
.44367
.29242
.19381
.12494
.07572
.04096
.01773
.00437
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APPENDIX 5 OUTPUT FILES OF HOMOG FOR THE ANALYSIS OF
19.2 AND S21 DATA IN THE FAMILIES WITH 
X-LINKED AGAMMAGLOBULINAEMIA
Program HOMOG J. Ott
Heterogeneity: two family types, one linked, the other unlinked 
XLAHOMO-S21
Family Lod scores
1 0.5400 0.5300 0.5200 0.5150 0.5050 0.5000 0.4500
0.3900 0.3500 0.2800 0.2300 0.1700 0.1200 0.0900
2 0.5400 0.5300 0.5200 0.5150 0.5050 0.5000 0.4500
0.3900 0.3500 0.2800 0.2300 0.1700 0.1200 0.0900
3 0.5400 0.5300 0.5200 0.5150 0.5050 0.5000 0.4500
0.3900 0.3500 0.2800 0.2300 0.1700 0.1200 0.0900
4 0.5400 0.5300 0.5200 0.5150 0.5050 0.5000 0.4500
0.3900 0.3500 0.2800 0.2300 0.1700 0.1200 0.0900
5 3.9100 3.6000 3.2000 2.9000 2.7500 2.6800 2.0800
1.5800 1.2000 0.9000 0.6800 0.4600 0.2800 0.1300
6 -3.8000 -2.8000 -2.2100 -1.8700 -1.6300 -1.4400 -0.8900
-0.5800 -0.3900 -0.2500 -0.1500 -0.0800 -0.0400 -0.0100
7 -4.4000 -3.0800 -2.5000 -2.1500 -1.9100 -1.7200 -1.1400
-0.8200 -0.5900 -0.4300 -0.3000 -0.2000 -0.1200 -0.0500
8 0.5820 0.5670 0.5510 0.5350 0.5194 0.5000 0.4300
0.3500 0.2700 0.2000 0.1400 0.0900 0.0400 0.0200
9 0.6020 0.5889 0.5757 0.5623 0.5489 0.5353 0.4700
0.3900 0.3200 0.2400 0.1700 0.1000 0.0500 0.0138
10 0.5820 0.5732 0.5647 0.5561 0.5474 0.5400 0.4900
0.4400 0.3900 0.3400 0.2800 0.2200 0.1500 0.0800
11 0.3010 0.2920 0.2836 0.2749 0.2663 0.2600 0.2100
0.1700 0.1300 0.0900 0.0600 0.0400 0.0200 0.0043
12 0.3010 0.2920 0.2836 0.2749 0.2663 0.2600 0.2100
0.1700 0.1300 0.0900 0.0600 0.0400 0.0200 0.0043
13 0.7269 0.7108 0.6946 0.6783 0.6620 0.6500 0.5600
0.4700 0.3900 0.3000 0.2200 0.1400 0.0700 0.0300
14 0.9030 0.8856 0.8679 0.8502 0.8322 0.8100 0.7200
0.6200 0.5200 0.4100 0.2900 0.1900 0.0900 0.0200
15 0.3010 0.2967 0.2922 0.2878 0.2833 0.2800 0.2600
0.2300 0.2000 0.1800 0.1500 0.1100 0.0800 0.0400
16 0.3010 0.2923 0.2836 0.2749 0.2663 0.2600 0.2100
0.1700 0.1300 0.0900 0.0600 0.0400 0.0200 0.0043
17 0.3010 0.2923 0.2836 0.2749 0.2663 0.2600 0.2100
0.1700 0.1300 0.0900 0.0600 0.0400 0.0200 0.0043
fheta = 0.0000 0.0100 0.0200 0.0300 0.0400 0.0500 0.1000
0.1500 0.2000 0.2500 0.3000 0.3500 0.4000 0.4500
Alpha In L(alpha,,theta)
1.0000 6.3802 10.6628 12.0897 12.6856 13.0980 13.5284 12.9405
11.3287 9.7399 7.7597 6.0788 4.3058 2.6710 1.4990
0.9900 15.9676 15.1147 14.3726 14.0113 13.9370 14.0814 13.0356
11.3281 9.7084 7.7210 6.0407 4.2742 2.6490 1.4855
0.9800 17.2404 16.2882 15.3166 14.7229 14.4638 14.4660 13.1130
11.3234 9.6755 7.6816 6.0022 4.2423 2.6269 1.4720
0.9700 17.9436 16.9575 15.8964 15.1955 14.8372 14.7529 13.1759
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11.3150 9.6413 7.6416
0.9600 18.4120 17.4094 16.3008
11.3030 9.6056 7.6009
0.9500 18.7513 17.7390 16.6014
11.2878 9.5687 7.5596
0.9400 19.0085 17.9901 16.8330
11.2695 9.5305 7.5177
0.9300 19.2087 18.1863 17.0153
11.2484 9.4911 7.4751
0.9200 19.3670 18.3419 17.1607
11.2245 9.4505 7.4319
0.9100 19.4930 18.4661 17.2771
11.1980 9.4086 7.3881
0.9000 19.5933 18.5653 17.3703
11.1691 9.3657 7.3436
0.8900 19.6728 18.6440 17.4443
11.1378 9.3215 7.2986
0.8800 19.7348 18.7056 17.5023
11.1043 9.2763 7.2529
0.8700 19.7820 18.7527 17.5464
11.0686 9.2300 7.2066
0.8600 19.8165 18.7872 17.5786
11.0309 9.1825 7.1597
0.8500 19.8398 18.8108 17.6004
10.9911 9.1340 7.1122
0.8400 19.8533 18.8247 17.6128
10.9494 9.0844 7.0641
0.8300 19.8581 18.8299 17.6170
10.9058 9.0338 7.0153
0.8200 19.8549 18.8274 17.6137
10.8604 8.9822 6.9660
0.8100 19.8446 18.8178 17.6036
10.8133 8.9295 6.9161
0.8000 19.8277 18.8018 17.5872
10.7644 8.8758 6.8655
0.7900 19.8048 18.7798 17.5650
10.7138 8.8211 6.8144
0.7800 19.7763 18.7523 17.5376
10.6615 8.7653 6.7626
0.7700 19.7427 18.7197 17.5051
10.6076 8.7086 6.7102
0.7600 19.7042 18.6823 17.4680
10.5522 8.6509 6.6572
0.7500 19.6611 18.6403 17.4265
10.4951 8.5922 6.6036
0.7400 19.6137 18.5941 17.3808
10.4365 8.5325 6.5494
0.7300 19.5622 18.5439 17.3312
10.3764 8.4718 6.4945
0.7200 19.5068 18.4898 17.2778
10.3148 8.4102 6.4390
0.7100 19.4476 18.4320 17.2208
10.2517 8.3475 6.3829
0.7000 19.3849 18.3706 17.1603
10.1871 8.2839 6.3262
0.6900 19.3187 18.3059 17.0965
10.1211 8.2192 6.2689
5.9634 4.2103 2.6047 1.4585
15.5383 15.1179 14.9752 13.2264
5.9243 4.1781 2.5824 1.4449
15.7989 15.3361 15.1514 13.2662
5.8848 4.1458 2.5601 1.4314
16.0026 15.5092 15.2928 13.2967
5.8449 4.1132 2.5376 1.4178
16.1646 15.6480 15.4069 13.3190
5.8048 4.0805 2.5152 1.4041
16.2945 15.7599 15.4990 13.3340
5.7642 4.0476 2.4926 1.3905
16.3988 15.8500 15.5730 13.3424
5.7234 4.0145 2.4699 1.3768
16.4824 15.9219 15.6317 13.3448
5.6821 3.9812 2.4472 1.3631
16.5486 15.9787 15.6773 13.3417
5.6406 3.9477 2.4244 1.3493
16.6001 16.0223 15.7115 13.3336
5.5986 3.9141 2.4015 1.3355
16.6389 16.0546 15.7357 13.3208
5.5564 3.8803 2.3785 1.3217
16.6668 16.0769 15.7510 13.3037
5.5138 3.8463 2.3554 1.3079
16.6849 16.0903 15.7584 13.2826
5.4708 3.8121 2.3323 1.2940
16.6943 16.0957 15.7586 13.2577
5.4274 3.7777 2.3090 1.2802
16.6959 16.0939 15.7523 13.2292
5.3838 3.7431 2.2857 1.2663
16.6904 16.0856 15.7399 13.1973
5.3397 3.7083 2.2623 1.2523
16.6785 16.0713 15.7221 13.1622
5.2953 3.6734 2.2389 1.2383
16.6606 16.0514 15.6992 13.1241
5.2505 3.6382 2.2153 1.2243
16.6373 16.0263 15.6714 13.0830
5.2054 3.6029 2.1916 1.2103
16.6088 15.9965 15.6393 13.0392
5.1599 3.5673 2.1679 1.1963
16.5756 15.9621 15.6029 12.9926
5.1140 3.5316 2.1441 1.1822
16.5379 15.9236 15.5625 12.9435
5.0678 3.4956 2.1202 1.1680
16.4960 15.8810 15.5184 12.8918
5.0212 3.4595 2.0962 1.1539
16.4501 15.8345 15.4706 12.8377
4.9742 3.4232 2.0721 1.1397
16.4004 15.7845 15.4195 12.7812
4.9268 3.3866 2.0480 1.1255
16.3470 15.7310 15.3650 12.7224
4.8791 3.3499 2.0237 1.1113
16.2902 15.6741 15.3074 12.6614
4.8309 3.3129 1.9994 1.0970
16.2300 15.6140 15.2467 12.5982
4.7824 3.2758 1.9749 1.0827
16.1665 15.5508 15.1830 12.5328
4.7335 3.2384 1.9504 1.0684
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0.6800 19.2491 18.2378 17.0295
10.0536 8.1536 6.2109
0.6700 19.1764 18.1665 16.9594
9.9847 8.0870 6.1522
0.6600 19.1005 18.0922 16.8862
9.9143 8.0194 6.0929
0.6500 19.0215 18.0148 16.8101
9.8425 7.9508 6.0330
0.6400 18.9395 17.9344 16.7310
9.7693 7.8813 5.9724
0.6300 18.8545 17.8512 16.6491
9.6946 7.8107 5.9112
0.6200 18.7667 17.7651 16.5645
9.6185 7.7391 5.8493
0.6100 18.6761 17.6762 16.4770
9.5410 7.6664 5.7867
0.6000 18.5826 17.5845 16.3869
9.4621 7.5928 5.7234
0.5900 18.4863 17.4901 16.2941
9.3817 7.5181 5.6595
0.5800 18.3873 17.3930 16.1987
9.2999 7.4424 5.5949
0.5700 18.2856 17.2932 16.1006
9.2167 7.3656 5.5295
0.5600 18.1811 17.1907 15.9998
9.1320 7.2877 5.4635
0.5500 18.0739 17.0855 15.8965
9.0458 7.2088 5.3967
0.5400 17.9640 16.9777 15.7906
8.9581 7.1288 5.3293
0.5300 17.8514 16.8672 15.6821
8.8690 7.0478 5.2611
0.5200 17.7361 16.7541 15.5709
8.7784 6.9656 5.1921
0.5100 17.6181 16.6383 15.4571
8.6863 6.8822 5.1224
0.5000 17.4973 16.5198 15.3407
8.5926 6.7978 5.0519
0.4900 17.3737 16.3985 15.2217
8.4974 6.7122 4.9807
0.4800 17.2474 16.2746 15.1000
8.4006 6.6254 4.9087
0.4700 17.1183 16.1479 14.9756
8.3022 6.5374 4.8359
0.4600 16.9863 16.0184 14.8485
8.2022 6.4482 4.7623
0.4500 16.8515 15.8861 14.7186
8.1006 6.3578 4.6878
0.4400 16.7138 15.7510 14.5860
7.9973 6.2662 4.6125
0.4300 16.5731 15.6130 14.4505
7.8923 6.1732 4.5364
0.4200 16.4294 15.4720 14.3122
7.7856 6.0790 4.4594
0.4100 16.2826 15.3280 14.1709
7.6771 5.9835 4.3815
0.4000 16.1327 15.1810 14.0267
16.1000 15.4847 15.1165 12.4653
4.6842 3.2008 1.9258 1.0541
16.0304 15.4155 15.0471 12.3957
4.6345 3.1630 1.9011 1.0397
15.9578 15.3436 14.9751 12.3241
4.5844 3.1250 1.8763 1.0253
15.8824 15.2688 14.9003 12.2505
4.5339 3.0868 1.8514 1.0108
15.8041 15.1914 14.8230 12.1748
4.4829 3.0484 1.8264 0.9963
15.7231 15.1112 14.7430 12.0971
4.4316 3.0097 1.8014 0.9818
15.6394 15.0284 14.6605 12.0175
4.3799 2.9708 1.7762 0.9673
15.5530 14.9431 14.5756 11.9360
4.3277 2.9317 1.7509 0.9527
15.4639 14.8551 14.4881 11.8524
4.2751 2.8924 1.7256 0.9381
15.3722 14.7647 14.3982 11.7670
4.2221 2.8529 1.7001 0.9235
15.2780 14.6717 14.3059 11.6796
4.1686 2.8131 1.6746 0.9088
15.1811 14.5762 14.2111 11.5902
4.1147 2.7731 1.6489 0.8941
15.0817 14.4783 14.1140 11.4990
4.0604 2.7328 1.6232 0.8794
14.9798 14.3778 14.0144 11.4058
4.0056 2.6923 1.5974 0.8647
14.8753 14.2749 13.9124 11.3106
3.9504 2.6516 1.5714 0.8499
14.7683 14.1696 13.8081 11.2135
3.8947 2.6107 1.5454 0.8351
14.6587 14.0617 13.7013 11.1144
3.8385 2.5695 1.5192 0.8202
14.5465 13.9514 13.5921 11.0134
3.7818 2.5280 1.4930 0.8053
14.4318 13.8385 13.4805 10.9104
3.7247 2.4863 1.4667 0.7904
14.3145 13.7232 13.3664 10.8053
3.6671 2.4444 1.4402 0.7755
14.1946 13.6053 13.2499 10.6982
3.6090 2.4022 1.4137 0.7605
14.0721 13.4848 13.1309 10.5891
3.5505 2.3597 1.3870 0.7455
13.9469 13.3618 13.0093 10.4779
3.4914 2.3170 1.3603 0.7304
13.8190 13.2362 12.8853 10.3645
3.4318 2.2740 1.3334 0.7153
13.6884 13.1079 12.7586 10.2491
3.3717 2.2308 1.3064 0.7002
13.5551 12.9770 12.6294 10.1314
3.3110 2.1873 1.2794 0.6851
13.4189 12.8433 12.4974 10.0116
3.2498 2.1435 1.2522 0.6699
13.2799 12.7068 12.3628 9.8895
3.1881 2.0994 1.2249 0.6547
13.1380 12.5675 12.2254 9.7651
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7.5669 5.8866 4.3028 3.1258 2.0551 1.1975 0.6394
0.3900 15.9797 15.0309 13.8794 12.9931 12.4253 12.0853 9.6383
7.4548 5.7883 4.2231 3.0630 2.0105 1.1700 0.6241
0.3800 15.8234 14.8776 13.7291 12.8452 12.2802 11.9422 9.5092
7.3408 5.6886 4.1425 2.9996 1.9656 1.1424 0.6088
0.3700 15.6637 14.7211 13.5756 12.6942 12.1321 11.7962 9.3776
7.2250 5.5875 4.0609 2.9356 1.9204 1.1146 0.5935
0.3600 15.5007 14.5612 13.4188 12.5400 11.9810 11.6473 9.2436
7.1071 5.4849 3.9784 2.8710 1.8750 1.0868 0.5781
0.3500 15.3342 14.3979 13.2587 12.3826 11.8266 11.4952 9.1069
6.9873 5.3808 3.8949 2.8058 1.8292 1.0588 0.5627
0.3400 15.1640 14.2311 13.0952 12.2219 11.6690 11.3400 8.9677
6.8654 5.2752 3.8104 2.7400 1.7831 1.0308 0.5472
0.3300 14.9902 14.0608 12.9282 12.0578 11.5081 11.1816 8.8257
6.7413 5.1679 3.7248 2.6736 1.7368 1.0026 0.5317
0.3200 14.8126 13.8867 12.7575 11.8901 11.3438 11.0198 8.6809
6.6151 5.0591 3.6382 2.6065 1.6901 0.9743 0.5162
0.3100 14.6311 13.7087 12.5832 11.7187 11.1760 10.8546 8.5332
6.4867 4.9485 3.5505 2.5388 1.6431 0.9458 0.5006
0.3000 14.4455 13.5269 12.4050 11.5437 11.0045 10.6859 8.3826
6.3559 4.8362 3.4616 2.4704 1.5958 0.9173 0.4851
0.2900 14.2557 13.3409 12.2228 11.3647 10.8292 10.5134 8.2289
6.2227 4.7222 3.3717 2.4013 1.5482 0.8886 0.4694
0.2800 14.0615 13.1507 12.0365 11.1817 10.6500 10.3372 8.0720
6.0870 4.6063 3.2805 2.3316 1.5002 0.8599 0.4538
0.2700 13.8628 12.9560 11.8459 10.9946 10.4668 10.1570 7.9119
5.9488 4.4885 3.1881 2.2611 1.4519 0.8310 0.4381
0.2600 13.6594 12.7568 11.6508 10.8031 10.2794 9.9727 7.7483
5.8078 4.3687 3.0945 2.1899 1.4033 0.8019 0.4223
0.2500 13.4511 12.5528 11.4511 10.6070 10.0875 9.7841 7.5811
5.6641 4.2469 2.9997 2.1180 1.3544 0.7728 0.4065
0.2400 13.2377 12.3439 11.2465 10.4063 9.8911 9.5911 7.4102
5.5175 4.1230 2.9034 2.0453 1.3051 0.7435 0.3907
0.2300 13.0189 12.1296 11.0369 10.2006 9.6899 9.3933 7.2353
5.3679 3.9969 2.8059 1.9718 1.2554 0.7141 0.3749
0.2200 12.7945 11.9099 10.8219 9.9896 9.4836 9.1907 7.0564
5.2151 3.8685 2.7069 1.8976 1.2054 0.6846 0.3590
0.2100 12.5641 11.6845 10.6013 9.7733 9.2720 8.9829 6.8731
5.0589 3.7377 2.6065 1.8225 1.1550 0.6549 0.3431
0.2000 12.3275 11.4529 10.3748 9.5511 9.0549 8.7697 6.6853
4.8992 3.6044 2.5045 1.7465 1.1043 0.6251 0.3271
0.1900 12.0842 11.2148 10.1420 9.3229 8.8318 8.5506 6.4927
4.7359 3.4685 2.4010 1.6697 1.0532 0.5952 0.3111
0.1800 11.8338 10.9699 9.9025 9.0881 8.6023 8.3254 6.2949
4.5685 3.3298 2.2958 1.5921 1.0017 0.5651 0.2951
0.1700 11.5760 10.7177 9.6559 8.8464 8.3662 8.0937 6.0917
4.3970 3.1882 2.1890 1.5135 0.9498 0.5350 0.2790
0.1600 11.3100 10.4575 9.4016 8.5972 8.1228 7.8549 5.8825
4.2211 3.0436 2.0804 1.4339 0.8975 0.5046 0.2629
0.1500 11.0353 10.1889 9.1391 8.3400 7.8716 7.6085 5.6670
4.0403 2.8956 1.9699 1.3534 0.8448 0.4742 0.2468
0.1400 10.7511 9.9110 8.8676 8.0741 7.6119 7.3538 5.4446
3.8543 2.7443 1.8575 1.2718 0.7917 0.4436 0.2306
0.1300 10.4566 9.6231 8.5863 7.7986 7.3430 7.0901 5.2147
3.6628 2.5892 1.7431 1.1893 0.7382 0.4129 0.2144
0.1200 10.1506 9.3240 8.2941 7.5126 7.0638 6.8164 4.9764
3.4650 2.4301 1.6265 1.1056 0.6842 0.3820 0.1981
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0.1100 9.8320 9.0126 7.9900
3.2605 2.2668 1.5077
0.1000 9.4991 8.6871 7.6722
3.0484 2.0988 1.3865
0.0900 9.1498 8.3457 7.3388
2.8278 1.9257 1.2628
0.0800 8.7814 7.9856 6.9872
2.5976 1.7470 1.1364
0.0700 8.3903 7.6032 6.6139
2.3562 1.5622 1.0071
0.0600 7.9711 7.1934 6.2137
2.1016 1.3704 0.8748
0.0500 7.5160 6.7481 5.7789
1.8311 1.1708 0.7391
0.0400 7.0118 6.2544 5.2969
1.5410 0.9622 0.5999
0.0300 6.4343 5.6886 4.7446
1.2257 0.7431 0.4568
0.0200 5.7304 4.9981 4.0711
0.8762 0.5117 0.3094
0.0100 4.7324 4.0182 3.1207
0.4775 0.2652 0.1573
Theta = 0.0000 0.0100 0.0200
0.1500 0.2000 0.2500
7.2148 6.7733 6.5316 4.7288
1.0209 0.6299 0.3510 0.1818
6.9038 6.4698 6.2341 4.4708
0.9349 0.5750 0.3198 0.1655
6.5776 6.1516 5.9223 4.2008
0.8478 0.5197 0.2885 0.1491
6.2337 5.8161 5.5935 3.9168
0.7594 0.4640 0.2571 0.1327
5.8686 5.4600 5.2446 3.6162
0.6698 0.4078 0.2255 0.1163
5.4774 5.0784 4.8707 3.2954
0.5787 0.3511 0.1937 0.0998
5.0526 4.6642 4.4648 2.9489
0.4863 0.2939 0.1618 0.0833
4.5820 4.2054 4.0152 2.5685
0.3923 0.2362 0.1298 0.0667
4.0434 3.6807 3.5011 2.1401
0.2968 0.1779 0.0976 0.0501
3.3890 3.0445 2.8780 1.6368
0.1996 0.1192 0.0652 0.0334
2.4762 2.1637 2.0184 0.9963
0.1007 0.0599 0.0327 0.0167
0.0300 0.0400 0.0500 0.1000
0.3000 0.3500 0.4000 0.4500
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Hypotheses
H2: linkage, heterogeneity 
HI: linkage, homogeneity 
HO: no linkage
Estimates of 
Max.InL alpha theta
19.8581 0.8300 0.0000
13.5284 (1) 0.0500
(0) (0) (0.5)
d.f.
Components of chi-square 
Source a  *
H2 vs. HI Heterogeneity 1 
HI vs. HO Linkage 1
H2 vs. HO Total 2
chi-square p-value 
12.659 0.0002
27.057 0.0000
39.716 0.0000
Approx. 95% confidence intervals: 
Alpha 0.4600 0.9800
Theta 0.0000 0.0200
Family Posterior prob. Approx.conf .limits
no. of linkage lower upper
1 0.9442 0.7471 0.9941
2 0.9442 0.7471 0.9941
3 0.9442 0.7471 0.9941
4 0.9442 0.7471 0.9941
5 1.0000 0.9997 1.0000
6 0.0008 0.0001 0.0757
7 0.0002 0.0000 0.0403
8 0.9491 0.7649 0.9947
9 0.9513 0.7731 0.9949
10 0.9491 0.7649 0.9947
11 0.9071 0.6301 0.9899
12 0.9071 0.6301 0.9899
13 0.9630 0.8196 0.9962
14 0.9750 0.8720 0.9975
15 0.9071 0.6301 0.9899
16 0.9071 0.6301 0.9899
17 0.9071 0.6301 0.9899
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Program HOMOG J. Ott
Heterogeneity: two family types, one linked, the other unlinked 
XLAHOMO-19-2
Family Lod scores
1 -4.3980 -0.8140 -0.7220 -0.6470 -0.4440 -0.3130 -0.2930
0.2870 -0.1940 -0.1250 -0.0760 -0.0410 -0.0180 -0.0040
2 0.7270 0.6530 0.6340 0.6150 0.5390 0.4620 0.4430
0.4230 0.3470 0.2550 0.1680 0.0940 0.0370 0.0040
3 0.5677 0.5357 0.5275 0.5191 0.4845 0.4481 0.4387
0.4291 0.3895 0.3366 0.2796 0.2180 0.1500 0.0780
4 0.6020 0.5489 0.5350 0.5220 0.4650 0.4070 0.3930
0.3770 0.3180 0.2430 0.1700 0.1040 0.0490 0.0130
5 -4.3979 -0.8135 -0.7210 -0.6466 -0.4440 -0.3170 -0.2920
-0.2695 -0.1940 -0.1250 -0.0760 -0.0410 -0.0180 -0.0040
6 0.6020 0.5489 0.5350 0.5220 0.4650 0.4070 0.3930
0.3770 0.3180 0.2430 0.1700 0.1040 0.0490 0.0130
7 0.3010 0.2660 0.2580 0.2490 0.2150 0.1810 0.1730
0.1650 0.1340 0.0970 0.0640 0.0370 0.0170 0.0040
8 0.2847 0.2674 0.2630 0.2587 0.2410 0.2230 0.2180
0.2137 0.1890 0.1650 0.1390 0.1100 0.0770 0.0410
9 1.2040 1.1160 1.0940 1.0710 0.9800 0.8879 0.8650
0.8410 0.7460 0.6250 0.5030 0.3790 0.2550 0.1290
10 0.6020 0.5665 0.5580 0.5483 0.5110 0.4710 0.4600
0.4500 0.4080 0.3520 0.2920 0.2280 0.1580 0.0830
11 -3.1100 0.3010 0.3720 0.4230 0.5320 0.5595 0.5590
0.5560 0.5270 0.4598 0.3680 0.2630 0.1550 0.0620
12 0.6020 0.5665 0.5575 0.5480 0.5110 0.4710 0.4610
0.4510 0.4080 0.3520 0.2920 0.2280 0.1580 0.0830
13 -3.5600 -0.5300 -0.4420 -0.3720 -0.1880 -0.0810 -0.0620
-0.0442 0.0100 0.0510 0.0704 0.0730 0.0610 0.0370
14 0.3010 0.2830 0.2790 0.2740 0.2550 0.2355 0.2300
0.2250 0.2040 0.1760 0.1460 0.1140 0.0790 0.0410
15 -3.7680 -3.4900 -3.2728 -3.0400 -2.2700 -1.7360 -1.6300
-1.5260 -1.1800 -0.8500 -0.5950 -0.3910 -0.2290 -0.1000
16 0.9030 0.8320 0.8100 0.7950 0.7200 0.6410 0.6210
0.6010 0.5170 0.4080 0.2980 0.1900 0.0940 0.0250
17 -3.7160 -0.8132 -0.7210 -0.6460 -0.4440 -0.3170 -0.2920
-0.2690 -0.1940 -0.1250 -0.0760 -0.0410 -0.0180 -0.0040
18 -99.0000 3.2740 3.2960 3.2989 3.2100 3.0367 2.9850
2.9300 2.6890 2.3450 1.9600 1.5400 1.0700 0.5600
19 -99.0000 0.3650 0.3640 0.3600 0.3410 0.3140 0.3030
0.2940 0.2590 0.2120 0.1620 0.1150 0.0700 0.0310
20 -99.0000 0.3650 0.3640 0.3600 0.3410 0.3140 0.3030
0.2940 0.2590 0.2120 0.1620 0.1150 0.0700 0.0310
21 -99.0000 0.3650 0.3640 0.3600 0.3410 0.3140 0.3030
0.2940 0.2590 0.2120 0.1620 0.1150 0.0700 0.0310
22 -99.0000 0.3650 0.3640 0.3600 0.3410 0.3140 0.3030
0.2940 0.2590 0.2120 0.1620 0.1150 0.0700 0.0310
23 -99.0000 0.3650 0.3640 0.3600 0.3410 0.3140 0.3030
0.2940 0,2590 0.2120 0.1620 0.1150 0.0700 0.0310
24 -99.0000 0.3650 0.3640 0.3600 0.3410 0.3140 0.3030
0.2940 0.2590 0.2120 0.1620 0.1150 0.0700 0.0310
25 -99.0000 0.3650 0.3640 0.3600 0.3410 0.3140 0.3030
Appendix 5 Page 224
0.2940 0.2590 0.2120
26 -99.0000 0.3650 0.3640
0.2940 0.2590 0.2120
27 -99.0000 0.3650 0.3640
0.2940 0.2590 0.2120
28 -99.0000 0.3650 0.3640
0.2940 0.2590 0.2120
Theta = 0.0000 0.0400 0.0500
0.1600 0.2000 0.2500
Alpha In L(alpha,, theta)
1.0000 -99.0000 15.9988 17.2238
21.0850 18.4955 16.1259
0.9900 -62.8031 19.4979 20.2011
21.2493 18.5230 16.0867
0.9800 -51.1709 20.2021 20.8573
21.3504 18.5342 16.0436
0.9700 -44.3822 20.6202 21.2368
21.4109 18.5324 15.9969
0.9600 -39.5844 20.9150 21.4973
21.4428 18.5199 15.9470
0.9500 -35.8794 21.1386 21.6897
21.4535 18.4984 15.8941
0.9400 -32.8665 21.3148 21.8371
21.4478 18.4691 15.8384
0.9300 -30.3318 21.4565 21.9520
21.4288 18.4332 15.7800
0.9200 -28.1474 21.5714 22.0421
21.3988 18.3913 15.7192
0.9100 -26.2308 21.6649 22.1122
21.3596 18.3442 15.6560
0.9000 -24.5257 21.7404 22.1659
21.3125 18.2924 15.5907
0.8900 -22.9917 21.8007 22.2055
21.2585 18.2362 15.5233
0.8800 -21.5994 21.8476 22.2331
21.1983 18.1761 15.4538
0.8700 -20.3260 21.8828 22.2499
21.1326 18.1123 15.3825
0.8600 -19.1541 21.9074 22.2572
21.0619 18.0451 15.3093
0.8500 -18.0698 21.9225 22.2559
20.9867 17.9748 15.2343
0.8400 -17.0618 21.9289 22.2466
20.9073 17.9015 15.1576
0.8300 -16.1211 21.9272 22.2301
20.8240 17.8253 15.0792
0.8200 -15.2400 21.9181 22.2069
20.7371 17.7465 14.9992
0.8100 -14.4122 21.9020 22.1774
20.6467 17.6651 14.9176
0.8000 -13.6323 21.8794 22.1419
20.5532 17.5813 14.8345
0.7900 -12.8958 21.8506 22.1009
20.4565 17.4951 14.7499
0.7800 -12.1986 21.8160 22.0545
20.3569 17.4066 14.6638
0.1620 0.1150 0.0700 0.0310
0.3600 0.3410 0.3140 0.3030
0.1620 0.1150 0.0700 0.0310
0.3600 0.3410 0.3140 0.3030
0.1620 0.1150 0.0700 0.0310
0.3600 0.3410 0.3140 0.3030
0.1620 0.1150 0.0700 0.0310
0.0600 0.1000 0.1400 0.1500
0.3000 0.3500 0.4000 0.4500
18.1729 20.1442 20.2782 20.0341
13.1639 9.9426 6.5071 3.1568
20.6217 21.1082 20.6048 20.2794
13.1071 9.8878 6.4648 3.1326
21.2353 21.5226 20.8008 20.4331
13.0490 9.8325 6.4223 3.1082
21.5850 21.7668 20.9266 20.5327
12.9898 9.7767 6.3796 3.0837
21.8201 21.9260 21.0081 20.5962
12.9294 9.7204 6.3366 3.0592
21.9897 22.0336 21.0590 20.6340
12.8678 9.6636 6.2935 3.0346
22.1161 22.1062 21.0872 20.6522
12.8051 9.6063 6.2500 3.0098
22.2116 22.1534 21.0980 20.6549
12.7413 9.5485 6.2064 2.9850
22.2834 22.1810 21.0947 20.6452
12.6765 9.4902 6.1625 2.9601
22.3364 22.1931 21.0799 20.6250
12.6106 9.4314 6.1184 2.9352
22.3739 22.1923 21.0553 20.5959
12.5437 9.3722 6.0740 2.9101
22.3984 22.1807 21.0224 20.5592
12.4759 9.3124 6.0294 2.8849
22.4115 22.1598 20.9821 20.5156
12.4070 9.2522 5.9845 2.8596
22.4146 22.1307 20.9354 20.4661
12.3372 9.1914 5.9394 2.8343
22.4089 22.0944 20.8828 20.4111
12.2664 9.1302 5.8941 2.8088
22.3952 22.0516 20.8250 20.3512
12.1946 9.0685 5.8485 2.7833
22.3743 22.0029 20.7624 20.2867
12.1220 9.0062 5.8026 2.7576
22.3466 21.9488 20.6953 20.2181
12.0484 8.9435 5.7565 2.7319
22.3126 21.8896 20.6240 20.1455
11.9739 8.8803 5.7102 2.7060
22.2729 21.8258 20.5489 20.0693
11.8985 8.8165 5.6636 2.6801
22.2277 21.7575 20.4702 19.9896
11.8222 8.7523 5.6167 2.6540
22.1774 21.6851 20.3880 19.9066
11.7450 8.6876 5.5695 2.6278
22.1221 21.6087 20.3024 19.8206
11.6669 8.6224 5.5221 2.6016
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0.7700 -11.5374 21.7758 22.0031 22.0621 21.5286 20.2138 19.7315
20.2545 17.3160 14.5763 11.5879 8.5566 5.4744 2.5752
0.7600 -10.9092 21.7303 21.9469 21.9977 21.4448 20.1221 19.6395
20.1494 17.2232 14.4873 11.5080 8.4903 5.4264 2.5487
0.7500 -10.3114 21.6797 21.8860 21.9290 21.3576 20.0275 19.5447
20.0417 17.1283 14.3969 11.4273 8.4236 5.3782 2.5221
0.7400 -9.7417 21.6241 21.8206 21.8561 21.2670 19.9301 19.4473
19.9314 17.0314 14.3051 11.3457 8.3563 5.3297 2.4954
0.7300 -9.1981 21.5639 21.7508 21.7791 21.1731 19.8299 19.3472
19.8186 16.9325 14.2119 11.2632 8.2884 5.2808 2.4686
0.7200 -8.6787 21.4991 21.6769 21.6982 21.0761 19.7270 19.2445
19.7034 16.8317 14.1173 11.1798 8.2201 5.2317 2.4417
0.7100 -8.1820 21.4298 21.5988 21.6136 20.9760 19.6216 19.1394
19.5859 16.7289 14.0215 11.0956 8.1512 5.1823 2.4146
0.7000 -7.7064 21.3562 21.5168 21.5252 20.8728 19.5135 19.0318
19.4660 16.6242 13.9242 11.0104 8.0818 5.1326 2.3875
0.6900 -7.2507 21.2784 21.4309 21.4331 20.7666 19.4030 18.9218
19.3438 16.5177 13.8256 10.9244 8.0118 5.0826 2.3602
0.6800 -6.8137 21.1964 21.3411 21.3375 20.6575 19.2899 18.8094
19.2194 16.4093 13.7257 10.8375 7.9413 5.0323 2.3328
0.6700 -6.3943 21.1105 21.2476 21.2384 20.5456 19.1745 18.6947
19.0928 16.2991 13.6245 10.7497 7.8702 4.9817 2.3053
0.6600 -5.9916 21.0206 21.1504 21.1358 20.4308 19.0565 18.5777
18.9639 16.1871 13.5219 10.6610 7.7986 4.9308 2.2776
0.6500 -5.6047 20.9268 21.0496 21.0299 20.3131 18.9362 18.4583
18.8329 16.0732 13.4180 10.5714 7.7264 4.8795 2.2499
0.6400 -5.2328 20.8292 20.9453 20.9205 20.1927 18.8135 18.3367
18.6997 15.9576 13.3128 10.4809 7.6536 4.8279 2.2220
0.6300 -4.8751 20.7278 20.8373 20.8078 20.0694 18.6885 18.2128
18.5643 15.8402 13.2062 10.3895 7.5803 4.7760 2.1939
0.6200 -4.5309 20.6226 20.7259 20.6918 19.9434 18.5611 18.0866
18.4268 15.7209 13.0983 10.2972 7.5064 4.7238 2.1658
0.6100 -4.1998 20.5138 20.6110 20.5725 19.8147 18.4313 17.9582
18.2871 15.5999 12.9891 10.2040 7.4318 4.6712 2.1375
0.6000 -3.8809 20.4013 20.4926 20.4499 19.6832 18.2991 17.8275
18.1452 15.4771 12.8785 10.1098 7.3567 4.6183 2.1090
0.5900 -3.5740 20.2852 20.3708 20.3240 19.5489 18.1646 17.6946
18.0012 15.3525 12.7666 10.0147 7.2810 4.5650 2.0805
0.5800 -3.2784 20.1654 20.2456 20.1949 19.4119 18.0278 17.5594
17.8551 15.2261 12.6533 9.9186 7.2046 4.5113 2.0518
0.5700 -2.9937 20.0421 20.1170 20.0626 19.2722 17.8886 17.4219
17.7067 15.0978 12.5386 9.8216 7.1276 4.4573 2.0229
0.5600 -2.7196 19.9151 19.9849 19.9269 19.1297 17.7470 17.2822
17.5562 14.9678 12.4226 9.7235 7.0500 4.4029 1.9939
0.5500 -2.4556 19.7846 19.8494 19.7881 18.9844 17.6030 17.1402
17.4035 14.8359 12.3051 9.6245 6.9717 4.3481 1.9648
0.5400 -2.2013 19.6505 19.7105 19.6459 18.8362 17.4566 16.9958
17.2485 14.7021 12.1863 9.5245 6.8927 4.2929 1.9355
0.5300 -1.9565 19.5127 19.5682 19.5005 18.6853 17.3078 16.8491
17.0913 14.5665 12.0660 9.4235 6.8131 4.2373 1.9060
0.5200 -1.7209 19.3714 19.4224 19.3517 18.5316 17.1565 16.7001
16.9319 14.4290 11.9443 9.3215 6.7328 4.1814 1.8764
0.5100 -1.4941 19.2265 19.2732 19.1997 18.3749 17.0028 16.5487
16.7702 14.2896 11.8212 9.2184 6.6518 4.1250 1.8467
0.5000 -1.2760 19.0779 19.1204 19.0443 18.2154 16.8466 16.3949
16.6062 14.1483 11.6965 9.1143 6.5700 4.0681 1.8168
0.4900 -1.0662 18.9257 18.9642 18.8855 18.0530 16.6878 16.2387
Appendix 5 Page 226
16.4399 14.0050 11.5704 9.0090 6.4876 4.0109 1.7867
0.4800 -0.8646 18.7697 18.8044 18.7233 17.8876 16.5265 16.0801
16.2712 13.8597 11.4428 8.9027 6.4044 3.9532 1.7564
0.4700 -0.6710 18.6101 18.6410 18.5576 17.7192 16.3626 15.9189
16.1001 13.7125 11.3136 8.7953 6.3204 3.8950 1.7260
0.4600 -0.4851 18.4467 18.4740 18.3885 17.5477 16.1960 15.7552
15.9266 13.5632 11.1828 8.6867 6.2357 3.8364 1.6954
0.4500 -0.3068 18.2795 18.3033 18.2158 17.3732 16.0268 15.5889
15.7505 13.4118 11.0504 8.5769 6.1501 3.7772 1.6646
0.4400 -0.1359 18.1084 18.1289 18.0395 17.1955 15.8548 15.4201
15.5720 13.2583 10.9164 8.4660 6.0638 3.7176 1.6337
0.4300 0.0277 17.9335 17.9508 17.8596 17.0147 15.6801 15.2485
15.3909 13.1027 10.7808 8.3538 5.9766 3.6575 1.6026
0.4200 0.1841 17.7546 17.7688 17.6760 16.8306 15.5026 15.0743
15.2073 12.9449 10.6435 8.2404 5.8885 3.5969 1.5712
0.4100 0.3335 17.5716 17.5829 17.4886 16.6432 15.3222 14.8973
15.0209 12.7848 10.5044 8.1258 5.7995 3.5357 1.5397
0.4000 0.4760 17.3846 17.3931 17.2973 16.4524 15.1388 14.7175
14.8318 12.6225 10.3635 8.0098 5.7097 3.4739 1.5080
0.3900 0.6116 17.1935 17.1992 17.1022 16.2581 14.9525 14.5348
14.6400 12.4579 10.2209 7.8925 5.6189 3.4116 1.4761
0.3800 0.7405 16.9981 17.0012 16.9030 16.0603 14.7630 14.3492
14.4453 12.2908 10.0764 7.7738 5.5271 3.3487 1.4440
0.3700 0.8627 16.7983 16.7990 16.6998 15.8589 14.5705 14.1605
14.2477 12.1214 9.9300 7.6537 5.4344 3.2852 1.4117
0.3600 0.9783 16.5942 16.5925 16.4924 15.6538 14.3747 13.9688
14.0471 11.9494 9.7817 7.5322 5.3406 3.2211 1.3791
0.3500 1.0874 16.3855 16.3815 16.2807 15.4450 14.1756 13.7739
13.8434 11.7749 9.6313 7.4091 5.2457 3.1563 1.3464
0.3400 1.1899 16.1721 16.1661 16.0647 15.2322 13.9731 13.5757
13.6366 11.5977 9.4789 7.2845 5.1498 3.0909 1.3134
0.3300 1.2860 15.9541 15.9460 15.8441 15.0154 13.7672 13.3742
13.4266 11.4178 9.3243 7.1583 5.0527 3.0248 1.2802
0.3200 1.3755 15.7311 15.7212 15.6189 14.7945 13.5576 13.1692
13.2132 11.2351 9.1676 7.0305 4.9544 2.9579 1.2468
0.3100 1.4587 15.5031 15.4914 15.3889 14.5694 13.3444 12.9607
12.9964 11.0495 9.0086 6.9009 4.8549 2.8903 1.2131
0.3000 1.5354 15.2699 15.2566 15.1540 14.3399 13.1273 12.7485
12.7761 10.8610 8.8472 6.7695 4.7541 2.8219 1.1792
0.2900 1.6056 15.0313 15.0166 14.9140 14.1058 12.9062 12.5325
12.5520 10.6693 8.6834 6.6363 4.6519 2.7526 1.1450
0.2800 1.6693 14.7873 14.7712 14.6687 13.8671 12.6811 12.3125
12.3242 10.4745 8.5171 6.5011 4.5483 2.6826 1.1105
0.2700 1.7265 14.5375 14.5202 14.4180 13.6235 12.4517 12.0885
12.0924 10.2763 8.3481 6.3640 4.4433 2.6116 1.0758
0.2600 1.7771 14.2817 14.2634 14.1617 13.3748 12.2179 11.8603
11.8565 10.0746 8.1764 6.2247 4.3367 2.5397 1.0409
0.2500 1.8211 14.0198 14.0006 13.8994 13.1209 11.9796 11.6276
11.6163 9.8694 8.0017 6.0831 4.2284 2.4669 1.0056
0.2400 1.8583 13.7515 13.7314 13.6311 12.8616 11.7364 11.3903
11.3716 9.6603 7.8241 5.9392 4.1185 2.3930 0.9701
0.2300 1.8887 13.4765 13.4558 13.3564 12.5965 11.4882 11.1482
11.1223 9.4473 7.6433 5.7929 4.0067 2.3180 0.9342
0.2200 1.9123 13.1944 13.1732 13.0749 12.3254 11.2347 10.9010
10.8681 9.2302 7.4591 5.6439 3.8930 2.2420 0.8981
0.2100 1.9287 12.9049 12.8835 12.7865 12.0481 10.9758 10.6485
10.6087 9.0086 7.2714 5.4921 3.7772 2.1647 0.8616
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0.2000 1.9380 12.6077 12.5862
10.3439 8.7825 7.0800
0.1900 1.9399 12.3024 12.2809
10.0733 8.5513 6.8845
0.1800 1.9342 11.9883 11.9671
9.7966 8.3150 6.6847
0.1700 1.9208 11.6650 11.6443
9.5134 8.0730 6.4803
0.1600 1.8993 11.3319 11.3118
9.2232 7.8250 6.2709
0.1500 1.8696 10.9882 10.9690
8.9253 7.5704 6.0560
0.1400 1.8312 10.6330 10.6151
8.6193 7.3086 5.8351
0.1300 1.7837 10.2654 10.2490
8.3042 7.0390 5.6076
0.1200 1.7269 9.8842 9.8696
7.9792 6.7606 5.3726
0.1100 1.6601 9.4880 9.4754
7.6431 6.4724 5.1292
0.1000 1.5828 9.0749 9.0647
7.2944 6.1729 4.8762
0.0900 1.4944 8.6426 8.6354
6.9313 5.8605 4.6120
0.0800 1.3941 8.1883 8.1844
6.5512 5.5328 4.3344
0.0700 1.2811 7.7080 7.7078
6.1508 5.1865 4.0405
0.0600 1.1541 7.1960 7.2002
5.7252 4.8171 3.7263
0.0500 1.0120 6.6440 6.6533
5.2669 4.4176 3.3855
0.0400 0.8531 6.0388 6.0538
4.7638 3.9763 3.0081
0.0300 0.6754 5.3559 5.3775
4.1938 3.4727 2.5766
0.0200 0.4765 4.5430 4.5722
3.5086 2.8622 2.0550
0.0100 0.2529 3.4408 3.4780
2.5642 2.0169 1.3492
Theta = 0.0000 0.0400 0.0500
0.1600 0.2000 0.2500
12.4906 11.7641 10.7110 10.3905
5.3374 3.6592 2.0861 0.8248
12.1869 11.4731 10.4400 10.1264
5.1794 3.5389 2.0062 0.7877
11.8750 11.1746 10.1625 9.8561
5.0180 3.4159 1.9249 0.7502
11.5543 10.8683 9.8780 9.5790
4.8530 3.2903 1.8421 0.7124
11.2242 10.5535 9.5861 9.2947
4.6838 3.1616 1.7576 0.6742
10.8839 10.2297 9.2861 9.0026
4.5103 3.0297 1.6714 0.6356
10.5328 9.8960 8.9773 8.7021
4.3318 2.8942 1.5833 0.5966
10.1698 9.5515 8.6590 8.3923
4.1479 2.7547 1.4932 0.5573
9.7937 9.1953 8.3301 8.0723
3.9580 2.6107 1.4009 0.5174
9.4033 8.8260 7.9895 7.7409
3.7611 2.4618 1.3061 0.4772
8.9967 8.4421 7.6357 7.3966
3.5563 2.3073 1.2088 0.4365
8.5718 8.0414 7.2667 7.0375
3.3422 2.1462 1.1086 0.3953
8.1258 7.6212 6.8799 6.6612
3.1172 1.9776 1.0052 0.3537
7.6546 7.1780 6.4719 6.2641
2.8788 1.8001 0.8983 0.3115
7.1530 6.7064 6.0377 5.8412
2.6240 1.6120 0.7874 0.2688
6.6127 6.1987 5.5697 5.3852
2.3479 1.4108 0.6720 0.2256
6.0205 5.6419 5.0555 4.8838
2.0435 1.1931 0.5516 0.1817
5.3524 5.0127 4.4725 4.3144
1.6987 0.9541 0.4253 0.1373
4.5562 4.2599 3.7711 3.6283
1.2915 0.6861 0.2921 0.0922
3.4724 3.2273 2.8021 2.6785
0.7738 0.3761 0.1509 0.0464
0.0600 0.1000 0.1400 0.1500
0.3000 0.3500 0.4000 0.4500
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Estimates of
Hypotheses
H2: linkage, heterogeneity 
HI: linkage, homogeneity 
HO: no linkage
Max.InL 
22.4146 
21.0850 
(0)
alpha
0.8700
(1)
(0)
theta
0.0600
0.1600
(0.5)
Components of chi-square 
Source 
H2 vs. HI 
HI vs. HO 
H2 vs. HO
d.f
Heterogeneity 1 
Linkage 1
Total 2
chi-square
2.659
42.170
44.829
p-value
0.0515
0.0000
0.0000
Approx. 95% confidence intervals: 
Alpha 0.5200 1.0000
Theta 0.0400 0.1600
Family Posterior prob. Approx.conf .limits
no. of linkage lower upper
1 0.6014 0.1475 1.0000
2 0.9650 0.8229 1.0000
3 0.9567 0.7849 1.0000
4 0.9570 0.7878 1.0000
5 0.6016 0.1477 1.0000
6 0.9570 0.7878 1.0000
7 0.9223 0.6624 1.0000
8 0.9239 0.6650 1.0000
9 0.9875 0.9300 1.0000
10 0.9594 0.7966 1.0000
11 0.9466 0.6928 1.0000
12 0.9594 0.7964 1.0000
13 0.7397 0.2497 1.0000
14 0.9263 0.6731 1.0000
15 0.0061 0.0004 1.0000
16 0.9766 0.8749 1.0000
17 0.6019 0.1478 1.0000
18 0.9999 0.9995 1.0000
19 0.9388 0.7147 1.0000
20 0.9388 0.7147 1.0000
21 0.9388 0.7147 1.0000
22 0.9388 0.7147 1.0000
23 0.9388 0.7147 1.0000
24 0.9388 0.7147 1.0000
25 0.9388 0.7147 1.0000
26 0.9388 0.7147 1.0000
27 0.9388 0.7147 1.0000
28 0.9388 0.7147 1.0000
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APPENDIX 6 INPUT AND OUTPUT FILES OF LIPED FOR THE ANALYSIS
OF cpX73, 19.2, pXG12 AND S21 DATA IN THE FAMILIES 
WITH X-LINKED SEVERE COMBINED IMMUNODEFICIENCY
1 0010 0.00001 SCID Linkage Study (cpX73)
(20A4)
(2A4,10F2.0)
(20A4)
m
2 2 
2 3 
0-1
9
0000 0000
0010 0010 
0100 0100 
0500 0500 
1000 1000 
1500 1500 
2000 2000 
2500 2500 
3000 3000 
3500 3500 
4000 4000 
4500 4500
60000
SCID A a aff n.a
0001 9999
A A 1 0
A a 0 1
a a 0 1
cpx U L UU UL
6700 3300
U U 1 0 0
U L 0 1 0
L L 0 0 1
17 OBejarano/Garcia/Gundin(family 16)
1.1 m n.a
1.2 f n.a
2.1 m n.a UU
2.2 1.1 1.2 f n.a UL
2.3 m n.a LL
2.4 1.1 1.2 f n.a UL
2.5 m n.a UU
2.6 1.1 1.2 f n.a UL
3.1 2.1 2.2 m n.a UU
3.2 2.1 2.2 m n.a UU
3.3 2.1 2.2 m aff
3.4 2.3 2.4 f n.a UL
3.5 2.3 2.4 m n.a UU
3.6 2.5 2.6 f n.a UU
3.7 2.5 2.6 m n.a UU
3.8 2.5 2.6 m aff
3.9 2.5 2.6 m aff
7000
12 OTebbe/Koenitz/Moller(family 17) 
1.1 m n.a LL
Appendix 6 Page 230
1.2 f n.a UL
2.1 m n.a UU
2.2 1.1 1.2 f n.a UL
2.3 m n.a LL
2.4 1.1 1.2 f n.a LL
2.5 1.1 1.2 m aff
2.6 1.1 1.2 m aff
2.7 1.1 1.2 m n.a UU
3.1 2.1 2.2 m n.a
3.2 2.3 2.4 f n.a LL
3.4
7000
2.3 2.4 m aff
10 OKhan(family 18)
1.1 m n.a LL
1.2
2.1
f
m
n. a 
n.a
UU
2.2 1.1 1.2 f n.a UL
2.3 1.1 1.2 m aff
2.4 1.1 1.2 m aff
2.5 1.1 1.2 m aff
2.6 1.1 1.2 m aff UU
2.7 1.1 1.2 m n.a UU
3.1
9000
2.1 2.2 m aff UU
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Program LIPED Version for IBM PC March 1987 J. Ott
PROBLEM 1 SCID Linkage Study 
**********
PEDIGREE 1 Bej arano/Garcia/Gundin
17 PERSONS
LOCUS 0 SCID VS. LOCUS 1 cpx
Mutation rate at current main locus = .000010000000
GENE FREQUENCIES FOR 0 SCID .0001 .9999
GENE FREQUENCIES FOR 1 cpx .6700 .3300
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -9.42633 .00000
.0000 .0000 -8.67245 .75388
.0010 .0010 -8.67451 .75181
.0100 .0100 -8.69314 .73319
.0500 .0500 -8.77633 .65000
.1000 .1000 -8.88103 .54530
.1500 .1500 -8.98592 .44041
.2000 .2000 -9.08969 .33664
.2500 .2500 -9.18990 .23643
.3000 .3000 -9.28227 .14406
.3500 .3500 -9.36019 .06614
.4000 .4000 -9.41502 .01131
.4500 .4500 -9.43843 -.01210
PEDIGREE 2 Tebbe/Koenitz/Moller
12 PERSONS
LOCUS 0 SCID VS. LOCUS 1 cpx
Mutation rate at current main locus = .000010000000
R MALE R FEM. L0G10(L(R)) LOD-SCORE
.5000 .5000 -7.72359 .00000
.0000 .0000 -7.29764 .42595
.0010 .0010 -7.29872 .42487
.0100 .0100 -7.30852 .41507
.0500 .0500 -7.35254 .37105
.1000 .1000 -7.40833 .31526
.1500 .1500 -7.46433 .25926
.2000 .2000 -7.51948 .20411
.2500 .2500 -7.57233 .15126
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3000 .3000 -7.62093 .10266
3500 .3500 -7.66290 .06069
4000 .4000 -7.69556 .02803
4500 .4500 -7.71641 .00718
PEDIGREE 3 Khan
10 PERSONS
LOCUS 0 SCID VS. LOCUS 1 cpx
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.93665 .00000
.0000 .0000 -6.63563 .30102
.0010 .0010 -6.63606 .30058
.0100 .0100 -6.63999 .29665
.0500 .0500 -6.65791 .27874
.1000 .1000 -6.68139 .25526
.1500 .1500 -6.70621 .23044
.2000 .2000 -6.73254 .20411
.2500 .2500 -6.76056 .17608
.3000 .3000 -6.79053 .14612
.3500 .3500 -6.82271 .11394
.4000 .4000 -6.85747 .07918
.4500 .4500 -6.89526 .04139
SUMMARY
R MALE R FEM. SUM OF LODS
.0000 .0000 1.48085
.0010 .0010 1.47726
.0100 .0100 1.44491
.0500 .0500 1.29979
.1000 .1000 1.11581
.1500 .1500 .93011
.2000 .2000 .74486
.2500 .2500 .56377
.3000 .3000 .39284
.3500 .3500 .24077
.4000 .4000 .11851
.4500 .4500 .03646
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1 0010 0.00001 SCID Linkage Study 
(20A4)
(2A4,10F2.0)
(20A4)
m
2 2 
2 3 
0-1
9
0000 0000
0010 0010 
0100 0100 
0500 0500 
1000 1000 
1500 1500 
2000 2000 
2500 2500 
3000 3000 
3500 3500 
4000 4000 
4500 4500
60000
SCID A a aff n.a
0001 9999
A A 1 0
A a 0 1
a a 0 1
19-2 U L UU UL
3800 6200
U U 1 0 0
U L 0 1 0
L L 0 0 1
17 OBejarano/Garcia/Gundin
1.1 m n.a
1.2 f n.a
2.1 m n.a LL
2.2 1.1 1.2 f n.a UL
2.3 m n.a LL
2.4 1.1 1.2 f n.a UU
2.5 m n.a UU
2.6 1.1 1.2 f n.a UL
3.1 2.1 2.2 m n.a LL
3.2 2.1 2.2 m n.a UU
3.3 2.1 2.2 m aff
3.4 2.3 2.4 f n.a UL
3.5 2.3 2.4 m n.a UU
3.6 2.5 2.6 f n.a UU
3.7 2.5 2.6 m n.a UU
3.8 2.5 2.6 m aff
3.9 2.5 2.6 m aff
7000
12 OTebbe/Koenitz/Moller
1.1 m n.a UU
1.2 f n.a UL
2.1 m n.a LL
2.2 1.1 1.2 f n.a UL
(19.2)
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2.3 m n.a LL
2.4 1.1 1.2 f n.a UU
2.5 1.1 1.2 m aff
2.6 1.1 1.2 m aff
2.7 1.1 1.2 m n.a LL
3.1 2.1 2.2 m n.a
3.2 2.3 2.4 f n.a UL
3.4 2.3 2.4 m aff
7000
15 OKhan
1.1 m n.a LL
1.2 f n.a UL
2.1 1.1 1.2 m aff
2.2 m n.a LL
2.3 1.1 1.2 f n.a UL
2.4 1.1 1.2 m n.a LL
2.5 1.1 1.2 m n.a LL
3.1 m n.a
3.2 2.2 2.3 f n.a UL
3.3 2.2 2.3 m aff UU
3.4 2.2 2.3 m n.a LL
3.5 2.2 2.3 m aff
3.6 2.2 2.3 m aff
3.7 2.2 2.3 m aff
4.1 3.1 3.2 m aff UU
9000
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Program LIPED Version for IBM PC March 1987 J. Ott
PROBLEM 1 SCID Linkage Study 
**********
PEDIGREE 1 Bejarano/Garcia/Gundin
17 PERSONS
LOCUS 0 SCID VS. LOCUS 1 19-2
Mutation rate at current main locus = .000010000000
GENE FREQUENCIES FOR 0 SCID .0001 .9999
GENE FREQUENCIES FOR 1 19-2 .3800 .6200
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -9.92197 .00000
.0000 .0000 -14.29197 -4.37000
.0010 .0010 -11.59405 -1.67208
.0100 .0100 -10.61249 -.69052
.0500 .0500 -9.99343 -.07146
.1000 .1000 -9.79516 .12681
.1500 .1500 -9.72471 .19726
.2000 .2000 -9.70758 .21439
.2500 .2500 -9.71958 .20239
.3000 .3000 -9.74892 .17305
.3500 .3500 -9.78830 .13367
.4000 .4000 -9.83250 .08947
.4500 .4500 -9.87777 .04420
PEDIGREE 2 Tebbe/Koenitz/Moller
12 PERSONS
LOCUS 0 SCID VS. LOCUS 1 19-2
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -7.39454 .00000
.0000 .0000 -6.96859 .42595
.0010 .0010 -6.96967 .42487
.0100 .0100 -6.97947 .41507
.0500 .0500 -7.02349 .37105
.1000 . 1000 -7.07928 .31526
.1500 .1500 -7.13528 .25926
.2000 .2000 -7.19043 .20411
.2500 .2500 -7.24328 .15126
Appendix 6 Page 236
3000
3500
4000
4500
.3000
.3500
.4000
.4500
•7.29188
■7.33385
■7.36651
■7.38736
.10266
.06069
.02803
.00718
PEDIGREE 3 Khan
15 PERSONS
LOCUS 0 SCID VS. LOCUS 1 19-2
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -9.85966 .00000
.0000 .0000 -8.05352 1.80614
.0010 .0010 -8.05656 1.80310
.0100 .0100 -8.08407 1.77559
.0500 .0500 -8.20939 1.65027
.1000 .1000 -8.37322 1.48643
.1500 .1500 -8.54520 1.31446
.2000 .2000 -8.72515 1.13451
.2500 .2500 -8.91229 .94737
.3000 .3000 -9.10491 .75475
.3500 .3500 -9.30010 .55955
.4000 .4000 -9.49373 .36593
.4500 .4500 -9.68126 .17840
SUMMARY
R MALE R FEM. SUM OF LODS
.0000 .0000 -2.13791
.0010 .0010 .55588
.0100 .0100 1.50013
.0500 .0500 1.94986
.1000 .1000 1.92850
.1500 .1500 1.77098
.2000 .2000 1.55300
.2500 .2500 1.30102
.3000 .3000 1.03045
.3500 .3500 .75391
.4000 .4000 .48342
.4500 .4500 .22978
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1 0010 0.00001 
(20A4)
(2A4,10F2.0)
(20A4)
2 2 
2 3 
0-1
9
0000 0000
0010 0010 
0100 0100 
0500 0500 
1000 1000 
1500 1500 
2000 2000 
2500 2500 
3000 3000 
3500 3500 
4000 4000 
4500 4500
60000 
SCID A
0001 
A A 1
A a 0
a a 0
XG12 U
6500 
U U 1
U L 0
L L 0 0 1
SCID Linkage Study (pXG 12)
m
a aff n.a 
9999
0
1
1
L UU 
3500 
0 0 
1 0
UL LL
17 OBejarano/Garcia/Gundin
1.1
1.2
2.1
2.2
2.3
2.4
2.5
2.6
3.1
3.2
3.3
3.4
3.5
3.6
3.7
3.8
3.9 
7000
12
1.1
1.2
2.1
2.2
1.1 1.2
1.1 1.2
1.1 1.2 
2.1 2.2 
2.1 2.2 
2.1 2.2
2.3 2.4
2.3 2.4
2.5 2.6
2.5 2.6
2.5 2.6
2.5 2.6
m n.a 
f n.a 
m n.a 
f n.a 
m n.a 
f n.a 
m n.a 
f n.a 
m n.a 
m n.a 
m aff 
f n.a 
m n.a 
f n.a 
m n.a 
m aff 
m aff
UU
UU
UU
OTebbe/Koenitz/Moller 
m n.a LL 
f n.a UU 
m n.a UU 
1.1 1.2 f n.a UL
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2.3 m n. a LL
2.4 1.1 1.2 f n. a UL
2.5 1.1 1.2 m aff
2.6 1.1 1.2 m aff
2.7 1.1 1.2 m n. a UU
3.1 2.1 2.2 m n. a
3.2 2.3 2.4 f n. a UL
3.4 2.3 2.4 m aff
7000
15 OKhan
1.1 m n. a
1.2 f n.a UL
2.1 1.1 1.2 m aff
2.2 m n.a
2.3 1.1 1.2 f n.a LL
2.4 1.1 1.2 m n.a UU
2.5 1.1 1.2 m n.a UU
3.1 m n.a
3.2 2.2 2.3 f n.a LL
3.3 2.2 2.3 m aff
3.4 2.2 2.3 m n.a
3.5 2.2 2.3 m aff
3.6 2.2 2.3 m aff
3.7 2.2 2.3 m aff
4.1 3.1 3.2 m aff
9000
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Program LIPED Version for IBM PC March 1987 J. Ott
PROBLEM 1 SCID Linkage Study 
**********
PEDIGREE 1 Bejarano/Garcia/Gundin
17 PERSONS
LOCUS 0 SCID VS. LOCUS 1 XG12
Mutation rate at current main locus = .000010000000
GENE FREQUENCIES FOR 0 SCID .0001 .9999
GENE FREQUENCIES FOR 1 XG12 .6500 .3500
R MALE R FEM. L0G10(L(R)) LOD-SCORE
.5000 .5000 -6.73873 .00000
.0000 .0000 -6.72189 .01684
.0010 .0010 -6.72196 .01677
.0100 .0100 -6.72254 .01618
.0500 .0500 -6.72504 .01369
.1000 .1000 -6.72788 .01085
.1500 .1500 -6.73039 .00833
.2000 .2000 -6.73259 .00614
.2500 .2500 -6.73445 .00427
.3000 .3000 -6.73599 .00274
.3500 .3500 -6.73718 .00154
.4000 .4000 -6.73804 .00069
.4500 .4500 -6.73855 .00017
PEDIGREE 2 Tebbe/Koenitz/Moller
12 PERSONS
LOCUS 0 SCID VS. LOCUS 1 XG12
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -7.10338 .00000
.0000 .0000 -7.10338 .00000
.0010 .0010 -7.10338 .00000
.0100 .0100 -7.10338 .00000
.0500 .0500 -7.10338 .00000
.1000 .1000 -7.10338 .00000
.1500 .1500 -7.10338 .00000
.2000 .2000 -7.10338 .00000
.2500 .2500 -7.10338 .00000
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3000 .3000 -7.10338 .00000
3500 .3500 -7.10338 .00000
4000 .4000 -7.10338 .00000
4500 .4500 -7.10338 .00000
PEDIGREE 3 Khan
15 PERSONS
LOCUS 0 SCID VS. LOCUS 1 XG12
Mutation rate at current main locus =
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -9.16738 .00000
.0000 .0000 -8.56533 .60205
.0010 .0010 -8.56664 .60074
.0100 .0100 -8.57843 .58895
.0500 .0500 -8.63210 .53528
.1000 .1000 -8.70201 .46537
.1500 .1500 -8.77469 .39269
.2000 .2000 -8.84933 .31805
.2500 .2500 -8.92435 .24303
.3000 .3000 -8.99712 .17026
.3500 .3500 -9.06358 .10380
.4000 .4000 -9.11816 .04922
.4500 .4500 -9.15454 .01284
SUMMARY
R MALE R FEM. SUM OF LODS
.0000 .0000 .61888
.0010 .0010 .61751
.0100 .0100 .60513
.0500 .0500 .54897
.1000 .1000 .47622
.1500 .1500 .40102
.2000 .2000 .32419
.2500 .2500 .24730
.3000 .3000 .17299
.3500 .3500 .10534
.4000 .4000 .04990
.4500 .4500 .01301
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1 0010 0.00001 SCID Linkage Study (S21) 
(20A4)
(2A4,10F2.0)
(20A4)
m
2 2 
2 3 
0-1
9
0000 0000
0010 0010 
0100 0100 
0500 0500 
1000 1000 
1500 1500 
2000 2000 
2500 2500 
3000 3000 
3500 3500 
4000 4000 
4500 4500
60000
SCID A a aff
0001 9999
A A 1 0
A a 0 1
a a 0 1
S21 U L UU
6500 3500
U U 1 0 0
U L 0 1 0
L L 0 0 1
17 OBejarano/Garcia/Gundin
1.1 m n.a
1.2 f n.a
2.1 m n.a UU
2.2 1.1 1.2 f n.a UL
2.3 m n.a UU
2.4 1.1 • to f n.a UL
2.5 m n.a LL
2.6 1.1 1.2 f n.a UL
3.1 2.1 2.2 m n.a UU
3.2 2.1 2.2 m n.a UU
3.3 2.1 2.2 m aff
3.4 2.3 2.4 f n.a UU
3.5 2.3 2.4 m n.a LL
3.6 2.5 2.6 f n.a UL
3.7 2.5 2.6 m n.a UU
3.8 2.5 2.6 m aff
3.9 2.5 2.6 m aff
'000
12 OTebbe/Koenitz/Mo.
1.1 m n.a
1.2 f n.a UU
2.1 m n.a
2.2 1.1 1.2 f n.a UU
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2.3 m n.a
2.4 1.1 1.2 f n.a
2.5 1.1 1.2 m aff
2.6 1.1 1.2 m aff
2.7 1.1 1.2 m n.a
3.1 2.1 2.2 m n.a
3.2 2.3 2.4 f n.a
3.4 2.3 2.4 m aff
7000
15 OKhan
1.1 m n.a
1.2 f n.a
2.1 1.1 1.2 m aff
2.2 m n.a
2.3 1.1 1.2 f n.a
2.4 1.1 1.2 m n.a
2.5 1.1 1.2 m n.a
3.1 m n.a
3.2 2.2 2.3 f n.a
3.3 2.2 2.3 m aff
3.4 2.2 2.3 m n.a
3.5 2.2 2.3 m aff
3.6 2.2 2.3 m aff
3.7 2.2 2.3 m aff
4.1 3.1 3.2 m aff
9000
UU
UU
UU
UU
UU
UL
UU
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Program LIPED Version for IBM PC March 1987 J. Ott
PROBLEM 1 SCID Linkage Study 
**********
PEDIGREE 1 Bej arano/Garcia/Gundin
17 PERSONS
LOCUS 0 SCID VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
GENE FREQUENCIES FOR 0 SCID .0001 .9999
GENE FREQUENCIES FOR 1 S21 .6500 .3500
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -9.41471 .00000
.0000 .0000 -9.24058 .17412
.0010 .0010 -9.23985 .17486
.0100 .0100 -9.23398 .18073
.0500 .0500 -9.22159 .19312
.1000 .1000 -9.22907 .18563
.1500 .1500 -9.25331 .16139
.2000 .2000 -9.28789 .12682
.2500 .2500 -9.32740 .08731
.3000 .3000 -9.36649 .04821
.3500 .3500 -9.39955 .01516
.4000 .4000 -9.42108 -.00637
.4500 .4500 -9.42677 -.01207
PEDIGREE 2 Tebbe/Koenitz/Moller
12 PERSONS
LOCUS 0 SCID VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -6.07757 .00000
.0000 .0000 -6.07757 .00000
.0010 .0010 -6.07757 .00000
.0100 .0100 -6.07757 .00000
.0500 .0500 -6.07757 .00000
.1000 .1000 -6.07757 .00000
.1500 .1500 -6.07757 .00000
.2000 .2000 -6.07757 .00000
.2500 .2500 -6.07757 .00000
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3000 .3000 -6.07757 .00000
3500 .3500 -6.07757 .00000
4000 .4000 -6.07757 .00000
4500 .4500 -6.07757 .00000
PEDIGREE 3 Khan
15 PERSONS
LOCUS 0 SCID VS. LOCUS 1 S21
Mutation rate at current main locus = .000010000000
R MALE R FEM. LOG10(L(R)) LOD-SCORE
.5000 .5000 -8.32866 .00000
.0000 .0000 -8.02764 .30102
.0010 .0010 -8.02808 .30058
.0100 .0100 -8.03201 .29665
.0500 .0500 -8.04992 .27874
.1000 .1000 -8.07340 .25526
.1500 .1500 -8.09822 .23044
.2000 .2000 -8.12455 .20411
.2500 .2500 -8.15258 .17608
.3000 .3000 -8.18254 .14612
.3500 .3500 -8.21472 .11394
.4000 .4000 -8.24948 .07918
.4500 .4500 -8.28727 .04139
SUMMARY
R MALE R FEM. SUM OF LODS
.0000 .0000 .47514
.0010 .0010 .47544
.0100 .0100 .47738
.0500 .0500 .47186
.1000 .1000 .44089
.1500 .1500 .39183
.2000 .2000 .33093
.2500 .2500 .26339
.3000 .3000 .19433
.3500 .3500 .12909
.4000 .4000 .07280
.4500 .4500 .02932
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